https://www.delveinsight.com daily 1.0 https://www.delveinsight.com/blog/ daily 0.9 https://www.delveinsight.com/insights 2025-12-09T11:56:51.068Z daily 0.8 https://www.delveinsight.com/asco-conference-2024/all 2025-12-02T04:55:16.178Z daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023 2025-11-13T05:36:05.112Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/all 2025-11-13T05:33:03.762Z daily 0.8 https://www.delveinsight.com/coronavirus-update-ceo-message 2025-09-17T07:04:51.613Z daily 0.8 https://www.delveinsight.com/contact-us 2025-08-06T09:13:43.164Z daily 0.8 https://www.delveinsight.com/esmo-conference-2024 2025-07-23T11:15:58.227Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020 2025-07-23T08:30:22.213Z daily 0.8 https://www.delveinsight.com/consulting/asset-prioritizaton-services 2025-07-09T04:26:08.630Z daily 0.8 https://www.delveinsight.com/aacr-annual-meeting 2025-05-22T04:53:43.455Z daily 0.8 https://www.delveinsight.com/ats-conference-coverage 2025-05-13T04:53:30.724Z daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024 2025-05-12T06:13:21.925Z daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024 2025-05-12T06:12:23.007Z daily 0.8 https://www.delveinsight.com/ers-conference/ers-2024 2025-05-12T06:10:18.171Z daily 0.8 https://www.delveinsight.com/events/ers-2024 2025-05-07T09:29:03.156Z daily 0.8 https://www.delveinsight.com/consulting-services 2025-05-06T12:37:36.960Z daily 0.8 https://www.delveinsight.com/asco-conference-2022/all 2025-02-06T04:05:25.757Z daily 0.8 https://www.delveinsight.com/eha-conference/all 2024-11-04T04:06:46.621Z daily 0.8 https://www.delveinsight.com/esmo-conference-2024/all 2024-08-23T12:13:42.552Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023 2024-06-25T11:56:05.288Z daily 0.8 https://www.delveinsight.com/asco-conference-2024 2024-05-31T06:44:45.364Z daily 0.8 https://www.delveinsight.com/sitemap-blog/posts-page-1 2024-05-28T07:09:23.589Z daily 0.8 https://www.delveinsight.com/sitemap-blog/posts-page-5 2024-05-28T04:44:14.025Z daily 0.8 https://www.delveinsight.com/sitemap-blog/posts-page-4 2024-05-28T04:42:44.738Z daily 0.8 https://www.delveinsight.com/sitemap-blog/posts-page-3 2024-05-28T04:41:04.452Z daily 0.8 https://www.delveinsight.com/sitemap-blog/posts-page-2 2024-05-28T04:38:42.310Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024 2024-05-22T05:02:52.920Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/all 2024-05-14T10:11:46.072Z daily 0.8 https://www.delveinsight.com/asco-conference/all 2024-05-10T12:32:10.396Z daily 0.8 https://www.delveinsight.com/events/bio-korea-2024 2024-05-10T12:25:20.996Z daily 0.8 https://www.delveinsight.com/consulting/primary-research-services 2024-05-10T12:06:27.693Z daily 0.8 https://www.delveinsight.com/sitemap/country-healthcare 2024-05-10T11:36:00.125Z daily 0.8 https://www.delveinsight.com/sitemap/competitive-landscape 2024-05-10T11:35:24.596Z daily 0.8 https://www.delveinsight.com/sitemap/epidemiology-insight-sample-page 2024-05-10T11:34:18.305Z daily 0.8 https://www.delveinsight.com/sitemap/epidemiology-insight 2024-05-10T11:29:25.574Z daily 0.8 https://www.delveinsight.com/events/esmo-2023 2024-05-10T07:11:35.675Z daily 0.8 https://www.delveinsight.com/sitemap/market-insight 2024-05-10T06:39:14.955Z daily 0.8 https://www.delveinsight.com/sitemap/market-insight 2024-05-10T06:08:26.364Z daily 0.8 https://www.delveinsight.com/asco-conference-coverage 2024-05-08T03:57:56.982Z daily 0.8 https://www.delveinsight.com/asco-conference-2021/all 2024-05-01T05:01:06.323Z daily 0.8 https://www.delveinsight.com/sitemap/api-manufacturers-marketed-and-phase-III-drugs-landscape 2024-05-01T04:58:58.945Z daily 0.8 https://www.delveinsight.com/sitemap/biosimilars-sample-page 2024-04-29T06:01:46.884Z daily 0.8 https://www.delveinsight.com/sitemap/cardiovascular-diseases 2024-04-29T06:01:28.447Z daily 0.8 https://www.delveinsight.com/sitemap/country-healthcare-sample-page 2024-04-29T06:00:57.805Z daily 0.8 https://www.delveinsight.com/sitemap/dental-and-oral-health 2024-04-29T06:00:38.490Z daily 0.8 https://www.delveinsight.com/sitemap/drug-insight-and-market-forecast-sample-page 2024-04-29T06:00:16.829Z daily 0.8 https://www.delveinsight.com/sitemap/drug-insight-sample-page 2024-04-29T06:00:01.040Z daily 0.8 https://www.delveinsight.com/sitemap/mechanism-of-action-insight-sample-page 2024-04-29T05:58:29.898Z daily 0.8 https://www.delveinsight.com/sitemap/specialised-reports-sample-page 2024-04-29T05:58:02.039Z daily 0.8 https://www.delveinsight.com/sitemap/vaccines-sample-page 2024-04-29T05:56:57.821Z daily 0.8 https://www.delveinsight.com/sitemap/drug-api-insight-sample-page 2024-04-22T09:17:39.493Z daily 0.8 https://www.delveinsight.com/sitemap/sitemap-infographics 2024-04-22T09:17:22.182Z daily 0.8 https://www.delveinsight.com/search 2024-03-11T05:33:25.116Z daily 0.8 https://www.delveinsight.com/ers-conference/all 2024-02-06T07:58:56.439Z daily 0.8 https://www.delveinsight.com/consulting/conference-coverage-services 2024-01-26T04:16:08.187Z daily 0.8 https://www.delveinsight.com/ats-conference/all 2024-01-16T06:05:20.358Z daily 0.8 https://www.delveinsight.com/covid19 2024-01-03T11:12:42.886Z daily 0.8 https://www.delveinsight.com/consulting/due-diligence-services 2024-01-03T11:12:10.856Z daily 0.8 https://www.delveinsight.com/events/bio-europe-2019 2024-01-02T15:27:37.272Z daily 0.8 https://www.delveinsight.com/register 2024-01-02T11:39:25.030Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/all 2023-12-27T13:11:48.095Z daily 0.8 https://www.delveinsight.com/events/cphi-barcelona-2023 2023-12-27T13:11:47.559Z daily 0.8 https://www.delveinsight.com/events/bio-japan-2023 2023-12-27T13:11:47.298Z daily 0.8 https://www.delveinsight.com/events/bio-europe-2023 2023-12-27T13:11:46.776Z daily 0.8 https://www.delveinsight.com/events/esmo-asia-2023 2023-12-27T13:11:46.524Z daily 0.8 https://www.delveinsight.com/events/duphat-2024 2023-12-27T13:11:46.262Z daily 0.8 https://www.delveinsight.com/refund-policy 2023-12-27T13:11:45.488Z daily 0.8 https://www.delveinsight.com/cancellation-policy 2023-12-27T13:11:45.227Z daily 0.8 https://www.delveinsight.com/sitemap/infographics-sitemap 2023-12-27T13:11:44.976Z daily 0.8 https://www.delveinsight.com/sitemap/market-insight-sample-page 2023-12-27T13:11:44.709Z daily 0.8 https://www.delveinsight.com/sitemap/ats 2023-12-27T13:11:44.454Z daily 0.8 https://www.delveinsight.com/sitemap/eular 2023-12-27T13:11:44.179Z daily 0.8 https://www.delveinsight.com/events/bio-asia-taiwan-2023 2023-12-27T13:11:43.926Z daily 0.8 https://www.delveinsight.com/thank-you 2023-12-27T13:11:43.662Z daily 0.8 https://www.delveinsight.com/asco-conference-2023/all 2023-12-27T13:11:43.409Z daily 0.8 https://www.delveinsight.com/asco-conference-2023 2023-12-27T13:11:43.145Z daily 0.8 https://www.delveinsight.com/events/bio-us-2023 2023-12-27T13:11:42.894Z daily 0.8 https://www.delveinsight.com/events/asco-2023 2023-12-27T13:11:42.630Z daily 0.8 https://www.delveinsight.com/events/bio-korea-2023 2023-12-27T13:11:42.380Z daily 0.8 https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage 2023-12-27T13:11:42.120Z daily 0.8 https://www.delveinsight.com/consulting/ci-tracking 2023-12-27T13:11:41.864Z daily 0.8 https://www.delveinsight.com/events/bio-europe-conference-2023 2023-12-27T13:11:41.603Z daily 0.8 https://www.delveinsight.com/case-study/asthma-and-copd-assets 2023-12-27T13:11:41.352Z daily 0.8 https://www.delveinsight.com/case-study/oncology-assets 2023-12-27T13:11:41.093Z daily 0.8 https://www.delveinsight.com/case-study/conference-intelligence-product-assessment 2023-12-27T13:11:40.840Z daily 0.8 https://www.delveinsight.com/case-study/conference-coverage-car-tcr-summit 2023-12-27T13:11:40.323Z daily 0.8 https://www.delveinsight.com/events/esmo-asia-2022 2023-12-27T13:11:39.806Z daily 0.8 https://www.delveinsight.com/events/duphat-conference-2022 2023-12-27T13:11:39.542Z daily 0.8 https://www.delveinsight.com/oncology 2023-12-27T13:11:39.282Z daily 0.8 https://www.delveinsight.com/rare-diseases 2023-12-27T13:11:39.027Z daily 0.8 https://www.delveinsight.com/events/bio-europe-spring-2022 2023-12-27T13:11:38.769Z daily 0.8 https://www.delveinsight.com/events/bio-japan-2022 2023-12-27T13:11:38.509Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/all 2023-12-27T13:11:37.991Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022 2023-12-27T13:11:37.740Z daily 0.8 https://www.delveinsight.com/request-for-proposal 2023-12-27T13:11:37.476Z daily 0.8 https://www.delveinsight.com/events/festival-of-biologics-2022 2023-12-27T13:11:37.222Z daily 0.8 https://www.delveinsight.com/events/bio-europe-2022 2023-12-27T13:11:36.958Z daily 0.8 https://www.delveinsight.com/events/eular-2022 2023-12-27T13:11:36.191Z daily 0.8 https://www.delveinsight.com/events/ats-2022 2023-12-27T13:11:35.933Z daily 0.8 https://www.delveinsight.com/eular-conference/all 2023-12-27T13:11:35.684Z daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022 2023-12-27T13:11:35.426Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022 2023-12-27T13:11:35.171Z daily 0.8 https://www.delveinsight.com/asco-conference-2022 2023-12-27T13:11:34.651Z daily 0.8 https://www.delveinsight.com/events/bio-trinity-2022 2023-12-27T13:11:34.129Z daily 0.8 https://www.delveinsight.com/events/asco-2022 2023-12-27T13:11:33.618Z daily 0.8 https://www.delveinsight.com/events/bio-us-2022 2023-12-27T13:11:33.357Z daily 0.8 https://www.delveinsight.com/events/pharma-ci-europe-swiss-2022 2023-12-27T13:11:33.102Z daily 0.8 https://www.delveinsight.com/sitemap/competitive-landscape-sample-page 2023-12-27T13:11:30.781Z daily 0.8 https://www.delveinsight.com/case-study/cdmo-competitive-assessment 2023-12-27T13:11:29.495Z daily 0.8 https://www.delveinsight.com/case-study/r-and-d-landscape-assessment 2023-12-27T13:11:29.235Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021 2023-12-27T13:11:28.469Z daily 0.8 https://www.delveinsight.com/case-study/oncology-product-assessment-dashboard 2023-12-27T13:11:28.205Z daily 0.8 https://www.delveinsight.com/case-study/immune-checkpoint-inhibitor-market-potential 2023-12-27T13:11:27.945Z daily 0.8 https://www.delveinsight.com/case-study/hematological-malignancy-competitive-intelligence 2023-12-27T13:11:27.681Z daily 0.8 https://www.delveinsight.com/case-study/cutaneous-squamous-cell-carcinoma-epidemiology-assessment 2023-12-27T13:11:27.424Z daily 0.8 https://www.delveinsight.com/case-study/breast-cancer-market-dynamics-dashboard 2023-12-27T13:11:27.165Z daily 0.8 https://www.delveinsight.com/case-study/competitive-landscape-of-covid-19-therapies 2023-12-27T13:11:26.907Z daily 0.8 https://www.delveinsight.com/asco-conference-2021 2023-12-27T13:11:17.645Z daily 0.8 https://www.delveinsight.com/events/bio-digital-2021 2023-12-27T13:11:17.381Z daily 0.8 https://www.delveinsight.com/medical-devices 2023-12-27T13:11:17.130Z daily 0.8 https://www.delveinsight.com/case-study/market-&-competitive-assessment 2023-12-27T13:11:16.871Z daily 0.8 https://www.delveinsight.com/case-study/competitive-landscape-assessment 2023-12-27T13:11:16.617Z daily 0.8 https://www.delveinsight.com/case-study/market-size-&-forecast-assessment 2023-12-27T13:11:16.351Z daily 0.8 https://www.delveinsight.com/sitemap/biosimilars 2023-12-27T13:11:15.566Z daily 0.8 https://www.delveinsight.com/sitemap/drug-insight-and-market-forecast 2023-12-27T13:11:15.300Z daily 0.8 https://www.delveinsight.com/sitemap/vaccines 2023-12-27T13:11:15.046Z daily 0.8 https://www.delveinsight.com/infographics 2023-12-27T13:11:14.267Z daily 0.8 https://www.delveinsight.com/asco-conference 2023-12-27T13:11:10.878Z daily 0.8 https://www.delveinsight.com/sitemap/drug-api-insight 2023-12-27T13:11:10.097Z daily 0.8 https://www.delveinsight.com/sitemap/drug-insight 2023-12-27T13:11:09.844Z daily 0.8 https://www.delveinsight.com/sitemap/mechanism-of-action-insight 2023-12-27T13:11:09.331Z daily 0.8 https://www.delveinsight.com/sitemap/pipeline-insight 2023-12-27T13:11:09.068Z daily 0.8 https://www.delveinsight.com/sitemap/specialised-reports 2023-12-27T13:11:08.814Z daily 0.8 https://www.delveinsight.com/case-study/r-and-d-analysis 2023-12-27T13:11:08.292Z daily 0.8 https://www.delveinsight.com/case-study/competitive-benchmarking 2023-12-27T13:11:08.029Z daily 0.8 https://www.delveinsight.com/case-study/mergers-and-acquisitions 2023-12-27T13:11:07.772Z daily 0.8 https://www.delveinsight.com/events/duphat-conference-2020 2023-12-27T13:11:07.509Z daily 0.8 https://www.delveinsight.com/sitemap 2023-12-27T13:11:07.258Z daily 0.8 https://www.delveinsight.com/case-study/regulatory-analysis 2023-12-27T13:11:06.485Z daily 0.8 https://www.delveinsight.com/case-study/partner-identification 2023-12-27T13:11:06.229Z daily 0.8 https://www.delveinsight.com/events/bio-asia-taiwan-2019 2023-12-27T13:11:05.966Z daily 0.8 https://www.delveinsight.com/case-study/due-diligence 2023-12-27T13:11:05.201Z daily 0.8 https://www.delveinsight.com/case-study/pipeline-assessment 2023-12-27T13:11:04.937Z daily 0.8 https://www.delveinsight.com/case-study/portfolio-management 2023-12-27T13:11:04.681Z daily 0.8 https://www.delveinsight.com/privacy-policy 2023-12-27T13:11:04.419Z daily 0.8 https://www.delveinsight.com/terms-and-conditions 2023-12-27T13:11:04.162Z daily 0.8 https://www.delveinsight.com/consulting/regulatory-analysis-services 2023-12-27T13:11:03.641Z daily 0.8 https://www.delveinsight.com/consulting/market-assessment-services 2023-12-27T13:11:03.377Z daily 0.8 https://www.delveinsight.com/consulting/r-and-d-analysis 2023-12-27T13:11:03.124Z daily 0.8 https://www.delveinsight.com/consulting/pharmaceutical-portfolio-management-solutions 2023-12-27T13:11:02.863Z daily 0.8 https://www.delveinsight.com/consulting/competitive-benchmarking-services 2023-12-27T13:11:02.604Z daily 0.8 https://www.delveinsight.com/consulting/partner-identification-services 2023-12-27T13:11:02.343Z daily 0.8 https://www.delveinsight.com/consulting/merger-and-acquisition 2023-12-27T13:11:02.089Z daily 0.8 https://www.delveinsight.com/consulting/licensing-services 2023-12-27T13:11:01.819Z daily 0.8 https://www.delveinsight.com/consulting/competitive-intelligence-services 2023-12-27T13:11:01.567Z daily 0.8 https://www.delveinsight.com/consulting/business-development-services 2023-12-27T13:11:01.303Z daily 0.8 https://www.delveinsight.com/case-study/product-assessment 2023-12-27T13:11:00.785Z daily 0.8 https://www.delveinsight.com/case-study/launch-landscape-analysis 2023-12-27T13:11:00.535Z daily 0.8 https://www.delveinsight.com/case-study/go-to-market-strategy 2023-12-27T13:11:00.273Z daily 0.8 https://www.delveinsight.com/case-study/in-licensing-opportunity 2023-12-27T13:11:00.021Z daily 0.8 https://www.delveinsight.com/case-study/out-licensing-opportunity 2023-12-27T13:10:59.755Z daily 0.8 https://www.delveinsight.com/case-study/asset-prioritization 2023-12-27T13:10:59.504Z daily 0.8 https://www.delveinsight.com/consulting 2023-12-27T13:10:59.247Z daily 0.8 https://www.delveinsight.com/report-store.php 2023-12-27T13:10:58.995Z daily 0.8 https://www.delveinsight.com/market-research 2023-12-27T13:10:58.731Z daily 0.8 https://www.delveinsight.com/events 2023-12-27T13:10:58.482Z daily 0.8 https://www.delveinsight.com/careers 2023-12-27T13:10:58.221Z daily 0.8 https://www.delveinsight.com/case-study 2023-12-27T13:10:57.950Z daily 0.8 https://www.delveinsight.com/press-release 2023-12-27T13:10:57.683Z daily 0.8 https://www.delveinsight.com/whitepaper-newsletter 2023-12-27T13:10:57.424Z daily 0.8 https://www.delveinsight.com/pharmdelve 2023-12-27T13:10:56.650Z daily 0.8 https://www.delveinsight.com/events/bio-japan-2019 2023-12-27T13:10:56.126Z daily 0.8 https://www.delveinsight.com/events/bio-pharm-america-2019 2023-12-27T13:10:55.872Z daily 0.8 https://www.delveinsight.com/events/bio-asia-taiwan-2019 2023-12-27T13:10:55.610Z daily 0.8 https://www.delveinsight.com/events/bio-us-2019 2023-12-27T13:10:55.356Z daily 0.8 https://www.delveinsight.com/consulting/pipeline-assessment-services 2023-12-27T13:10:55.097Z daily 0.8 https://www.delveinsight.com/about-us 2023-12-27T13:10:54.847Z daily 0.8 https://www.delveinsight.com/ers-conference/ers-2025/ipf-abstracts-at-ers-2025 2025-09-26T11:24:53.879Z https://assets.delveinsight.com/case-studies/1758885848889-ipf-abstracts-at-ers-2025.png Leading Poster and Oral Presentations on IPF at ERS 2025 daily 0.8 https://www.delveinsight.com/ers-conference/ers-2025/top-10-abstracts-at-ers-2025 2025-09-26T11:19:34.201Z https://assets.delveinsight.com/case-studies/1758885561356-top 10-abstracts-at-ers-2025.png ERS 2025 Top Abstracts: Redefining the Future of Respiratory Care with Next-Generation Therapies daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/captivate-study-findings 2025-06-24T05:36:31.198Z https://assets.delveinsight.com/case-studies/1750743382918-captivate-study-findings.png Durable Outcomes with Fixed-Duration Ibrutinib + Venetoclax: 97% OS at 5.5 Years in CLL/SLL daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/midas-trial-highlights 2025-06-24T05:21:15.703Z https://assets.delveinsight.com/case-studies/1750742470047-midas-trial-highlights.png Extended IsaKRD vs. ASCT: MIDAS Trial Suggests Equivalent MRD Clearance in MRD-Negative Myeloma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/phase-iii-inotuzumab-ozogamicin-vate-trial 2025-06-24T05:17:58.999Z https://assets.delveinsight.com/case-studies/1750742261578-phase-iii-inotuzumab-ozogamicin-vate-trial.png Balanced Outcomes with Lower-Dose BESPONSA: 50.9% Remission and 12.2-Month OS in Early Responders Pre-HSCT daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/vbp101-trial 2025-06-24T05:11:00.448Z https://assets.delveinsight.com/case-studies/1750741856463-vbp101-trial.png Selective CD33 Deletion with Trem-cel Supports Novel Post-Transplant Strategy to Prevent Relapse in AML daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/blincyto-phase-iii-e1910-trial 2025-06-24T04:47:01.139Z https://assets.delveinsight.com/case-studies/1750740415023-blincyto-phase-iii-e1910-trial.png BLINCYTO Outshines Chemo with 3-Year OS of 100% in BCR::ABL1-Like ALL, Reinforcing Its Role in High-Risk Disease. daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/bgb-16673-phase-i-ii-cadance-101 2025-06-24T04:43:46.296Z https://assets.delveinsight.com/case-studies/1750740222933-bgb-16673-phase-i-ii-cadance-101.png Progress in Waldenström Macroglobulinemia Treatment: Phase I/II CaDAnCe-101 Findings for BeiGene’s BTK Degrader daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/gilteritinib-phase-iii-commodore-trial 2025-06-20T11:32:57.201Z https://assets.delveinsight.com/case-studies/1750419173829-gilteritinib-phase-iii-commodore-trial.png Gilteritinib Shows Sustained Efficacy and Tolerability in Relapsed/Refractory FLT3+ AML: 34-Month Follow-Up Data daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/quizartinib-based-triplet-regimen 2025-06-20T11:30:26.439Z https://assets.delveinsight.com/case-studies/1750419021918-quizartinib-based-triplet-regimen.png Decitabine, Venetoclax, and Quizartinib Combination Demonstrates High Remission Rates in Newly Diagnosed FLT3-ITD Mutated AML daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/pfizer-phase-iii-part-1-magnetismm-6-trial 2025-06-20T11:27:10.412Z https://assets.delveinsight.com/case-studies/1750418827380-pfizer-phase-iii-part-1-magnetismm-6-trial.png ELREXFIO Combo Achieves 97% ORR in Phase III Myeloma Trial, with High Depth of Response daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/phase-iii-iraklia-study 2025-06-20T11:24:01.910Z https://assets.delveinsight.com/case-studies/1750418639499-phase-iii-iraklia-study.png Phase III IRAKLIA Study: Subcutaneous Isatuximab via OBI Matches IV Efficacy with Enhanced Patient Experience in Multiple Myeloma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/anito-cel-phase-ii-trial 2025-06-20T11:21:45.324Z https://assets.delveinsight.com/case-studies/1750418502423-anito-cel-phase-ii-trial.png Anito-cel (anitocabtagene autoleucel) Shows High Response and Low Toxicity in Phase II Trial for R/R Multiple Myeloma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/quizartinib-phase-iii-data 2025-06-20T11:16:36.266Z https://assets.delveinsight.com/case-studies/1750418193342-quizartinib-phase-iii-data.png Phase III Data Reveal Quizartinib’s Potential to Reverse Poor Outcomes in Molecularly Defined High-Risk AML daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/polivy-for-r-r-dlbcl 2025-06-20T11:00:19.566Z https://assets.delveinsight.com/case-studies/1750417217112-polivy-for-r-r-dlbcl.png LBCL Pola-R-GemOx Outperforms R-GemOx in OS for R/R DLBC, Increased Toxicities Underline Need for Risk Assessment daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/olverembatinib-driven-regimen-phase-ii-trial-highlight 2025-06-20T10:40:36.909Z https://assets.delveinsight.com/case-studies/1750416033771-olverembatinib-driven-regimen-phase-ii-trial-highlight.png Early Results from Phase II Trial Highlight Potential of Olverembatinib-Driven Regimen in Redefining Frontline Ph+ ALL Therapy daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/obe-cel-phase-ib-ii-felix-trial 2025-06-20T10:30:15.763Z https://assets.delveinsight.com/case-studies/1750415412692-obe-cel-phase-ib-ii-felix-trial.png Obe-cel Shows Promising Age-Inclusive Outcomes in R/R B-ALL with Favorable Safety and Durable Remissions daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/jnj-4496-phase-i-trial 2025-06-20T10:27:35.298Z https://assets.delveinsight.com/case-studies/1750415253150-jnj-4496-phase-i-trial.png Dual CD19/CD20 CAR-T JNJ-4496 Delivers Durable Responses in Heavily Pretreated LBCL Patients daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/kite-363-for-r-r-lbcl 2025-06-20T08:36:21.046Z https://assets.delveinsight.com/case-studies/1750408578284-kite-363-for-r-r-lbcl.png KITE-363 Demonstrates High Response Rates and Tolerability in Advanced LBCL, Including Post–CAR-T Settings daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/afm13-ab-101-combo-phase-ii-trial 2025-06-20T08:30:51.334Z https://assets.delveinsight.com/case-studies/1750408248778-afm13-ab-101-combo-phase-ii-trial.png Promising Outcomes with AFM13 + AB-101 in Relapsed/Refractory Classical Hodgkin Lymphoma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/trimm-3-trial-result 2025-06-20T08:28:48.963Z https://assets.delveinsight.com/case-studies/1750408126409-trimm-3-trial-result.png Evolving Role of GPRC5D-Targeted Therapies in RRMM: Clinical Promise of TALVEY and PD-1 Inhibitor Combinations daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/johnson-and-johnson-jnj-5322-in-multiple-myeloma 2025-06-20T08:26:12.702Z https://assets.delveinsight.com/case-studies/1750407970151-johnson-and-johnson-jnj-5322-in-multiple-myeloma.png Trispecifics in Multiple Myeloma: Johnson & Johnson’s JNJ-5322 Reveals Early Safety Signals daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/ordspono-phase-ii-results 2025-06-20T08:23:04.799Z https://assets.delveinsight.com/case-studies/1750407780209-ordspono-phase-ii-results.png Odronextamab Demonstrates Robust Efficacy and Sustained Remission in Relapsed/Refractory Follicular Lymphoma with a Consistent Safety Profile daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/ph-all-as-third-gen-tkis 2025-06-20T08:20:38.775Z https://assets.delveinsight.com/case-studies/1750407635297-ph-all-as-third-gen-tkis.png Post Hoc Insights Highlight Ponatinib’s MRD and Survival Benefit Despite Increased Toxicity in Ph+ ALL daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/besremi-phase-iii-data 2025-06-20T08:17:05.884Z https://assets.delveinsight.com/case-studies/1750407422820-besremi-phase-iii-data.png BESREMi Outperforms Anagrelide in Molecular and Clinical Endpoints in ET: FDA Label Expansion on Horizon daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/Brexu-cel-phase-ii-zuma-3-trial 2025-06-20T08:14:34.746Z https://assets.delveinsight.com/case-studies/1750407272384-Brexu-cel-phase-ii-zuma-3-trial.png Brexucabtagene Autoleucel Achieves 40% Five-Year OS in Adults with R/R B-ALL: Impact of Prior Therapies and Transplant daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/azd0486-phase-i-syrus-trial 2025-06-20T08:11:54.075Z https://assets.delveinsight.com/case-studies/1750407111517-azd0486-phase-i-syrus-trial.png Early Clinical Data Support AZD0486 as a Safe and Effective Option in Relapsed/Refractory B-ALL with High Disease Burden daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/momelotinib-phase-iii-data 2025-06-20T08:09:44.031Z https://assets.delveinsight.com/case-studies/1750406978293-momelotinib-phase-iii-data.png Phase III Data Support Momelotinib as a Disease-Modifying Therapy for Anemia-Associated Myelofibrosis daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/belantamab-mafodotin-dreamm-8-trial 2025-06-20T08:07:37.461Z https://assets.delveinsight.com/case-studies/1750406855175-belantamab-mafodotin-dreamm-8-trial.png Belantamab Mafodotin Combination Extends PFS to Over 32 Months in RRMM Without New Safety Signals daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/divesiran-for-polycythemia-vera 2025-06-20T08:04:43.786Z https://assets.delveinsight.com/case-studies/1750406673859-divesiran-for-polycythemia-vera.png Divesiran Demonstrates Safety, Pharmacodynamic Activity, and Hematocrit Control in Polycythemia Vera Patients daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/elritercept-and-ruxolitinib-combo-in-myelofibrosis 2025-06-20T08:02:05.269Z https://assets.delveinsight.com/case-studies/1750406522605-elritercept-and-ruxolitinib-combo-in-myelofibrosis.png Efficacy and Safety of Elritercept in Combination with Ruxolitinib in Myelofibrosis: Results from a Two-Arm Study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/phase-ii-unito-mm-01-forte-trial 2025-06-20T07:44:21.531Z https://assets.delveinsight.com/case-studies/1750405458158-phase-ii-unito-mm-01-forte-trial.png KRd-ASCT Outperforms KRd12 and KCd-ASCT in Progression-Free Survival at 93.6-Month Follow-Up daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/phase-ib-ii-cartitude-1-trial 2025-06-20T07:41:49.770Z https://assets.delveinsight.com/case-studies/1750405304460-phase-ib-ii-cartitude-1-trial.png Breakthrough in Myeloma Treatment as CARVYKTI Delivers 5-Year Remission Milestone daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/nuvisertib-phase-i-ii-myelofibrosis-trial 2025-06-20T07:39:06.654Z https://assets.delveinsight.com/case-studies/1750405144296-nuvisertib-phase-i-ii-myelofibrosis-trial.png Nuvisertib Shows Promising Efficacy and Tolerability in Relapsed or Refractory Myelofibrosis daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/pelabresib-plus-ruxolitinib-phase-iii-manifest-2-trial-results 2025-06-20T07:26:45.970Z https://assets.delveinsight.com/case-studies/1750404403003-pelabresib-plus-ruxolitinib-phase-iii-manifest-2-trial-results.png Pelabresib Plus Ruxolitinib Shows Enhanced Clinical Benefit in Myelofibrosis: Phase III MANIFEST-2 Trial Results daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/ropeginterferon-alfa-2b-phase-ii-trial 2025-06-20T07:24:19.439Z https://assets.delveinsight.com/case-studies/1750404256759-ropeginterferon-alfa-2b-phase-ii-trial.png Ropeginterferon Alfa-2b Delivers Robust Phase II Efficacy in Early Myelofibrosis, Marking a Potential Shift Toward Disease Modification and Long-Term Control. daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/kura-oncology-ziftomenib-in-aml 2025-06-20T07:22:02.518Z https://assets.delveinsight.com/case-studies/1750404111057-kura-oncology’-ziftomenib-in-aml.png Durable Responses and Early Survival Benefits Observed with Ziftomenib in High-Risk AML Subtypes daily 0.8 https://www.delveinsight.com/eha-conference/eha-2025/dec-c-venetoclax-phases-i-iib-trial 2025-06-20T07:18:59.468Z https://assets.delveinsight.com/case-studies/1750403934827-dec-c-venetoclax-phases-i-iib-trial.png DEC-C ± Venetoclax Demonstrates Consistent Remission Rates and Manageable Safety in AML: Results from Phases I–IIB daily 0.8 https://www.delveinsight.com/asco-conference/article/amivantamab-in-r-m-acc 2025-06-16T05:46:03.829Z https://assets.delveinsight.com/case-studies/1750052760464-amivantamab-in-r-m-acc.png Clinical activity of amivantamab in recurrent/metastatic adenoid cystic carcinoma daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-peak-1-trial 2025-06-16T05:43:03.775Z https://assets.delveinsight.com/case-studies/1750052559714-phase-iii-peak-1-trial.png Casdatifan and Cabozantinib in ccRCC: A Step towards New Treatment Horizons daily 0.8 https://www.delveinsight.com/asco-conference/article/nivolumab-ipilimumab-checkmate-901 2025-06-16T05:40:14.181Z https://assets.delveinsight.com/case-studies/1750052401524-nivolumab-ipilimumab-checkmate-901.png CheckMate 901 Misses Primary Endpoint in Cisplatin-Ineligible mUC, Undermining Practice Impact Despite Encouraging Long-Term Outcomes daily 0.8 https://www.delveinsight.com/asco-conference/article/ozuriftamab-vedotin-phase-ii-data 2025-06-13T06:52:33.941Z https://assets.delveinsight.com/case-studies/1749797547744-ozuriftamab-vedotin-phase-ii-data.png BioAtla highlights promising Phase II result of ozuriftamab vedotin in heavily pretreated head & neck cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/ember-3-trial-highlights 2025-06-13T06:22:37.173Z https://assets.delveinsight.com/case-studies/1749795744153-ember-3-trial-highlights.png EMBER-3 Marks First Phase III Success for Oral SERD Plus CDK4/6 Inhibitor Post-Progression daily 0.8 https://www.delveinsight.com/asco-conference/article/pf-08046054-and-pembrolizumab-combo-interim-phase-i-result 2025-06-13T06:19:19.997Z https://assets.delveinsight.com/case-studies/1749795525436-pf-08046054-and-pembrolizumab-combo-interim-phase-i-result.png Pfizer unveiled promising early data for PDL1V (PF-08046054) + pembrolizumab in R/M HNSCC daily 0.8 https://www.delveinsight.com/asco-conference/article/brentuximab-vedotin-plus-pembrolizumab-phase-ii-study 2025-06-13T06:11:59.706Z https://assets.delveinsight.com/case-studies/1749795114618-brentuximab-vedotin-plus-pembrolizumab-phase-ii-study.png Brentuximab vedotin plus pembrolizumab shows promise in metastatic HNSCC daily 0.8 https://www.delveinsight.com/asco-conference/article/sacituzumab-govitecan-pembrolizumab-combo-phase-ii-neostar-study 2025-06-11T12:13:20.868Z https://assets.delveinsight.com/case-studies/1749643980903-sacituzumab-govitecan-pembrolizumab-combo-phase-ii-neostar-study.png Sacituzumab govitecan/pembrolizumab combination demonstrates feasibility and Efficacy in Early-Stage TNBC: Results from NeoSTAR Arm A2 daily 0.8 https://www.delveinsight.com/asco-conference/article/dsp107-plus-atezolizumab-phase-ii-trial 2025-06-11T12:09:58.406Z https://assets.delveinsight.com/case-studies/1749643735636-dsp107-plus-atezolizumab-phase-ii-trial.png Only clinical stage CD47x4-1BB bi-specific Demonstrates Clinical Benefit in Third-Line MSS Colorectal Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/verzenio-clonevo-trial 2025-06-11T12:01:55.193Z https://assets.delveinsight.com/case-studies/1749643302929-verzenio-clonevo-trial.png CLONEVO Trial Explores Neoadjuvant VERZENIO in Cisplatin-ineligible MIBC with Promising Early Efficacy daily 0.8 https://www.delveinsight.com/asco-conference/article/trodelvy-and-pembrolizumab-combo-phase-ii-sure-02-study 2025-06-11T11:57:31.567Z https://assets.delveinsight.com/case-studies/1749643035244-trodelvy-and-pembrolizumab-combo-phase-ii-sure-02-study.png Exploring a bladder-sparing approach in MIBC using a combination of TRODELVY (sacituzumab govitecan) and Pembrolizumab: SURE-02 Interim Analysis daily 0.8 https://www.delveinsight.com/asco-conference/article/nivolumab-nivopostop-trial 2025-06-11T11:54:05.411Z https://assets.delveinsight.com/case-studies/1749642826159-nivolumab-nivopostop-trial.png First in Decades: Nivolumab Improves 3-Year Outcomes in High-Risk Head and Neck Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/petosemtamab-phase-ii-trial 2025-06-11T11:49:50.277Z https://assets.delveinsight.com/case-studies/1749642576567-petosemtamab-phase-ii-trial.png Merus reported a 80% 12-month overall survival rate along with 63% confirmed response rate in a Phase II trial daily 0.8 https://www.delveinsight.com/asco-conference/article/jmt101-sg001-plus-irinotecan-phase-ii-trial 2025-06-11T06:25:43.885Z https://assets.delveinsight.com/case-studies/1749623139076-jmt101-sg001-plus-irinotecan-phase-ii-trial.png JMT101 in combination with irinotecan shows promise for advanced colorectal cancer treatment. daily 0.8 https://www.delveinsight.com/asco-conference/article/atezolizumab-plus-mfolfox6-phase-iii-atomic-trial 2025-06-11T06:15:34.773Z https://assets.delveinsight.com/case-studies/1749622526333-atezolizumab-plus-mfolfox6-phase-iii-atomic-trial.png Atezolizumab Plus mFOLFOX6 with Improved DFS Redefines Adjuvant Treatment in dMMR Colon Cancer: Phase III ATOMIC Trial Results daily 0.8 https://www.delveinsight.com/asco-conference/article/padeliporfin-vtp-phase-iii-enlighted-trial 2025-06-11T06:12:32.322Z https://assets.delveinsight.com/case-studies/1749622313980-padeliporfin-vtp-phase-iii-enlighted-trial.png Phase III ENLIGHTED Trial Demonstrates Promising Interim Efficacy and Safety of Padeliporfin VTP in Low-Grade UTUC daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-ii-actuate-1801-trial 2025-06-11T06:09:26.207Z https://assets.delveinsight.com/case-studies/1749622152797-phase-ii-actuate-1801-trial.png Phase II Preliminary Results of Elraglusib Plus Gemcitabine/Nab-Paclitaxel Show Survival Benefit in Metastatic Pancreatic Ductal Adenocarcinoma daily 0.8 https://www.delveinsight.com/asco-conference/article/can-2409-phase-iii-trial 2025-06-10T10:10:20.860Z https://assets.delveinsight.com/case-studies/1749550209302-can-2409-phase-iii-trial.png Phase III study demonstrates efficacy of CAN-2409 plus EBRT in Intermediate-to-High-Risk Localized Prostate Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/akeega-phase-iii-amplitude-study 2025-06-10T10:07:44.204Z https://assets.delveinsight.com/case-studies/1749550037044-akeega-phase-iii-amplitude-study.png Niraparib plus abiraterone improves outcomes in metastatic castration-sensitive prostate cancer with HRR daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-veritac-2-clinical-trial 2025-06-10T10:03:51.318Z https://assets.delveinsight.com/case-studies/1749549807301-phase-iii-veritac-2-clinical-trial.png Vepdegestrant Surpasses Fulvestrant with 5-Month PFS Boost in ESR1-Mutant Breast Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/temab-a-phase-i-study 2025-06-09T11:17:44.892Z https://assets.delveinsight.com/case-studies/1749467853433-temab-a-phase-i-study.png c-MET Targeting ADC Temab-A Obtains Scope in Targeting EGFR-mutated NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/dato-dxd-keytruda-chemotherapy-in-nsclc 2025-06-09T11:14:45.657Z https://assets.delveinsight.com/case-studies/1749467666060-dato-dxd-keytruda-chemotherapy-in-nsclc.png Evaluating Dato-DXd + KEYTRUDA ± Platinum in Advanced NSCLC Amid Regulatory Realignments and Biomarker-Driven Focus daily 0.8 https://www.delveinsight.com/asco-conference/article/mytx-011-phase-i-results 2025-06-09T11:11:14.478Z https://assets.delveinsight.com/case-studies/1749467449496-mytx-011-phase-i-results.png MYTX-011 Brings a New Approach to NSCLC: Targeting c-MET–Driven Tumors with an Innovative ADC Across Expression Levels daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-matterhorn-trial 2025-06-09T11:06:03.929Z https://assets.delveinsight.com/case-studies/1749467116770-phase-iii-matterhorn-trial.png Perioperative IMFINZI + FLOT Improves Outcomes in Resectable Gastric/GEJ Cancer: MATTERHORN Phase III Trial daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-serena-6-trial 2025-06-05T10:51:32.100Z https://assets.delveinsight.com/case-studies/1749120680186-phase-iii-serena-6-trial.png ctDNA-Guided Switch To “First And Only Next-Generation Oral SERD Camizestrant” Nearly Halves (56%) Progression Risk or Death in HR+/HER2– Breast Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/t-dxd-pertuzumab-destiny-breast09-trial 2025-06-05T10:47:36.723Z https://assets.delveinsight.com/case-studies/1749120443039-t-dxd-pertuzumab-destiny-breast09-trial.png DESTINY-Breast09: T-DXd + Pertuzumab Extends Response, Reduces Risk in HER2+ mBC daily 0.8 https://www.delveinsight.com/asco-conference/article/olomorasib-plus-keytruda-loxo-ras-20001-study 2025-06-05T10:42:26.403Z https://assets.delveinsight.com/case-studies/1749120124664-olomorasib-plus-keytruda-loxo-ras-20001-study.png Eli Lilly’s Olomorasib Plus KEYTRUDA Demonstrates Promising Efficacy and Manageable Safety in First-Line Treatment of KRAS G12C-Mutant Advanced NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-ii-savannah-trial 2025-06-05T10:35:55.868Z https://assets.delveinsight.com/case-studies/1749119722975-phase-ii-savannah-trial.png SAVANNAH Trial Highlights Market Potential of Savolitinib–TAGRISSO Combination in MET+ NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/targisso-neoadaura-phase-iii-trial 2025-06-05T10:32:00.635Z https://assets.delveinsight.com/case-studies/1749119517250-targisso-neoadaura-phase-iii-trial.png Neoadjuvant TAGRISSO (Osimertinib) Demonstrates Up to 26% MPR and 50% EFS Risk Reduction With or Without Chemotherapy in Resectable EGFR-Mutant NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/patritumab-deruxtecan-phase-iii-results 2025-06-05T10:28:32.192Z https://assets.delveinsight.com/case-studies/1749119282776-patritumab-deruxtecan-phase-iii-results.png Disappointing Phase III Results and Safety Concerns Derail Patritumab Deruxtecan’s Prospects in EGFR-Mutated NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/sasanlimab-phase-iii-crest-study 2025-06-05T10:23:01.031Z https://assets.delveinsight.com/case-studies/1749118967209-sasanlimab-phase-iii-crest-study.png Sasanlimab in combination with BCG could fill a major treatment gap and redefine the standard of care for high-risk, BCG-naive NMIBC daily 0.8 https://www.delveinsight.com/asco-conference/article/her3-dxd-phase-ii-tuxedo-3-study 2025-06-05T06:00:47.862Z https://assets.delveinsight.com/case-studies/1749103209717-her3-dxd-phase-ii-tuxedo-3-study.png Findings from first study (TUXEDO-3) to evaluate the intracranial and extracranial efficacy in advanced stages of the cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/zepzelca-and-tecentriq-combo-imforte-phase-iii-trial 2025-06-05T05:40:16.432Z https://assets.delveinsight.com/case-studies/1749101998610-zepzelca-and-tecentriq-combo-imforte-phase-iii-trial.png Improved Survival with Dual Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/tagitanlimab-phase-iii-study 2025-06-05T05:35:07.216Z https://assets.delveinsight.com/case-studies/1749101687366-tagitanlimab-phase-iii-study.png Tagitanlimab plus GP could be a new standard first-line treatment for recurrent or metastatic NPC daily 0.8 https://www.delveinsight.com/asco-conference/article/toripalimab-phase-iii-diamond-study 2025-06-05T05:24:07.272Z https://assets.delveinsight.com/case-studies/1749101032726-toripalimab-phase-iii-diamond-study.png Toripalimab demonstrates non-inferior efficacy in 3-year- FFS and -OS in high-risk LANPC daily 0.8 https://www.delveinsight.com/asco-conference/article/becotatug-vedotin-for-nasopharyngeal-carcinoma 2025-06-05T05:17:16.848Z https://assets.delveinsight.com/case-studies/1749100614194-becotatug-vedotin-for-nasopharyngeal-carcinoma.png Lepu Biopharma’s EGFR ADC Shows Superior Efficacy Over Chemotherapy in R/M NPC, with Promising Survival Benefits daily 0.8 https://www.delveinsight.com/asco-conference/article/sacituzumab-govitecan-and-pembrolizumab-combo-phase-iii-results 2025-06-05T05:08:30.789Z https://assets.delveinsight.com/case-studies/1749100092536-sacituzumab-govitecan-and-pembrolizumab-combo-phase-iii-results.png Sacituzumab Govitecan and Pembrolizumab Combination to Target TNBC: Phase III Breakthrough Results. daily 0.8 https://www.delveinsight.com/asco-conference/article/imdelltra-phase-iii-dellphi-304-trial 2025-06-04T13:34:54.227Z https://assets.delveinsight.com/case-studies/1749044059507-imdelltra-phase-iii-dellphi-304-trial.png Phase III DeLLphi-304 Trial Shows IMDELLTRA Reduces Risk of Death by 40% Compared to Chemotherapy in Relapsed SCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/checkmate-816-trial-results 2025-06-04T13:31:28.123Z https://assets.delveinsight.com/case-studies/1749043870663-checkmate-816-trial-results.png Significant overall survival with neoadjuvant OPDIVO and chemotherapy combination in patients with resectable NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-inavo120-study 2025-06-04T13:27:48.991Z https://assets.delveinsight.com/case-studies/1749043654523-phase-iii-inavo120-study.png Revolutionizing PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer Treatment: Itovebi-Based Regimen achieves 17.2 Months PFS and Enhanced Survival daily 0.8 https://www.delveinsight.com/asco-conference/article/paxg-cassandra-trial 2025-06-04T13:24:24.466Z https://assets.delveinsight.com/case-studies/1749043450071-paxg-cassandra-trial.png CASSANDRA Trial Establishes PAXG as a Promising Neoadjuvant Option in Resectable or Borderline Resectable Pancreatic Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/t-dxd-destiny-gastric04-trial 2025-06-04T13:21:00.118Z https://assets.delveinsight.com/case-studies/1749043246711-t-dxd-destiny-gastric04-trial.png DESTINY-Gastric04 data validates T-DXd (ENHERTU) as “new global second-line standard of care” for HER2+ Gastric/GEJ Cancer, Outperforming Ramucirumab plus Paclitaxel daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-i-kandlelit-001-trial-results 2025-06-04T13:17:40.023Z https://assets.delveinsight.com/case-studies/1749043048034-phase-i-kandlelit-001-trial-results.png MK-1084-Based Regimens Show Promising Activity and Manageable Safety in KRAS G12C-Mutant Colorectal Cancer: Results from the Phase I KANDLELIT-001 Trial daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-i-ii-loxo-ras-20001-trial-result 2025-06-04T13:14:39.537Z https://assets.delveinsight.com/case-studies/1749042867602-phase-i-ii-loxo-ras-20001-trial-result.png Second-generation KRAS G12C inhibitor (Olomorasib) in combination with EGFR blockade (cetuximab) could overcome resistance in CRC daily 0.8 https://www.delveinsight.com/asco-conference/article/vabametkib-phase-ii-findings 2025-06-03T14:20:25.921Z https://assets.delveinsight.com/case-studies/1748960411196-vabametkib-phase-ii-findings.png Vabametkib Yields Durable Responses in MET Exon 14 Skipping NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/dato-dxd-and-rilvegostomig-combo-in-mNSCLC 2025-06-03T14:16:39.768Z https://assets.delveinsight.com/case-studies/1748960180874-dato-dxd-and-rilvegostomig-combo-in-mNSCLC.png DATROWAY and Rilvegostomig Combination Shows Encouraging Efficacy in Frontline Advanced NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/mk-1084-phase-i-kandlelit-001-study 2025-06-03T14:12:14.088Z https://assets.delveinsight.com/case-studies/1748959906748-mk-1084-phase-i-kandlelit-001-study.png Next-Gen KRAS G12C Inhibitor MK-1084 Demonstrates High Response Rates in Frontline NSCLC Trials daily 0.8 https://www.delveinsight.com/asco-conference/article/emrelis-luminosity-study 2025-06-03T14:08:20.168Z https://assets.delveinsight.com/case-studies/1748959677063-emrelis-luminosity-study.png EMRELIS for Advanced c-Met Overexpressing NSCLC, Backed by Durable Responses in LUMINOSITY Study daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-i-codebreak-101-study 2025-06-03T13:01:56.151Z https://assets.delveinsight.com/case-studies/1748955701202-phase-i-codebreak-101-study.png Updated Phase Ib CodeBreaK 101 Data Supports Expansion of KRAS G12C-directed therapy Beyond Dual Blockade, Reinforcing The Role Of Triplet Therapy daily 0.8 https://www.delveinsight.com/asco-conference/article/rybrevant-chemotherapy-mariposa-2-trial 2025-06-03T12:11:16.145Z https://assets.delveinsight.com/case-studies/1748952669316-rybrevant-chemotherapy-mariposa-2-trial.png RYBREVANT Plus Chemotherapy Demonstrates Superior Efficacy Over TAGRISSO and Chemotherapy Alone in EGFR-Mutant NSCLC. daily 0.8 https://www.delveinsight.com/asco-conference/article/anlotinib-capeox-phase-iii-anchor-trial 2025-06-03T11:53:31.015Z https://assets.delveinsight.com/case-studies/1748951226718-anlotinib-capeox-phase-iii-anchor-trial.png Does intravenous-free maintenance strategy of anlotinib/CapeOX has the potential in first-line metastatic colorectal cancer? daily 0.8 https://www.delveinsight.com/asco-conference/article/ficera-pembro-combo-phase-i-ib-result 2025-06-03T11:35:03.939Z https://assets.delveinsight.com/case-studies/1748950483176-ficera-pembro-combo-phase-i-ib-result.png With confirmed ORR of 54% and prolonged OS in the Phase I/Ib Expansion Cohort of Ficerafusp Alfa with Pembrolizumab observes promising efficacy in R/M HNSCC daily 0.8 https://www.delveinsight.com/asco-conference/article/iza-bren-phase-ib-trial 2025-06-03T05:19:40.106Z https://assets.delveinsight.com/case-studies/1748927920399-iza-bren-phase-ib-trial.png Iza-Bren Shows Strong Promise in NSCLC with Targeted Mutations: High Response Rates and Manageable Safety Profile daily 0.8 https://www.delveinsight.com/asco-conference/article/braftovi-cetuximab-mfolfox6-phase-iii-breakwater-trial 2025-06-03T05:13:03.997Z https://assets.delveinsight.com/case-studies/1748927470742-braftovi-cetuximab-mfolfox6-phase-iii-breakwater-trial.png BRAFTOVI/cetuximab-based regimen cut the risk in half in first-line BRAF V600E-mutant mCRC daily 0.8 https://www.delveinsight.com/asco-conference/article/sac-tmt-phase-ii-results 2025-06-03T04:09:38.564Z https://assets.delveinsight.com/case-studies/1748923701756-sac-tmt-phase-ii-results.png Preliminary Phase II results of Sac-TMT as first-line therapy in a/mTNBC shows promise daily 0.8 https://www.delveinsight.com/asco-conference/article/egfr-her3-adc-izalontamab-brengitecan-phase-i-trial-result 2025-06-03T03:55:03.907Z https://assets.delveinsight.com/case-studies/1748922900047-egfr-her3-adc-izalontamab-brengitecan-phase-i-trial-result.png In previously treated ES-SCLC patients, especially in those previously treated with 1 prior line, iza-bren showed cORR of 75.0% with mOS of 15.0 months daily 0.8 https://www.delveinsight.com/asco-conference/article/nivolumab-ipilimumab-combo-checkmate-8hw-study 2025-06-03T03:50:15.131Z https://assets.delveinsight.com/case-studies/1748922610576-nivolumab-ipilimumab-combo-checkmate-8hw-study.png Latest findings from ASCO 2025 added weight to previously reported results from CheckMate-8HW study (Nivolumab plus Ipilimumab) daily 0.8 https://www.delveinsight.com/asco-conference/article/fulvestrant-plus-ipatasertib-finer-trial-highlights 2025-06-02T13:05:11.999Z https://assets.delveinsight.com/case-studies/1748869461021-finer-trial-highlights.png With a median PFS of 5.32 months, fulvestrant in combination with ipatasertib could be a potential treatment option post CDK4/6 and aromatase inhibitor disease progression daily 0.8 https://www.delveinsight.com/asco-conference/article/late-breaking-sessions-asco-2025 2025-05-30T13:10:51.714Z https://assets.delveinsight.com/case-studies/1748610586485-late-breaking-sessions-asco-2025.png ASCO 2025 Late-Breaking Sessions daily 0.8 https://www.delveinsight.com/asco-conference/article/key-genitourinary-cancers-abstracts-asco-2025 2025-05-30T10:02:19.635Z https://assets.delveinsight.com/case-studies/1748599282545-key-genitourinary-cancers-abstracts-asco-2025.png Key Genitourinary Cancers Clinical Trials to Watch daily 0.8 https://www.delveinsight.com/asco-conference/article/top-gastrointestinal-cancers-abstracts-asco-2025 2025-05-30T09:59:53.868Z https://assets.delveinsight.com/case-studies/1748599155604-top-gastrointestinal-cancers-abstracts-asco-2025.png ASCO 2025 Gastrointestinal Cancer Preview: Key Studies to Watch According to DelveInsight daily 0.8 https://www.delveinsight.com/asco-conference/article/head-and-neck-cancer-abstracts-asco-2025 2025-05-28T15:48:09.834Z https://assets.delveinsight.com/case-studies/1748447219364-head-and-neck-cancer-abstracts-asco-2025.png ASCO 2025 Preview: Key Abstracts in Head and Neck Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/trispecific-therapies-in-oncology-abstracts-asco-2025 2025-05-28T15:45:27.708Z https://assets.delveinsight.com/case-studies/1748447071841-trispecific-therapies-in-oncology-abstracts-asco-2025.png A Glimpse into Trispecific Therapies in Oncology: ASCO 2025 in Focus daily 0.8 https://www.delveinsight.com/asco-conference/article/top-breast-cancer-abstracts-asco-2025 2025-05-28T11:58:07.041Z https://assets.delveinsight.com/case-studies/1748433432553-top-breast-cancer-abstracts-asco-2025.png Breast Cancer at ASCO 2025 daily 0.8 https://www.delveinsight.com/asco-conference/article/lung-cancer-abstracts-asco-2025 2025-05-28T11:01:24.956Z https://assets.delveinsight.com/case-studies/1748430082449-lung-cancer-abstracts-asco-2025.png Lung Cancer at ASCO 2025 daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/esg401-phase-ia-ib-study 2024-09-17T06:38:36.514Z https://assets.delveinsight.com/case-studies/1726555012463-esg401-phase-ia-ib-study.png Results from a Phase Ia/Ib Study of ESG401, a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/23me-00610-phase-i-ii-data 2024-09-17T06:31:37.092Z https://assets.delveinsight.com/case-studies/1726554673082-23me-00610-phase-i-ii-data.png Efficacy, safety, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country Phase 1/2a expansion cohort daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/amivantamab-chemotherapy-combo-phase-i-ii-origami-1-study 2024-09-17T06:28:03.997Z https://assets.delveinsight.com/case-studies/1726554381192-amivantamab-chemotherapy-combo-phase-i-ii-origami-1-study.png OrigAMI-1: Phase Ib/II open-label study evaluating RYBREVANT (Amivantamab) with FOLFOX or FOLFIRI in metastatic colorectal cancer. daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/encorafenib-folfiri-phase-iii-breakwater-study 2024-09-17T06:20:55.254Z https://assets.delveinsight.com/case-studies/1726554037778-encorafenib-folfiri-phase-iii-breakwater-study.png Updated BREAKWATER safety lead-in results: Encorafenib + Cetuximab (EC) with FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/bt8009-phase-i-ii-duravelo-1-trial 2024-09-17T06:17:01.738Z https://assets.delveinsight.com/case-studies/1726553804773-bt8009-phase-i-ii-duravelo-1-trial.png Updated results of Duravelo-1: BT8009 monotherapy in PADCEV-naïve metastatic urothelial carcinoma (mUC) patients. daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/xtandi-phase-iii-peace-3-trial 2024-09-17T06:11:37.932Z https://assets.delveinsight.com/case-studies/1726553420551-xtandi-phase-iii-peace-3-trial.png Initial Findings from the Phase III EORTC-GUCG 1333/PEACE-III Trial: Comparing XTANDI Alone vs XTANDI with XOFIGO in Asymptomatic/Mildly Symptomatic Bone Metastatic mCRPC daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/dato-dxd-tropion-lung01-trial 2024-09-17T06:06:43.582Z https://assets.delveinsight.com/case-studies/1726553199061-dato-dxd-tropion-lung01-trial.png AstraZeneca/Daiichi’s next-gen ADC Dato-DXd shows superior survival and response over docetaxel in advanced nonsquamous NSCLC, with/without brain metastases. daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/amivantamab-mariposa-and-mariposa-2-trials 2024-09-14T16:17:25.029Z https://assets.delveinsight.com/case-studies/1726330531794-amivantamab-mariposa-and-mariposa-2-trials.png Johnson & Johnson’s Amivantamab: Key Findings from MARIPOSA & MARIPOSA-2 Trials daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/davutamig-promise-in-targeting-met-alterations-esmo-2024 2024-09-14T16:11:59.625Z https://assets.delveinsight.com/case-studies/1726330261936-davutamig-promise-in-targeting-met-alterations-esmo-2024.png Early Results on Davutamig in MET-Altered Advanced NSCLC Presented at ESMO 2024 daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/belrestotug-dostarlimab-galaxies-lung-201-phase-ii-study-esmo-2024 2024-09-14T13:40:03.859Z https://assets.delveinsight.com/case-studies/1726321131861-belrestotug-dostarlimab-galaxies-lung-201-phase-ii-study-esmo-2024.png Belrestotug-Dostarlimab Doublet Shows Strong Promise in PD-L1 High NSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/azd8205-phase-i-iia-trial-result-esmo-2024 2024-09-14T13:32:43.938Z https://assets.delveinsight.com/case-studies/1726320638470-azd8205-phase-i-iia-trial-result-esmo-2024.png Initial results from a first-in-human study of the B7-H4-directed ADC, AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/nkt2152-phase-1-2-study-esmo-2024 2024-09-14T13:27:36.345Z https://assets.delveinsight.com/case-studies/1726320397204-nkt2152-phase-12-study-esmo-2024.png NKT2152, a novel oral HIF-2α inhibitor, in participants with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a Phase 1/2 study daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/bl-bBo1d1-phase-i-data 2024-09-14T13:20:32.681Z https://assets.delveinsight.com/case-studies/1726319975516-bl-bBo1d1-phase-i-data.png SystImmune’s dual targeting EGFR and HER3 ADC, demonstrated promising efficacy in Urothelial Carcinoma daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/fotivda-opdivo-combo-phase-iii-tinivo-2-study 2024-09-14T13:15:45.434Z https://assets.delveinsight.com/case-studies/1726319729224-fotivda-opdivo-combo-phase-iii-tinivo-2-study.png Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor (ICI) – Results of the Phase III TiNivo-2 Study daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/breast-cancer-esmo-2024-preview 2024-09-13T04:35:56.150Z https://assets.delveinsight.com/case-studies/1726202153364-breast-cancer-esmo-2024-preview.png Breast Cancer Breakthroughs at ESMO 2024 daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/gastrointestinal-cancers-esmo-2024-preview 2024-09-13T04:29:02.561Z https://assets.delveinsight.com/case-studies/1726201480114-gastrointestinal-cancers-esmo-2024-preview.png ESMO 2024: Unveiling the Next Frontier in Gastrointestinal Cancers—Breakthroughs in Colorectal, Gastric, Pancreatic, and Neuroendocrine Tumors daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/ovarian-endometrial-and-cervical-cancer-esmo-2024-preview 2024-09-13T04:20:38.343Z https://assets.delveinsight.com/case-studies/1726200873178-ovarian-endometrial-and-cervical-cancer-esmo-2024-preview.png ESMO 2024 Preview- Key Developments in Ovarian, Endometrial, and Cervical Cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/nsclc-at-esmo-2024 2024-09-13T04:11:00.667Z https://assets.delveinsight.com/case-studies/1726200449139-nsclc-at-esmo-2024.png A brief preview of upcoming NSCLC updates at ESMO 2024. daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/esmo-2024-genitourinary-cancer-glimpse 2024-09-10T12:26:50.404Z https://assets.delveinsight.com/case-studies/1725971050176-esmo-2024-genitourinary-cancer-glimpse.png ESMO 2024 Glimpse: Advancements and Anticipations in Genitourinary (GU) Cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/fralpha-targeting-adcs-esmo-2024-preview 2024-09-10T12:14:15.527Z https://assets.delveinsight.com/case-studies/1725970395014-frα-targeting-adcs-esmo-2024-preview.png The Rise of FRα-Targeting ADCs in Ovarian and Endometrial Cancers daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/her2-targeting-adcs-esmo-2024-preview 2024-09-10T11:54:06.910Z https://assets.delveinsight.com/case-studies/1725969101502-her2-targeting-adcs-esmo-2024-preview.png ENHERTU in HER2 ultra-low and new ADCs beyond ENHERTU? daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/next-gen-adcs-esmo-2024-preview 2024-09-10T11:47:54.375Z https://assets.delveinsight.com/case-studies/1725968569481-next-gen-adcs-esmo-2024-preview.png Next-Gen ADCs at ESMO 2024: Exploring Novel Targets beyond TROP-2, HER2-, NECTIN-4, and FRα daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/trop-2-adc-showdown-esmo-2024-preview 2024-09-10T11:36:31.120Z https://assets.delveinsight.com/case-studies/1725967984134-trop-2-adc-showdown-esmo-2024-preview.png ESMO 2024 Sparks a TROP-2 ADC Showdown: New Contenders likely to Challenge TRODELVY’s Dominance daily 0.8 https://www.delveinsight.com/esmo-conference-2024/article/esmo-2024-preview-content 2024-09-10T11:26:55.467Z https://assets.delveinsight.com/case-studies/1725967407071-esmo-2024-preview-content.png Unveiling the Next Wave of Game-Changing New Classes daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/rinvoq-insights-in-eular-2024 2024-07-02T06:04:33.708Z https://assets.delveinsight.com/case-studies/1719900230010-rinvoq-insights-in-eular-2024.png Insights from EULAR 2024: RINVOQ (upadacitinib) in Psoriatic Arthritis and Axial Spondyloarthritis daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/sjogrens-syndrome-treatment-in-eular-2024 2024-06-28T13:00:28.344Z https://assets.delveinsight.com/case-studies/1719579620686-sjogrens-syndrome-treatment-in-eular-2024.png Advancements and Challenges in Sjogren’s Syndrome Treatment: EULAR 2024 Insights daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/mepolizumab-in-eosinophilic-granulomatosis-with-polyangiitis 2024-06-28T12:56:27.832Z https://assets.delveinsight.com/case-studies/1719579378058-mepolizumab-in-eosinophilic-granulomatosis-with-polyangiitis.png Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis: Insights from Japanese Cohort and Multicenter Propensity Score Matching Analysis daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/tak-279-phase-iib-trial 2024-06-28T12:52:56.073Z https://assets.delveinsight.com/case-studies/1719579164654-tak-279-phase-iib-trial.png TAK-279 Demonstrates Efficacy and Safety in 12-Week Phase IIb Trial for Psoriatic Arthritis daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/izokibep-phase-iib-iii-study 2024-06-28T12:48:11.682Z https://assets.delveinsight.com/case-studies/1719578882816-izokibep-phase-iib-iii-study.png After Setback in Hidradenitis Suppurativa, Izokibep Shines in Psoriatic Arthritis: Promising 16-Week Results from Phase IIb/III Study daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/risankizumab-keepsake-1-and-keepsake-2-trials 2024-06-28T12:38:57.139Z https://assets.delveinsight.com/case-studies/1719578251574-risankizumab-keepsake-1-and-keepsake-2-trials.png Effect of Risankizumab on Enthesitis and Dactylitis in Psoriatic Arthritis: A Comprehensive Analysis of Location and Baseline Severity from KEEPsAKE 1 and KEEPsAKE 2 Trials daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/sonelokimab-phase-ii-argo-trial 2024-06-28T12:33:53.576Z https://assets.delveinsight.com/case-studies/1719578022146-sonelokimab-phase-ii-argo-trial.png Efficacy and Safety of Sonelokimab in Active Psoriatic Arthritis: Phase II ARGO Trial Results daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/guselkumab-phase-iii-trials 2024-06-28T12:30:22.866Z https://assets.delveinsight.com/case-studies/1719577815606-guselkumab-phase-iii-trials.png Effectiveness and Durability of TREMFYA in Psoriatic Arthritis: Pain Relief and Functional Assessment Findings from Phase III Trials daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/bimzelx-in-psoriatic-arthritis-and-axial-spondyloarthritis 2024-06-28T12:25:49.248Z https://assets.delveinsight.com/case-studies/1719577540542-bimzelx-in-psoriatic-arthritis-and-axial-spondyloarthritis.png Insights from EULAR 2024: BIMZELX (bimekizumab) Maintains Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/ppv-06-phase-i 2024-06-28T12:11:31.821Z https://assets.delveinsight.com/case-studies/1719576683966-ppv-06-phase-i.png Post EULAR 2024 Osteoarthritis Insights daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/lupus-nephritis-analysis-eular-2024 2024-06-27T09:44:31.046Z https://assets.delveinsight.com/case-studies/1719481439615-lupus-nephritis-analysis-eular-2024.png Post EULAR 2024 Lupus Nephritis Insights daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/afimetoran-in-cutaneous-lupus-erythematosus 2024-06-27T09:40:43.815Z https://assets.delveinsight.com/case-studies/1719481225949-afimetoran-in-cutaneous-lupus-erythematosus.png Afimetoran Shows Significant Promise in Treating CLE: Clinical Trial Results Highlight Safety and Efficacy daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/anifrolumab-tulip-1-2-and-lte-trials 2024-06-27T09:26:55.539Z https://assets.delveinsight.com/case-studies/1719480408138-anifrolumab-tulip-1-2-and-lte-trials.png Anifrolumab's Impact on Hematological Parameters and Treatment Response in SLE: Insights from TULIP-1/-2 and LTE Trials daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/ytb323-phase-i-ii-findings 2024-06-27T09:22:28.468Z https://assets.delveinsight.com/case-studies/1719480139402-ytb323-phase-i-ii-findings.png YTB323 CAR-T Cell Therapy in Severe Refractory SLE: Safety, PK/PD, and Early Efficacy Insights from Phase I/II Study daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/kpg-818-phase-iia-study 2024-06-27T09:19:34.053Z https://assets.delveinsight.com/case-studies/1719479966443-kpg-818-phase-iia-study.png Phase IIa Study in Systemic Lupus Erythematosus Reveals Promising Safety and Efficacy of KPG-818 daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/e6742-phase-i-ii-data 2024-06-27T09:16:15.501Z https://assets.delveinsight.com/case-studies/1719479766530-e6742-phase-i-ii-data.png E6742 Phase I/II Data Highlights Promising Safety and Tolerability Profile in Systemic Lupus Erythematosus daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/ds-7011a-phase-ib-study 2024-06-27T09:12:36.520Z https://assets.delveinsight.com/case-studies/1719479542148-ds-7011a-phase-ib-study.png Pharmacokinetic and Pharmacodynamic Profile of DS-7011a: Consistent Efficacy in SLE Treatment Across Diverse Populations daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/ianalumab-phase-ii-results 2024-06-27T09:08:12.018Z https://assets.delveinsight.com/case-studies/1719479284410-ianalumab-phase-ii-results.png Ianalumab Demonstrates Significant Efficacy in Reducing B Cells and Autoantibodies in Systemic Lupus Erythematosus Patients daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/belimumab-phase-iii-trial 2024-06-27T08:59:07.109Z https://assets.delveinsight.com/case-studies/1719478735028-belimumab-phase-iii-trial.png Belimumab in Systemic Lupus Erythematosus: Improving Mucocutaneous Manifestations and Preventing Flares daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/deucravacitinib-phase-ii-paisley-study 2024-06-27T08:55:41.197Z https://assets.delveinsight.com/case-studies/1719478523973-deucravacitinib-phase-ii-paisley-study.png Comprehensive Efficacy of Deucravacitinib in Active Systemic Lupus Erythematosus: Key Endpoint Summaries daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/rheumatoid-arthritis-drugs-in-eular-2024 2024-06-26T11:57:32.350Z https://assets.delveinsight.com/case-studies/1719403049569-rheumatoid-arthritis-drugs-in-eular-2024.png Top Abstracts on New Rheumatoid Arthritis Drugs Presented at EULAR 2024 daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/vdj-001-phase-ii-study 2024-06-26T11:49:05.282Z https://assets.delveinsight.com/case-studies/1719402523175-vdj-001-phase-ii-study.png VDJ-001: A Promising Humanized Monoclonal Antibody with Enhanced IL-6R Interaction and Efficacy in Rheumatoid Arthritis Treatment daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/rituximab-abatacept-study 2024-06-26T11:46:15.901Z https://assets.delveinsight.com/case-studies/1719402354184-rituximab-abatacept-study.png Challenges in Halting ACPA and Restoring Immune Tolerance in Rheumatoid Arthritis: Insights from a Sequential Rituximab/Abatacept Study daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/olokizumab-phase-iii-trials 2024-06-26T11:42:03.634Z https://assets.delveinsight.com/case-studies/1719402106819-olokizumab-phase-iii-trials.png Transitioning to Olokizumab in Rheumatoid Arthritis: Efficacy, Safety, and Clinical Outcomes Over 12 Months daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/abiprubart-phase-ii-ra-study 2024-06-26T11:39:21.177Z https://assets.delveinsight.com/case-studies/1719401958676-abiprubart-phase-ii-ra-study.png Kiniksa’s Abiprubart Showed Significant Reduction in DAS28-CRP in Refractory Rheumatoid Arthritis daily 0.8 https://www.delveinsight.com/eular-conference/eular-2024/azd1163-phase-i-study 2024-06-26T11:24:07.763Z https://assets.delveinsight.com/case-studies/1719401026576-azd1163-phase-i-study.png AstraZeneca’s first-in-class Bispecific Antibody targeting PADs for the treatment of Rheumatoid Arthritis daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/mb-106-phase-i-ii-clinical-trial 2024-06-24T12:38:42.672Z https://assets.delveinsight.com/case-studies/1719232693799-mb-106-phase-i-ii-clinical-trial.png High Efficacy and Favorable Safety Of CD20-Targeted CAR-T Therapy for BTK Inhibitor refractory WM/LPL daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/rp-l301-phase-i-trial 2024-06-24T12:35:23.067Z https://assets.delveinsight.com/case-studies/1719232508728-rp-l301-phase-i-trial.png Rocket Pharmaceuticals’s RP-L301 Pioneers Hope for Severe Pyruvate Kinase Deficiency Treatment: Encouraging Interim Results from a Global Phase I Study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/calquence-phase-iii-echo-trial 2024-06-24T12:22:57.381Z https://assets.delveinsight.com/case-studies/1719231767294-calquence-phase-iii-echo-trial.png CALQUENCE plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the Phase III, double-blind, placebo-controlled ECHO trial daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/linvoseltamab-phase-i-ii-linker-mm1-trial 2024-06-24T12:19:21.730Z https://assets.delveinsight.com/case-studies/1719231507830-linvoseltamab-phase-i-ii-linker-mm1-trial.png Linvoseltamab in the LINKER-MM1 study showed depth and durability of response at 14-month median follow-up daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/cevostamab-phase-i-ii-camma-2 2024-06-24T12:13:40.666Z https://assets.delveinsight.com/case-studies/1719231209119-cevostamab-phase-i-ii-camma-2.png Cevostamab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: Initial results from the Phase I/II CAMMA 2 study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/blenrep-combo-in-dreamm-7-study 2024-06-24T11:56:33.969Z https://assets.delveinsight.com/case-studies/1719230181574-blenrep-combo-in-dreamm-7-study.png Belamaf’s DREAMM-7 Triumphs: BVd Outshines DVd in Enhancing PFS and Response Depth for Relapsed/Refractory Multiple Myeloma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/icp-248-phase-i-results 2024-06-20T13:31:56.295Z https://assets.delveinsight.com/case-studies/1718890299991-icp-248-phase-i-results.png Preliminary safety and efficacy data from patients with relapsed/refractory B-cell malignancies treated with ICP-248, a novel BCL2 inhibitor daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/orelabrutinib-phase-ii-study 2024-06-20T13:27:42.024Z https://assets.delveinsight.com/case-studies/1718890037896-orelabrutinib-phase-ii-study.png InnoCare’s Orelabrutinib Represents a Promising Solution for BTKi-Intolerant iNHL Patients with Enhanced Safety Profile daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/bi-1206-phase-i-iia-clinical-trial 2024-06-20T13:18:57.473Z https://assets.delveinsight.com/case-studies/1718889527479-bi-1206-phase-i-iia-clinical-trial.png BI-1206 showed Impressive Early High Response Rates and Enhanced Safety Signals daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/boven-combination-therapy 2024-06-20T13:13:51.549Z https://assets.delveinsight.com/case-studies/1718889227699-boven-combination-therapy.png Preliminary Safety and Efficacy of BOVen combo (Zanubrutinib, Obinutuzumab, and Venetoclax) in Treatment-Naive, TP53-Mutant MCL patients daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/golcadomide-phase-i-ii-study 2024-06-20T13:09:53.150Z https://assets.delveinsight.com/case-studies/1718888980967-golcadomide-phase-i-ii-study.png BMS’s Golcadomide with its Dual Mechanism of Action, showing enhanced efficacy in Follicular Lymphoma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/epcoritamab-epcore-nhl-1 2024-06-20T13:06:39.447Z https://assets.delveinsight.com/case-studies/1718888786501-epcoritamab-epcore-nhl-1.png Epcoritamab Induces Early Deep Responses and Manageable Safety in Outpatient Treatment in Relapsed or Refractory Follicular Lymphoma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/c-car039-updated-results 2024-06-19T11:48:56.007Z https://assets.delveinsight.com/case-studies/1718797731750-c-car039-updated-results.png C-CAR039 is a promising next generation CAR-T therapy for patients with R/R B-NHL shows deep and durable clinical benefits in long term follow up daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/brl-201-phase-i-ii-trial 2024-06-19T11:42:58.415Z https://assets.delveinsight.com/case-studies/1718797375335-brl-201-phase-i-ii-trial.png BRL-201, A Novel CRISPR-based non-viral pd-1 locus specific integrated anti-cd19 CART addressing the limitations of conventional methods daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/sar579-phase-i-ii-study 2024-06-19T11:39:54.833Z https://assets.delveinsight.com/case-studies/1718797192099-sar579-phase-i-ii-study.png The Potential of NK-Cell Therapies—SAR’579, the leading candidate in the ANKET platform, continues to show clinical efficacy. daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/ela026-iin-shlh-patients 2024-06-19T11:30:54.738Z https://assets.delveinsight.com/case-studies/1718796650862-ela026-iin-shlh-patients.png Early treatment with ELA026 resulted in 100% ORR and improved survival in Secondary HLH—New Clinical Findings from Phase Ib study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/atra-plus-ato-apollo-trial 2024-06-19T11:26:24.502Z https://assets.delveinsight.com/case-studies/1718796348652-atra-plus-ato-apollo-trial.png First Results from APOLLO Trial Show Superior Efficacy and Safety of New ATRA and ATO Combination daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/mitapivat-phase-iii-energize-study 2024-06-19T11:11:51.024Z https://assets.delveinsight.com/case-studies/1718795493422-mitapivat-phase-iii-energize-study.png Agios Pharmaceuticals' Mitapivat Meets Primary Endpoint in Phase III ENERGIZE Study; Company Plans Approval Filing by Late 2024 daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/gleevec-in-phase-iii-asc4first-trial 2024-06-19T11:08:15.509Z https://assets.delveinsight.com/case-studies/1718795245573-gleevec-in-phase-iii-asc4first-trial.png Novartis’ SCEMBLIX outperforms GLEEVEC in Phase III ASC4FIRST Trial daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/columvi-phase-iii-starglo-study 2024-06-19T11:05:08.147Z https://assets.delveinsight.com/case-studies/1718795057008-columvi-phase-iii-starglo-study.png Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) for relapsed/refractory DLBCL: Results of a global randomized Phase III trial (STARGLO) daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/oms906-phase-ii-finding 2024-06-19T10:56:38.075Z https://assets.delveinsight.com/case-studies/1718794585371-oms906-phase-ii-finding.png Omeros’s MASP-3 inhibitor improved hematologic parameters in PNH patients with suboptimal response to ravulizumab treatment: Phase II dose finding study interim results daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/kp104-phase-ii-study 2024-06-19T10:52:08.224Z https://assets.delveinsight.com/case-studies/1718794307446-kp104-phase-ii-study.png KP104, A bi-functional C5 Mab-Factor H fusion protein, effectively controls intravascular and extravascular hemolysis in complement inhibitor-naïve PNH patients: Long-Term results from a Phase II study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/crovalimab-phase-iii-commodore-1-and-2-studies 2024-06-18T11:40:31.328Z https://assets.delveinsight.com/case-studies/1718710827475-crovalimab-phase-iii-commodore-1-and-2-studies.png Treatment satisfaction and preference in patients with PNH treated with crovalimab, eculizumab, or ravulizumab: Findings of Phase III COMMODORE 1 AND COMMODORE 2 trials daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/efficacy-and-safety-of-pozelimab-plus-cemdisiran 2024-06-18T11:33:11.221Z https://assets.delveinsight.com/case-studies/1718710361570-efficacy-and-safety-of-pozelimab-plus-cemdisiran.png Efficacy and safety of pozelimab plus cemdisiran in patients with paroxysmal nocturnal haemoglobinuria who are naïve to complement inhibition daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/abbv-383-phase-iii-trial 2024-06-18T11:20:18.531Z https://assets.delveinsight.com/case-studies/1718709615570-abbv-383-phase-iii-trial.png ABBV-383, a BCMA Bispecific Antibody: Optimizing Treatment Convenience with 60mg Q4W Dosing, paving the way for Phase III Trial daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/ide-cel-karmma-2-cohort-2b 2024-06-18T11:15:40.031Z https://assets.delveinsight.com/case-studies/1718709327029-ide-cel-karmma-2-cohort-2b.png In KarMMa-2 Cohort 2B, Ide-cel Shows Sustained Deep Responses in High-Risk Multiple Myeloma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/blenrep-dreamm-8-trial 2024-06-17T15:28:18.536Z https://assets.delveinsight.com/case-studies/1718638080190-blenrep-dreamm-8-trial.png Combination of GSK’s BLENREP and BMS' POMALYST with dexamethasone "significantly" outperformed standard-of-care daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/marstacimab-lte-study 2024-06-17T15:25:16.868Z https://assets.delveinsight.com/case-studies/1718637909561-marstacimab-lte-study.png Marstacimab: A Potential First Flat-Dose Treatment for Hemophilia A or B in the US and EU, Demonstrating Sustained Efficacy daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/isatuximab-phase-iii-gmmg-hd7-trial 2024-06-17T15:22:26.980Z https://assets.delveinsight.com/case-studies/1718637737147-isatuximab-phase-iii-gmmg-hd7-trial.png High MRD Negativity Rates observed With Isa-RVd combination in Transplant-Eligible, Newly Diagnosed Myeloma: Insights from Phase III GMMG-HD7 Trial daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/darzalex-vrd-combo-perseus-study 2024-06-17T15:19:44.659Z https://assets.delveinsight.com/case-studies/1718637581948-darzalex-vrd-combo-perseus-study.png DARZALEX-VRd combo showed high MRD negativity rates compared to VRd for after 3 years (65% vs. 30%) daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/cd19-car-t-therapy-phase-i-castle-study 2024-06-17T15:16:37.683Z https://assets.delveinsight.com/case-studies/1718637395025-cd19-car-t-therapy-phase-i-castle-study.png Interim analysis of the Castle Study (Phase I safety run in cohort) of the monocentric “Cd19.Car-T Cells” In Systemic B Cell-Mediated Autoimmune Disease daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/cilta-cel-cartitude-2-study 2024-06-17T15:13:02.451Z https://assets.delveinsight.com/case-studies/1718637178371-cilta-cel-cartitude-2-study.png With 18-month DOR, PFS and OS rates of over 90%, single infusion of CARVYKTI with or without REVLIMID maintenance demonstrated deep and durable responses daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/sanofi-phase-3-bortezomib-lenalidomide-dexamethasone-Isa-VRd-study-results 2024-06-16T12:24:05.466Z https://assets.delveinsight.com/case-studies/1718540523954-sanofi-phase-3-bortezomib-lenalidomide-dexamethasone-Isa-VRd-study-results.png IMROZ Trial Breakthrough: Isatuximab-VRd Slashes Progression Risk by 40% and Sets New Standard for Non-Transplant Multiple Myeloma Treatment daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/abbvie-phase-3-navitoclax-ruxolitinib-study-results 2024-06-16T12:13:33.500Z https://assets.delveinsight.com/case-studies/1718539927280-abbvie-phase-3-navitoclax-ruxolitinib-study-results.png Efficacy and safety of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis in the Phase III Randomized, double-blind TRANSFORM-1 study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/keros-therapeutics-phase-2-elritercept-study-results 2024-06-16T12:04:31.079Z https://assets.delveinsight.com/case-studies/1718539311776-keros-therapeutics-phase-2-elritercept-study-results.png Elritercept (KER-050) demonstrated potential to treat myelofibrosis and mitigate ruxolitinib-associated cytopenias in the Phase II restore trial daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/morphosys-promising-results-pelabresib-ruxolitinib 2024-06-16T11:47:08.942Z https://assets.delveinsight.com/case-studies/1718538317142-morphosys-promising-results-pelabresib-ruxolitinib.png In JAK inhibitor–naive patients with myelofibrosis, addition of pelabresib and ruxolitinib led to a significant and durable reduction in splenomegaly, among other improvements daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/editas-medicines-phase-I-II-III-ascas12a-study-results 2024-06-16T11:33:18.651Z https://assets.delveinsight.com/case-studies/1718537451760-editas-medicines-phase-I-II-III-ascas12a-study-results.png Reni-cel, the first ASCAS12A gene-edited cell therapy, led to hemoglobin normalization and increased fetal hemoglobin in severe sickle cell disease patients in an interim analysis of the Phase I/II/III RUBY trial daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/astraZeneca-promising-preliminary-results-gc012f 2024-06-16T11:19:10.817Z https://assets.delveinsight.com/case-studies/1718536592278-astraZeneca-promising-preliminary-results-gc012f.png AstraZeneca sees promise for GC012F as First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/promising-results-of-fucaso-equecabtagene-autoleucel 2024-06-16T11:05:13.463Z https://assets.delveinsight.com/case-studies/1718535689878-promising-results-of-fucaso-equecabtagene-autoleucel.png IASO Bio presented new data of Eque-Cel, a Novel Fully Human BCMA-Targeting CAR-T Therapy in Patients with High-Risk Newly Diagnosed Multiple Myeloma. daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/phase-ib-trial-results-of-disc-0974 2024-06-16T10:25:55.544Z https://assets.delveinsight.com/case-studies/1718533112346-phase-ib-trial-results-of-disc-0974.png A Phase Ib trial of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/incytes-phase-1-incb057643-study-results 2024-06-16T10:25:24.273Z https://assets.delveinsight.com/case-studies/1718533372545-incytes-phase-1-incb057643-study-results.png Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A Phase I study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/bristol-myers-squibb-phase-1-bms-986393-study-results 2024-06-16T10:11:47.534Z https://assets.delveinsight.com/case-studies/1718532642088-bristol-myers-squibb-phase-1-bms-986393-study results.png Single Infusion of BMS-986393, potential first-in-class GPRC5D-targeted CAR T-cell therapy Shows Safety and High Response Rates in RRMM Patients with 1–3 Prior Regimens: Promising First Results from Phase I Study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/carsgen-therapeutics-study-results-ct071 2024-06-16T09:59:09.996Z https://assets.delveinsight.com/case-studies/1718531863201-carsgen-therapeutics-study-results-ct071.png CARsgen Therapeutics Presented Promising Results of CT071 from a First-in-Human, Single-Arm, Open-Label Exploratory Clinical Trial in Patients with Relapsed/Refractory Multiple Myeloma. daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/promising-results-of-mezigdomide-tazemetostat-dexamethasone 2024-06-16T09:46:53.082Z https://assets.delveinsight.com/case-studies/1718531642667-promising-results-of-mezigdomide-tazemetostat-dexamethasone.png Bristol Myers Squibb Presented Promising Preliminary Results of a Potential Trio, Mezigdomide, Tazemetostat, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma. daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/wugen-phase-ii-wu-cart-007-study-results 2024-06-16T09:05:09.562Z https://assets.delveinsight.com/case-studies/1718531619137-wugen-phase-ii-wu-cart-007-study-results.png Wugen presented data from the Phase II portion of WU-CART-007 in patients with Relapsed/Refractory T-cell leukemia and Lymphoma. daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/epcoritamab-pola-r-chp-dlbcl 2024-06-16T08:30:53.337Z https://assets.delveinsight.com/case-studies/1718526430249-epcoritamab-and-pola-r-chp-in-newly-diagnosed-dlbcl.png High Overall and Complete Response Rates with Epcoritamab and Pola-R-CHP in Newly Diagnosed DLBCL: A Promising Safety Profile (#S239) daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/janssen-bleximenib-with-venetoclax-azacitidine 2024-06-16T08:12:15.100Z https://assets.delveinsight.com/case-studies/1718525815209-beximenib-with-venetoclax-azacitidine.png Evaluating the Safety and Preliminary Efficacy of Janssen’s bleximenib combined with venetoclax and azacitidine in adult patients with relapsed/refractory AML featuring KMT2A or NPM1 alterations (#S133). daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/pociredir-phase-ib-study-pioneer 2024-06-14T18:57:37.343Z https://assets.delveinsight.com/case-studies/1718391444680-pociredir-phase-ib-study-pioneer.png Interim results of a Phase Ib study (PIONEER) of an oral HBF inducer, pociredir, in sickle cell disease daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/epkinly-phase-ib-ii-epcore-nhl-5-study 2024-06-14T17:32:43.633Z https://assets.delveinsight.com/case-studies/1718386360981-epkinly-phase-ib-ii-epcore-nhl-5-study.png High Overall and Complete Response Rates with Epcoritamab and Pola-R-CHP in Newly Diagnosed DLBCL: A Promising Safety Profile daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/bleximenib-phase-ib-findings 2024-06-14T17:28:50.352Z https://assets.delveinsight.com/case-studies/1718386112348-bleximenib-phase-ib-findings.png Evaluating the Safety and Preliminary Efficacy of Janssen’s bleximenib combined with venetoclax and azacitidine in adult patients with relapsed/refractory AML featuring KMT2A or NPM1 alterations daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/osivelotor-phase-ii-iii-trial-results 2024-06-14T17:25:58.266Z https://assets.delveinsight.com/case-studies/1718385934852-osivelotor-phase-ii-iii-trial-results.png Preliminary results from a multicenter Phase II/III study of next-generation HBS polymerization inhibitor osivelotor (GBT021601) for the treatment of patients with sickle cell disease daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/wu-cart-007-phase-ii-result 2024-06-14T17:22:30.313Z https://assets.delveinsight.com/case-studies/1718385736998-wu-cart-007-phase-ii-result.png Wugen presented data from the Phase II portion of WU-CART-007 in patients with Relapsed/Refractory T-cell leukemia and Lymphoma. daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/obecabtagene-autoleucel-felix-study-result 2024-06-14T17:19:09.879Z https://assets.delveinsight.com/case-studies/1718385507130-obecabtagene-autoleucel-felix-study-result.png Autolus’s Obecabtagene Autoleucel in Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia: Impact of CAR-T Cell Persistence and Stem Cell Transplantation on Survival in the FELIX Study daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/hematologic-cancer-preview-content-eha-2024 2024-06-13T12:33:28.776Z https://assets.delveinsight.com/case-studies/1718282005184-hematologic-cancer-preview-content-eha-2024.png Decoding the Future of Hematologic Cancer: A First Look at Game-Changing Research from EHA 2024's High Priority Sessions daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/myelofibrosis-preview-content-eha-2024 2024-06-13T12:29:24.933Z https://assets.delveinsight.com/case-studies/1718281762540-myelofibrosis-preview-content-eha-2024.png "Focus on Myelofibrosis: Key Highlights Ahead of the EHA 2024 Congress" daily 0.8 https://www.delveinsight.com/eha-conference/eha-2024/multiple-myeloma-top-abstracts-eha-2024 2024-06-13T12:22:12.957Z https://assets.delveinsight.com/case-studies/1718281328956-multiple-myeloma-top-abstracts-eha-2024.png Decoding the Future of Multiple Myeloma: A Sneak Peek into the Top Abstracts of Multiple Myeloma at 2024 European Hematology Association (EHA) Congress daily 0.8 https://www.delveinsight.com/asco-conference/article/dy-wise-asco-2024-summary 2024-06-13T12:05:22.393Z https://assets.delveinsight.com/case-studies/1718280319551-dy-wise-asco-2024-summary.png ASCO 2024 Quick Recap: Day-wise Recap Summary daily 0.8 https://www.delveinsight.com/asco-conference/article/bi-specific-antibodies-asco-2024 2024-06-13T11:59:51.059Z https://assets.delveinsight.com/case-studies/1718279986534-bi-specific-antibodies-asco-2024.png ASCO 2024 Takeways: Bi-specific Antibodies daily 0.8 https://www.delveinsight.com/asco-conference/article/asco-2024-top-gainers-and-losers 2024-06-13T04:28:23.583Z https://assets.delveinsight.com/case-studies/1718252899722-asco-2024-top-gainers-and-losers.png Top Gainers and Losers at ASCO 2024: Catching up with the Trend! daily 0.8 https://www.delveinsight.com/asco-conference/article/bay2927088-soho-01-phase-i-ii-study 2024-06-07T05:51:51.214Z https://assets.delveinsight.com/case-studies/1717739508770-bay2927088-soho-01-phase-i-ii-study.png Advancements in HER2-targeted therapies, exemplified by BAY 2927088, signify a pivotal shift in treating NSCLC patients with HER2 mutations, offering hope for better outcomes daily 0.8 https://www.delveinsight.com/asco-conference/article/lacutamab-tellomak-phase-ii-results 2024-06-07T05:48:30.427Z https://assets.delveinsight.com/case-studies/1717739307756-lacutamab-tellomak-phase-ii-results.png Innate Pharma's Lacutamab showed promise in mycosis fungoides based on positive TELLOMAK Phase II results daily 0.8 https://www.delveinsight.com/asco-conference/article/adcetris-phase-ii-sgn35-032-study-results 2024-06-07T05:45:03.156Z https://assets.delveinsight.com/case-studies/1717739098762-adcetris-phase-ii-sgn35-032-study-results.png Seagen’s CD30-directed ADC, brentuximab vedotin showed promising results from SGN35-032 study in PTCL patients with less than 10% CD30 expression daily 0.8 https://www.delveinsight.com/asco-conference/article/tq-B3525-phase-i-trial 2024-06-07T05:42:03.073Z https://assets.delveinsight.com/case-studies/1717738888523-tq-B3525-phase-i-trial.png TQ-B3525 emerges as a promising treatment for refractory/relapsed follicular lymphoma daily 0.8 https://www.delveinsight.com/asco-conference/article/caribou-biosciences-car-t-therapy-cb-010 2024-06-07T05:34:20.197Z https://assets.delveinsight.com/case-studies/1717738410810-caribou-biosciences-car-t-therapy-cb-010.png CB-010’s rapid treatment timeline makes it stand out for aggressive r/r B-NHL. Stay updated on CB-010's progress through Health Horizon daily 0.8 https://www.delveinsight.com/asco-conference/article/foresight-clarity-mrd-detection 2024-06-06T12:26:04.728Z https://assets.delveinsight.com/case-studies/1717676761782-foresight-clarity-mrd-detection.png Foresight and its partners assessed the capability of Foresight CLARITY to identify MRD-positive patients following surgery and predict survival benefits from adjuvant therapy daily 0.8 https://www.delveinsight.com/asco-conference/article/mercy-halo-ovarian-cancer-screening-test 2024-06-06T12:19:54.354Z https://assets.delveinsight.com/case-studies/1717676391486-mercy-halo-ovarian-cancer-screening-test.png Mercy BioAnalytics' Extracellular Vesicles (EV) blood test appears to be a promising candidate for ovarian cancer screening daily 0.8 https://www.delveinsight.com/asco-conference/article/prevecol-test-for-colorectal-cancer-screening 2024-06-06T12:16:55.726Z https://assets.delveinsight.com/case-studies/1717676212989-prevecol-test-for-colorectal-cancer-screening.png PreveCol has demonstrated to have the potential to offer a great benefit to patients with colorectal cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/billiontoone-northstar-select 2024-06-06T12:13:14.755Z https://assets.delveinsight.com/case-studies/1717675954410-billiontoone-northstar-select.png BillionToOne revealed the outcomes from a head-to-head comparison of Northstar Select against on-market liquid biopsy daily 0.8 https://www.delveinsight.com/asco-conference/article/personalis-next-personal-test 2024-06-06T12:09:24.949Z https://assets.delveinsight.com/case-studies/1717675722366-personalis-next-personal-test.png Personalis highlights the ultra-sensitive MRD performance of NeXT Personal in detecting early-stage breast cancer recurrence daily 0.8 https://www.delveinsight.com/asco-conference/article/arv-766-phase-i-ii-study 2024-06-06T04:11:42.711Z https://assets.delveinsight.com/case-studies/1717647093652-arv-766-phase-i-ii-study.png Addressing resistance in mCRPC. The Potential of ARV-766 as a novel targeted therapy daily 0.8 https://www.delveinsight.com/asco-conference/article/mced-screening-data 2024-06-05T12:24:36.249Z https://assets.delveinsight.com/case-studies/1717590265493-mced-screening-data.png Findings from Exact Sciences suggest that MCED screening could be effective in reducing Stage IV cancer incidence daily 0.8 https://www.delveinsight.com/asco-conference/article/foresight-clarity-in-early-stage-nsclc 2024-06-05T12:21:45.594Z https://assets.delveinsight.com/case-studies/1717590102909-foresight-clarity-in-early-stage-nsclc.png Foresight and its partners assessed the capability of Foresight CLARITY to identify MRD-positive patients following surgery and predict survival benefits from adjuvant therapy daily 0.8 https://www.delveinsight.com/asco-conference/article/petosemtamab-for-hnscc-treatment 2024-06-05T12:18:14.961Z https://assets.delveinsight.com/case-studies/1717589883286-petosemtamab-for-hnscc-treatment.png Merus' rapid oral presentation unveiled encouraging early clinical efficacy findings in first-line HNSCC patients daily 0.8 https://www.delveinsight.com/asco-conference/article/adela-mrd-assay-performance 2024-06-05T12:13:37.899Z https://assets.delveinsight.com/case-studies/1717589614190-adela-mrd-assay-performance.png Adela showcased the use of a tissue-agnostic genome-wide methylome enrichment platform that predicts and detects recurrence, providing relative quantification in all head and neck cancers daily 0.8 https://www.delveinsight.com/asco-conference/article/guardant-radiohead-study 2024-06-05T12:08:32.708Z https://assets.delveinsight.com/case-studies/1717589309106-guardant-radiohead-study.png Use of a tissue-free epigenomic ctDNA assay for quantification of tumor fraction and association with outcomes from RADIOHEAD real-world advanced pan-cancer cohort daily 0.8 https://www.delveinsight.com/asco-conference/article/labcorp-plasma-complete-test 2024-06-05T12:03:56.221Z https://assets.delveinsight.com/case-studies/1717589027978-labcorp-plasma-complete-test.png The Labcorp Plasma Complete test identifies actionable and clinically relevant variants in advanced and metastatic solid cancers across 521 genes daily 0.8 https://www.delveinsight.com/asco-conference/article/precede-biosciences-liquid-biopsy-assay 2024-06-04T14:51:40.030Z https://assets.delveinsight.com/case-studies/1717512696733-precede-biosciences-liquid-biopsy-assay.png Precede Biosciences unveiled new data at ASCO 2024, demonstrating the accurate detection of HER2 status across multiple cancers daily 0.8 https://www.delveinsight.com/asco-conference/article/eisais-bb-1701-in-her2-low-expressing-breast-cancer 2024-06-04T14:45:51.877Z https://assets.delveinsight.com/case-studies/1717512340180-eisais-bb-1701-in-her2-low-expressing-breast-cancer.png BB-1701 has shown promising antitumor activity in patients who received prior anti-HER2 ADCs daily 0.8 https://www.delveinsight.com/asco-conference/article/blu-222-phase-i-data 2024-06-04T12:56:44.594Z https://assets.delveinsight.com/case-studies/1717505800310-blu-222-phase-i-data.png Blueprint Medicines' findings on CDK2 inhibitor, BLU-222 in combination with Fulvestrant and KISQALI remain very early daily 0.8 https://www.delveinsight.com/asco-conference/article/sacituzumab-tirumotecan-phase-iii-data 2024-06-04T12:43:31.057Z https://assets.delveinsight.com/case-studies/1717505008484-sacituzumab-tirumotecan-phase-iii-data.png Sacituzumab tirumotecan shows consistent clinical benefits regardless of TROP2 expression, with improved PFS in high TROP2 patients daily 0.8 https://www.delveinsight.com/asco-conference/article/colofuture-and-eaarly-detect-studies 2024-06-04T12:16:38.057Z https://assets.delveinsight.com/case-studies/1717503326801-colofuture-and-eaarly-detect-studies.png Demonstrating the significance of its innovative screening approach, Mainz Biomed releases data combining results from the ColoFuture and eAArly DETECT studies daily 0.8 https://www.delveinsight.com/asco-conference/article/signatera-circulate-japan-study 2024-06-04T12:07:23.596Z https://assets.delveinsight.com/case-studies/1717502841138-signatera-circulate-japan-study.png Evaluating ctDNA-based MRD and actionable biomarkers in resectable CRC: CIRCULATE-Japan GALAXY study daily 0.8 https://www.delveinsight.com/asco-conference/article/grail-pathfinder-study 2024-06-04T12:02:14.238Z https://assets.delveinsight.com/case-studies/1717502530950-grail-pathfinder-study.png New Findings from GRAIL's PATHFINDER Study daily 0.8 https://www.delveinsight.com/asco-conference/article/nadunolimab-canfour-trial 2024-06-03T11:23:18.979Z https://assets.delveinsight.com/case-studies/1717413791858-nadunolimab-canfour-trial.png Cantargia Reveals New Data in ASCO 2024: Nadunolimab Mitigates Chemotherapy-Induced Neuropathy alongside Promising Antitumor Effects daily 0.8 https://www.delveinsight.com/asco-conference/article/fg-m108-phase-ib-study 2024-06-03T11:18:15.548Z https://assets.delveinsight.com/case-studies/1717413480282-fg-m108-phase-ib-study.png Preliminary Results of Phase Ib Study: FG-M108 Plus Nab-Paclitaxel and Gemcitabine as 1L Treatment for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/mk-0482-phase-i-data 2024-06-03T11:11:39.293Z https://assets.delveinsight.com/case-studies/1717413091002-mk-0482-phase-i-data.png Merck unveils Phase I data on novel ILT3-targeting antibody MK-0482 daily 0.8 https://www.delveinsight.com/asco-conference/article/mitazalimab-optimize-1-trial 2024-06-03T11:07:28.027Z https://assets.delveinsight.com/case-studies/1717412843998-mitazalimab-optimize-1-trial.png Alligator Bioscience set to initiate Phase III after meeting primary endpoint in OPTIMIZE-1 trial with mitazalimab in pancreatic cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/enhertu-destiny-pantumor02-data 2024-06-03T11:00:44.316Z https://assets.delveinsight.com/case-studies/1717412435275-enhertu-destiny-pantumor02-data.png AstraZeneca presented DESTINY-PanTumor02 Data following Accelerated Approval for Advanced HER2+ Solid Tumors daily 0.8 https://www.delveinsight.com/asco-conference/article/inavolisib-inavO120-trial 2024-06-02T16:59:46.975Z https://assets.delveinsight.com/case-studies/1717347552770-inavolisib-inavO120-trial.png Exciting news for Roche’s PIKCA-mutated, Inavolisib in HR+HER2 metastatic Breast Cancer patients as it yields better results than Novartis’ PIQRAY daily 0.8 https://www.delveinsight.com/asco-conference/article/enfortumab-vedotin-ev-202-study 2024-06-02T16:42:16.341Z https://assets.delveinsight.com/case-studies/1717346529103-enfortumab-vedotin-ev-202-study.png Enfortumab vedotin demonstrated strong antitumor activity in both TNBC and HR+/HER2- breast cancer, with manageable and consistent safety across cohorts daily 0.8 https://www.delveinsight.com/asco-conference/article/enhertu-phase-ib-ii-destiny-breast07-trial 2024-06-02T16:37:39.713Z https://assets.delveinsight.com/case-studies/1717343656420-enhertu-phase-ib-ii-destiny-breast07-trial.png Trastuzumab Deruxtecan's potent impact in untreated HER2+ metastatic breast cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/m9140-phase-i-results 2024-06-02T15:49:01.012Z https://assets.delveinsight.com/case-studies/1717343337565-m9140-phase-i-results.png With a preliminary median progression-free survival of 6.7 months, the Phase I results indicate that M9140 may present a promising new approach for treating mCRC daily 0.8 https://www.delveinsight.com/asco-conference/article/pf-07220060-phase-i-iia-trial 2024-06-02T15:43:31.868Z https://assets.delveinsight.com/case-studies/1717343007909-pf-07220060-phase-i-iia-trial.png Pfizer unveiled the promising journey of its CDK4-selective inhibitor, PF-07220060, through its first-in-Human Phase I/IIa trial daily 0.8 https://www.delveinsight.com/asco-conference/article/cue-102-phase-i-trial 2024-06-02T15:38:31.042Z https://assets.delveinsight.com/case-studies/1717342704758-cue-102-phase-i-trial.png Promising tolerability profile of CUE-102, along with preliminary evidence of its selective immune stimulation, paves the way for exciting future explorations daily 0.8 https://www.delveinsight.com/asco-conference/article/botensilimab-balstilimab-phase-ib-trial 2024-06-02T15:34:23.036Z https://assets.delveinsight.com/case-studies/1717342448730-botensilimab-balstilimab-phase-ib-trial.png Compelling results from the Phase Ib study support further investigation in the fully enrolled, randomized, global Phase II trial in MSS CRC and a planned global Phase III trial daily 0.8 https://www.delveinsight.com/asco-conference/article/ibi363-phase-i-clinical-data 2024-06-02T15:24:36.438Z https://assets.delveinsight.com/case-studies/1717341867957-ibi363-phase-i-clinical-data.png IBI363 shows acceptable tolerability and manageable safety profiles in patients with advanced CRC daily 0.8 https://www.delveinsight.com/asco-conference/article/polypepl1018-phase-ii-trial 2024-06-02T15:01:54.058Z https://assets.delveinsight.com/case-studies/1717340217508-polypepl1018-phase-ii-trial.png PolyPEPI1018 vaccine well-tolerated in late-stage microsatellite stable metastatic colorectal cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/com701-com902-pembrolizumab-in-mss-crc 2024-06-02T14:53:26.264Z https://assets.delveinsight.com/case-studies/1717339997452-com701-com902-pembrolizumab-in-mss-crc.png Data presented supports the antitumor activity of the combination of COM701 + COM902 + pembrolizumab in MSS-CRC specifically in patients with liver metastases daily 0.8 https://www.delveinsight.com/asco-conference/article/verzenio-phase-iii-cyclone-2-study 2024-06-02T14:26:34.099Z https://assets.delveinsight.com/case-studies/1717338390882-verzenio-phase-iii-cyclone-2-study.png Lilly’s CDK4/6 inhibitor, VERZENIO fails to meet the primary endpoint of improved radiographic progression-free survival in mCRPC patients daily 0.8 https://www.delveinsight.com/asco-conference/article/sunvozertinib-wu-kong1-study 2024-06-02T14:15:27.306Z https://assets.delveinsight.com/case-studies/1717337715870-sunvozertinib-wu-kong1-study.png Sunvozertinib achieves primary objective in WU-KONG1 study as potential NSCLC treatment for EGFR Exon20ins mutations daily 0.8 https://www.delveinsight.com/asco-conference/article/taletrectinib-phase-ii-trust-i-study 2024-06-02T13:58:26.837Z https://assets.delveinsight.com/case-studies/1717336702692-taletrectinib-phase-ii-trust-i-study.png Data from Pivotal Phase II TRUST-I study of taletrectinib, a ROS1 inhibitor: One of the largest trials to date among people with ROS1-positive NSCLC! daily 0.8 https://www.delveinsight.com/asco-conference/article/sigvotatug-vedotin-phase-i-data 2024-06-02T13:29:31.643Z https://assets.delveinsight.com/case-studies/1717334967646-sigvotatug-vedotin-phase-i-data.png Sigvotatug vedotin may present a promising new approach for treating NSCLC, with a confirmed ORR of 19.0% in NSCLC (all dose group) and 31% in taxane-naive non-Sq NSCLC group in an updated phase I results daily 0.8 https://www.delveinsight.com/asco-conference/article/verzenio-phase-iii-postmonarch-trial 2024-06-02T13:11:26.267Z https://assets.delveinsight.com/case-studies/1717333881843-verzenio-phase-iii-postmonarch-trial.png Abemaciclib + Fulvestrant demonstrates continued benefit in HR+ HER2- metastatic BC, showing a 27% reduction in PFS across subgroups and biomarkers. daily 0.8 https://www.delveinsight.com/asco-conference/article/adagrasib-krystal-12-trial 2024-06-02T12:51:13.606Z https://assets.delveinsight.com/case-studies/1717332661532-adagrasib-krystal-12-trial.png Bristol Myers' KRAS confirmatory data of adagrasib showed significant improvement in the risk of tumor progression in the Phase III KRYSTAL-12 study daily 0.8 https://www.delveinsight.com/asco-conference/article/fulzerasib-phase-ii-krocus-study 2024-06-02T12:23:29.604Z https://assets.delveinsight.com/case-studies/1717330988403-fulzerasib-phase-ii-krocus-study.png With a superior efficacy in advanced KRAS G12C-mutated NSCLC, fulzerasib in combination with cetuximab is all set to enter the KRAS G12C-mutated NSCLC segment daily 0.8 https://www.delveinsight.com/asco-conference/article/pelabresib-and-ruxolitinib-combo-manifest-2-data 2024-06-01T15:52:58.271Z https://assets.delveinsight.com/case-studies/1717257174308-pelabresib-and-ruxolitinib-combo-manifest-2-data.png MANIFEST-2 data supports the notion that the combination of Pelabresib and Ruxolitinib could potentially revolutionize the treatment of myelofibrosis daily 0.8 https://www.delveinsight.com/asco-conference/article/obe-cel-phase-ib-ii-felix-study 2024-06-01T15:48:28.081Z https://assets.delveinsight.com/case-studies/1717256879182-obe-cel-phase-ib-ii-felix-study.png Longer-term follow-up and additional data analysis of Pivotal Phase II FELIX study of obe-cel shows 40% of responders remain in CR without SCT or other intervention daily 0.8 https://www.delveinsight.com/asco-conference/article/cn201-phase-i-study 2024-06-01T15:41:59.164Z https://assets.delveinsight.com/case-studies/1717256477979-cn201-phase-i-study.png Phase I study of CN201 reports manageable CRS and no ICANS so far daily 0.8 https://www.delveinsight.com/asco-conference/article/dato-dxd-phase-ii-icarus-lung01-study 2024-06-01T14:50:40.988Z https://assets.delveinsight.com/case-studies/1717253436087-dato-dxd-phase-ii-icarus-lung01-study.png Patients with a wide range of TROP2 expression may benefit from Dato-DXd daily 0.8 https://www.delveinsight.com/asco-conference/article/sacituzumab-tirumotecan-phase-ii-optitrop-lung01-study 2024-06-01T14:39:51.937Z https://assets.delveinsight.com/case-studies/1717252733967-sacituzumab-tirumotecan-phase-ii-optitrop-lung01-study.png The Phase II OptiTROP-Lung01 study has uncovered promise in using sacituzumab tirumotecan alongside KL-A167 (anti-PD-L1) as a first-line treatment for advanced NSCLC daily 0.8 https://www.delveinsight.com/asco-conference/article/amivantamab-lazertinib-phase-iii-mariposa-study 2024-06-01T14:34:12.906Z https://assets.delveinsight.com/case-studies/1717252432860-amivantamab-lazertinib-phase-iii-mariposa-study.png The groundbreaking combination of amivantamab and lazertinib represents a significant leap forward in the treatment landscape for advanced non-small cell lung cancer (NSCLC). daily 0.8 https://www.delveinsight.com/asco-conference/article/ivonescimab-harmoni-a-trial 2024-06-01T14:22:06.686Z https://assets.delveinsight.com/case-studies/1717251712676-ivonescimab-harmoni-a-trial.png Ivonescimab combined with chemotherapy not only boosted progression-free survival (PFS) but also upheld a well-handled safety record among patients previously unsuccessful with EGFR-TKI therapies daily 0.8 https://www.delveinsight.com/asco-conference/article/scemblix-asc4first-phase-iii-study 2024-06-01T14:11:08.105Z https://assets.delveinsight.com/case-studies/1717251035794-scemblix-asc4first-phase-iii-study.png SCEMBLIX in newly diagnosed CML patients appears to be a more favorable option than GLEEVEC daily 0.8 https://www.delveinsight.com/asco-conference/article/trodelvy-evoke-01-trial 2024-06-01T14:04:06.495Z https://assets.delveinsight.com/case-studies/1717250642044-trodelvy-evoke-01-trial.png Gilead's development plan for sacituzumab govitecan in NSCLC stands to benefit from the insights gained in the EVOKE-01 trial, offering hope for improved outcomes in this challenging disease setting daily 0.8 https://www.delveinsight.com/asco-conference/article/rybrevant-paloma-3-trial-data 2024-06-01T13:54:28.826Z https://assets.delveinsight.com/case-studies/1717250057030-rybrevant-paloma-3-trial-data.png The PALOMA-3 trial has unveiled subcutaneous amivantamab as a promising alternative to intravenous administration, boasting several advantages daily 0.8 https://www.delveinsight.com/asco-conference/article/head-and-neck-cancer-preview-asco-2024 2024-05-31T07:13:29.037Z https://assets.delveinsight.com/case-studies/1717139592972-head-and-neck-cancer-preview-asco-2024.png ASCO 2024: Head and Neck Cancer Abstracts daily 0.8 https://www.delveinsight.com/asco-conference/article/hematology-preview-asco-2024 2024-05-31T07:11:06.462Z https://assets.delveinsight.com/case-studies/1717139463452-hematology-preview-asco-2024.png ASCO 2024: Hematology Abstracts daily 0.8 https://www.delveinsight.com/asco-conference/article/melanoma-preview-asco-2024 2024-05-31T07:08:16.459Z https://assets.delveinsight.com/case-studies/1717139292376-melanoma-preview-asco-2024.png ASCO 2024: Melanoma Abstracts daily 0.8 https://www.delveinsight.com/asco-conference/article/small-cell-lung-cancer-asco-2024-preview 2024-05-30T12:40:51.926Z https://assets.delveinsight.com/case-studies/1717072680363-small-cell-lung-cancer-asco-2024-preview.png Major Milestone in the Treatment for Limited-stage Small-cell Lung Cancer! daily 0.8 https://www.delveinsight.com/asco-conference/article/hepatocellular-carcinoma-asco-2024-preview 2024-05-30T12:35:33.655Z https://assets.delveinsight.com/case-studies/1717072463412-hepatocellular-carcinoma-asco-2024-preview.png ASCO 2024: Hepatocellular Carcinoma Abstract Summary daily 0.8 https://www.delveinsight.com/asco-conference/article/endometrial-cancer-preview-asco-2024 2024-05-30T09:44:35.151Z https://assets.delveinsight.com/case-studies/1717062269218-endometrial-cancer-preview-asco-2024.png ASCO 2024 Preview: Evolving Treatments in Endometrial Cancer Research daily 0.8 https://www.delveinsight.com/asco-conference/article/breast-cancer-preview-asco-2024 2024-05-30T09:41:48.600Z https://assets.delveinsight.com/case-studies/1717062103078-breast-cancer-preview-asco-2024.png ASCO 2024: Breast Cancer Abstract Summary daily 0.8 https://www.delveinsight.com/asco-conference/article/gastric-and-arc-9-crc-asco-2024-preview 2024-05-30T09:39:31.703Z https://assets.delveinsight.com/case-studies/1717061950419-gastric-and-arc-9-crc-asco-2024-preview.png ASCO 2024: Captivating Insights into Edge-Gastric and ARC-9 CRC! daily 0.8 https://www.delveinsight.com/asco-conference/article/prostate-cancer-asco-2024-preview 2024-05-30T05:31:37.671Z https://assets.delveinsight.com/case-studies/1717047093280-prostate-cancer-asco-2024-preview.png ASCO 2024: Prostate Cancer Abstract Summary daily 0.8 https://www.delveinsight.com/asco-conference/article/lung-cancer-preview-asco-2024 2024-05-29T11:52:46.984Z https://assets.delveinsight.com/case-studies/1716983562099-lung-cancer-preview-asco-2024.png ASCO 2024: Shaping Tomorrow's Lung Cancer Landscape daily 0.8 https://www.delveinsight.com/asco-conference/article/pd-l1-inhibitors-top-abstracts-asco-2024 2024-05-28T09:18:12.748Z https://assets.delveinsight.com/case-studies/1716887887155-pd-l1-inhibitors-top-abstracts-asco-2024.png A Sneak Peek into the Top 10 Abstracts on PD-(L)1 Inhibitors at ASCO 2024 daily 0.8 https://www.delveinsight.com/asco-conference/article/top-posters-on-early-cancer-detection-at-asco-2024 2024-05-28T09:15:30.716Z https://assets.delveinsight.com/case-studies/1716887708969-top-posters-on-early-cancer-detection-at-asco-2024.png Early Cancer Detection Posters of Interest for ASCO 2024! daily 0.8 https://www.delveinsight.com/asco-conference/article/first-of-its-kind-human-trial-asco-2024-preview 2024-05-28T08:18:50.796Z https://assets.delveinsight.com/case-studies/1716884288704-first-of-its-kind-human-trial-asco-2024-preview.png ASC0 2024 Spotlight: Unveiling First-of-its-kind Human Trial Abstracts! daily 0.8 https://www.delveinsight.com/asco-conference/article/bi-specific-antibodies-asco-2024-preview 2024-05-28T06:11:26.950Z https://assets.delveinsight.com/case-studies/1716876682017-bi-specific-antibodies-asco-2024-preview.png ASCO 2024 Preview: Top Bi-specific Antibodies expected Data readouts daily 0.8 https://www.delveinsight.com/asco-conference/article/antibody-drug-conjugates-asco-2024-preview 2024-05-28T06:08:40.233Z https://assets.delveinsight.com/case-studies/1716876510651-antibody-drug-conjugates-asco-2024-preview.png ASCO 2024 Glimpse ahead: Unveiling the Latest in Antibody-Drug Conjugates daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/ats-2024-day-3-summary 2024-05-24T12:51:59.683Z https://assets.delveinsight.com/case-studies/1716554989628-ats-2024-day-3-summary.png Day 3 Highlights of ATS 2024 daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/ats-2024-day-2-summary-insights 2024-05-24T12:47:07.126Z https://assets.delveinsight.com/case-studies/1716554650498-ats-2024-day-2-summary-insights.png ATS 2024 Day 2 Summary - Key Insights daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/ats-2024-day-1-summary 2024-05-24T12:39:28.584Z https://assets.delveinsight.com/case-studies/1716554139137-ats-2024-day-1-summary.png ATS 2024 Day 1 Summary: Key Insights daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/dupilumab-vestige-trial 2024-05-23T10:00:55.989Z https://assets.delveinsight.com/case-studies/1716458408158-dupilumab-vestige-trial.png Unveiling Dupilumab's Impact: Insights from the Vestige Trial on Airway Dynamics and Mucus in Moderate-to-Severe Asthma daily 0.8 https://www.delveinsight.com/asco-conference/article/genitourinary-cancer-preview 2024-05-23T07:31:19.197Z https://assets.delveinsight.com/case-studies/1716449458837-genitourinary-cancer-preview.png ASCO 2024 Preview: Listing top data presentations in Genitourinary Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/gastrointestinal-cancer-preview 2024-05-23T07:26:54.348Z https://assets.delveinsight.com/case-studies/1716449203591-gastrointestinal-cancer-preview.png ASCO 2024 Preview: Groundbreaking Advances in Gastrointestinal (GI) Cancer! daily 0.8 https://www.delveinsight.com/asco-conference/article/innovations-in-cancer-diagnostics 2024-05-23T07:23:50.929Z https://assets.delveinsight.com/case-studies/1716448961104-innovations-in-cancer-diagnostics.png Industry Expert Theater Sessions at ASCO 2024: Showcasing Innovations in Cancer Diagnostics daily 0.8 https://www.delveinsight.com/asco-conference/article/breast-cancer-readouts 2024-05-23T07:19:55.676Z https://assets.delveinsight.com/case-studies/1716448670431-breast-cancer-readouts.png Top Data Readouts in Breast Cancer: ASCO 2024 daily 0.8 https://www.delveinsight.com/asco-conference/article/lung-cancer-10-plus-data-readouts 2024-05-23T07:08:39.415Z https://assets.delveinsight.com/case-studies/1716448111081-lung-cancer-10-plus-data-readouts.png ASCO 2024: Lung Cancer’s 10+ interesting data readouts to look forward daily 0.8 https://www.delveinsight.com/asco-conference/article/hematologic-malignancies-preview-asco-2024 2024-05-23T06:53:14.749Z https://assets.delveinsight.com/case-studies/1716447180542-hematologic-malignancies-preview-asco-2024.png ASCO 2024: Get a sneak peek of Cutting-edge breakthroughs in hematologic malignancies! daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/tslp-for-severe-asthma 2024-05-23T06:44:59.115Z https://assets.delveinsight.com/case-studies/1716446611079-tslp-for-severe-asthma.png TSLP and Severe Asthma: ATS 2024 Research Reveals Connections daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/dupixent-phase-iii-notus-trial 2024-05-22T13:07:04.863Z https://assets.delveinsight.com/case-studies/1716382999487-dupixent-phase-iii-notus-trial.png DUPIXENT’s Symphony: Raising the Curtain on the NOTUS COPD Trial daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/fb-045-windward-phase-ii-study 2024-05-21T12:56:09.793Z https://assets.delveinsight.com/case-studies/1716365012054-fb-045-windward-phase-ii-study.png WINDWARD Phase II Study Highlights: Foresee’s FP-045 at ATS Conference daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/aer-901-phase-ii-trial 2024-05-21T12:51:49.454Z https://assets.delveinsight.com/case-studies/1716295852803-aer-901-phase-ii-trial.png AER-901 Outperforms DPI-Imatinib in Lung Deposition: Insights from ATS 2024 daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/haduvi-phase-ii-canal-trial 2024-05-21T12:48:07.101Z https://assets.delveinsight.com/case-studies/1716365074259-haduvi-phase-ii-canal-trial.png HADUVI Shines at ATS 2024: Significantly Alleviates Chronic Cough Burden daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/hs135-phase-i-clinical-development 2024-05-21T11:47:39.089Z https://assets.delveinsight.com/case-studies/1716365107849-hs135-phase-i-clinical-development.png Spotlight on 35Pharma: Presenting Groundbreaking Research at 2024 ATS Conference daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/env-101-phase-iia-trial-data 2024-05-21T05:00:00.493Z https://assets.delveinsight.com/case-studies/1716267483036-env-101-phase-iia-trial-data.png Is ENV-101 the First Disease-modifying Treatment for Idiopathic Pulmonary Fibrosis? daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/seralutinib-phase-ib-and-phase-ii-torrey-trial 2024-05-20T12:53:38.143Z https://assets.delveinsight.com/case-studies/1716209524466-seralutinib-phase-ib-and-phase-ii-torrey-trial.png Gossamer Bio Presents Promising Seralutinib Data at ATS 2024 daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/av-101-impahct-trial 2024-05-20T12:23:48.807Z https://assets.delveinsight.com/case-studies/1716207703334-av-101-impahct-trial.png Unlocking Potential: AV-101’s ‘IMPAHCT’ on Pulmonary Arterial Hypertension daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/solrikitug-phase-ii-clinical-trial 2024-05-20T08:52:10.640Z https://assets.delveinsight.com/case-studies/1716194930528-solrikitug-phase-ii-clinical-trial.png Transformative Therapies on the Horizon: Solrikitug’s Journey daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/liquidia-lL606-updates 2024-05-20T08:46:30.616Z https://assets.delveinsight.com/case-studies/1716194705037-liquidia-lL606-updates.png Charting Progress: Liquidia’s L606 Updates at ATS 2024 daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/airsupra-fda-approval-for-asthma 2024-05-20T07:41:54.011Z https://assets.delveinsight.com/case-studies/1716190765950-airsupra-fda-approval-for-asthma.png Unprecedented Advancement: AIRSUPRA Debuts as Sole FDA-approved Anti-inflammatory Asthma Rescue Option daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/dupixent-phase-iii-boreas-and-notus-studies 2024-05-20T07:37:07.231Z https://assets.delveinsight.com/case-studies/1716190559778-dupixent-phase-iii-boreas-and-notus-studies.png Pioneering COPD Innovation: DUPIXENT’s Breakthrough in Reducing FeNO Levels in BOREAS Phase III daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/aro-rage-phase-i-iia-arorage-1001-trial 2024-05-20T07:31:08.425Z https://assets.delveinsight.com/case-studies/1716190032411-aro-rage-phase-i-iia-arorage-1001-trial.png Arrowhead’s ARO-RAGE: A New Era in RNAi-based Asthma Therapy daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/ensifentrine-phase-iii-enhance-study 2024-05-20T07:08:45.939Z https://assets.delveinsight.com/case-studies/1716188764870-ensifentrine-phase-iii-enhance-study.png Envisioning a Future Without COPD Exacerbations: Ensifentrine’s Promise daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/vicore-pharma-atrags 2024-05-20T07:00:30.259Z https://assets.delveinsight.com/case-studies/1716188258702-vicore-pharma-atrags.png Breaking Barriers: Vicore Pharma’s Trailblazing Efforts in IPF Research daily 0.8 https://www.delveinsight.com/ats-conference/ats-2024/tezepelumab-phase-ii-copd-data 2024-05-20T06:50:52.229Z https://assets.delveinsight.com/case-studies/1716187652063-tezepelumab-phase-ii-copd-data.png The Moment Approaches: Tezepelumab’s Phase II COPD Data to Take the Stage at ATS 2024 daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/tarlatamab-phase-ii-dellphi-301-study 2023-12-13T03:58:02.333Z https://assets.delveinsight.com/products/asco/1701768822-tarlatamab-phase-ii-dellphi-301-study.png Phase 2 DeLLphi-301 primary analysis of Tarlatamab in previously treated small cell lung cancer (SCLC). daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/dato-dxd-phase-iii-study-tropion-lung01 2023-12-13T03:58:02.322Z https://assets.delveinsight.com/products/asco/1701768655-dato-dxd-phase-iii-study-tropion-lung01.png Datopotamab deruxtecan (Dato-DXd) versus docetaxel in previously treated advanced/metastatic non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01 daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/alecensa-alina-trial-results 2023-12-13T03:58:02.303Z https://assets.delveinsight.com/products/asco/1701768485-alecensa-alina-trial-results.png Adjuvant Alectinib in Asian Patients with Resected Stage IB–IIIA ALK+ NSCLC: Insights from the ALINA Trial and Implications for Treatment Strategies daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/milademetan-versus-trabectedin-phase-iii-mantra-study 2023-12-13T03:58:02.294Z https://assets.delveinsight.com/products/asco/1701768182-milademetan-versus-trabectedin-phase-iii-mantra-study.png Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan versus trabectedin in patients with dedifferentiated liposarcomas daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/keytruda-and-lenvima-phase-ii-lara-trial 2023-12-13T03:58:02.284Z https://assets.delveinsight.com/products/asco/1701767702-keytruda-and-lenvima-phase-ii-lara-trial.png Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3) daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/sintilimab-for-gynecological-squamous-cell-carcinoma-patients 2023-12-13T03:58:02.275Z https://assets.delveinsight.com/products/asco/1701767322-sintilimab-for-gynecological-squamous-cell-carcinoma-patients.png Efficacy and Safety of Topical Sintilimab with CRT and Californium-252 Neutron Brachytherapy in First-line Advanced Gynecological SCC Patients daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/astellas-seagen-padcev-keytruda-combo 2023-12-13T03:58:02.264Z https://assets.delveinsight.com/products/asco/1701749898-astellas-seagen-padcev-keytruda-combo.png EV-302 trial results back PADCEV-KEYTRUDA as a new first-line standard for advanced urothelial carcinoma. daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/t-dxd-destiny-pan-tumor02-results 2023-12-13T03:58:02.255Z https://assets.delveinsight.com/products/asco/1701689043-t-dxd-destiny-pan-tumor02-results.png Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/imfinzi-phase-iii-matterhorn-study 2023-12-13T03:58:02.245Z https://assets.delveinsight.com/products/asco/1701688833-imfinzi-phase-iii-matterhorn-study.png Interim Analysis Suggests AstraZeneca's IMFINZI Could Transform Cancer Care daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/keytruda-keynote-811-data 2023-12-13T03:58:02.233Z https://assets.delveinsight.com/products/asco/1701688622-keytruda-keynote-811-data.png KEYNOTE-811 Data Supports KEYTRUDA Combination as Standard Treatment for HER2+ and PD-L1-Positive Tumors daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/low-dose-nivolumab-in-recurrent-metastatic-cervical-cancer 2023-12-13T03:58:02.224Z https://assets.delveinsight.com/products/asco/1701687233-low-dose-nivolumab-in-recurrentmetastatic-cervical-cancer.png Efficacy of Low Dose Nivolumab in Recurrent/Metastatic Cervical Cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/seagen-tivdak-innovatv-301-phase-iii-results 2023-12-13T03:58:02.212Z https://assets.delveinsight.com/products/asco/1701686929-seagen-tivdak-innovatv-301-phase-iii-results.png InnovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase III Study of Tisotumab Vedotin vs. Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/fruquintinib-plus-sintilimab-in-advanced-cervical-cancer 2023-12-13T03:58:02.201Z https://assets.delveinsight.com/products/asco/1701686718-fruquintinib-plus-sintilimab-in-advanced-cervical-cancer.png Fruquintinib Plus Sintilimab In Advanced Cervical Cancer (CC) Patients: Results From A Multicenter, Single-arm Phase II Study daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/amivantamab-plus-lazertinib-vs-osimertinib-mariposa-subgroup-analysis 2023-12-13T03:58:02.192Z https://assets.delveinsight.com/products/asco/1701686039-amivantamab-plus-lazertinib-vs-osimertinib-mariposa-subgroup-analysis.png Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/amivantamab-plus-chemotherapy-vs-chemotherapy-mariposa-2-subgroup-analysis 2023-12-13T03:58:02.188Z https://assets.delveinsight.com/products/asco/1701685845-amivantamab-plus-chemotherapy-vs-chemotherapy-mariposa-2-subgroup-analysis.png Amivantamab plus chemotherapy vs. chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/ibi351-for-nsclc-esmo-asia-2023 2023-12-13T03:58:02.183Z https://assets.delveinsight.com/products/asco/1701426102-ibi351-for-nsclc-esmo-asia-2023.png Efficacy and safety of IBI351 (GFH925), a selective KRAS G12C inhibitor, monotherapy in advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation: initial results from a registrational phase II study daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/gastrointestinal-tumors-preview-content-esmo-asia-2023 2023-12-13T03:58:02.179Z https://assets.delveinsight.com/products/asco/1701328377-gastrointestinal-tumors-preview-content-esmo-asia-2023.png ESMO ASIA 2023 PREVIEW CONTENT FOR GASTROINTESTINAL TUMORS daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/head-and-neck-cancers-preview-esmo-asia-2023 2023-12-13T03:58:02.175Z https://assets.delveinsight.com/products/asco/1701328019-head-and-neck-cancers-preview-esmo-asia-2023.png ESMO ASIA 2023 PREVIEW CONTENT FOR HEAD AND NECK CANCERS daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/lung-cancer-preview-content-esmo-asia-2023 2023-12-13T03:58:02.169Z https://assets.delveinsight.com/products/asco/1701327836-lung-cancer-preview-content-esmo-asia-2023.png ESMO ASIA 2023 PREVIEW CONTENT FOR LUNG CANCER daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/genitourinary-cancers-preview-content-esmo-asia-2023 2023-12-13T03:58:02.165Z https://assets.delveinsight.com/products/asco/1701258634-genitourinary-cancers-preview-content-esmo-asia-2023.png ESMO ASIA 2023 PREVIEW CONTENT FOR GENITOURINARY CANCERS daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/hematological-malignancies-preview-content-esmo-asia-2023 2023-12-13T03:58:02.160Z https://assets.delveinsight.com/products/asco/1701258140-hematological-malignancies-preview-content-esmo-asia-2023.png ESMO ASIA 2023 PREVIEW CONTENT FOR HEMATOLOGICAL MALIGNANCIES daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/solid-tumors-preview-content-esmo-asia-2023 2023-12-13T03:58:02.155Z https://assets.delveinsight.com/products/asco/1701257885-solid-tumors-preview-content-esmo-asia-2023.png ESMO ASIA 2023 PREVIEW CONTENT FOR SOLID TUMORS daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/esmo-asia-2023-gyneocological-cancers-preview-content 2023-12-13T03:58:02.150Z https://assets.delveinsight.com/products/asco/1701174642-esmo-asia-2023-gyneocological-cancers-preview-content.png ESMO ASIA 2023 PREVIEW CONTENT FOR GYNECOLOGICAL CANCERS daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/esmo-asia-2023-preview-content 2023-12-13T03:58:02.145Z https://assets.delveinsight.com/products/asco/1701174537-ESMO-ASIA-2023-PREVIEW-CONTENT.png PREVIEW CONTENT: ESMO ASIA 2023 daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/janssens-mariposa-trial-for-egfr-mutated-nsclc 2023-12-13T03:58:02.141Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/janssens-rybrevant-in-egfr-mutated-lung-cancer 2023-12-13T03:58:02.130Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/immuteps-eftilagimod-alpha-with-keytruda-for-nsclc 2023-12-13T03:58:02.118Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/gileads-trop-2-adc-trodelvy-for-esclc 2023-12-13T03:58:02.108Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/beijing-Immunopharms-car-t-therapy-im96 2023-12-13T03:58:02.097Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/amgens-lumakras-vectibix-breakthrough-in-codebreak-300-colon-cancer-study 2023-12-13T03:58:02.086Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/Qilu-Pharma-bi-specific-PD-1-CTLA-4-blocker-QL1706 2023-12-13T03:58:02.075Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/BeiGenes-tislelizumab-and-ociperlimab-combination 2023-12-13T03:58:02.065Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/toripalimab-axitinib-combination 2023-12-13T03:58:02.056Z https://assets.delveinsight.com/products/asco/1698408896-toripalimab-axitinib-combination.png Toripalimab-Axitinib combination offers superior outcomes in the Phase III RENOTORCH study daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/skb264-for-her2-metastatic-breast-cancer 2023-12-13T03:58:02.044Z https://assets.delveinsight.com/products/asco/1698408214-skb264-for-her2-metastatic-breast-cancer.png The efficacy data for SKB264 (MK-2870), an innovative TROP2-ADC is promising, positioning it as a potential option in the therapeutic landscape of previously treated HR+/HER2- metastatic breast cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/abbv-637-combination-therapy-with-osimertinib 2023-12-13T03:58:02.033Z https://assets.delveinsight.com/products/asco/1698407672-abbv-637-combination-therapy-with-osimertinib.png Innovative ABBV-637 Combination Therapy with Osimertinib Shows Strong Antitumor Effects in EGFR-Mutated NSCLC: Phase I Study (Part 3) Outcomes and Safety Profile daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/systimmune-bl-b01d1-phase-i-trial 2023-12-13T03:58:02.021Z https://assets.delveinsight.com/products/asco/1698323056-systimmune-bl-b01d1-phase-i-trial.png SystImmune Shares Updated Findings from Phase I Trial of BL-B01D1, a Pioneering EGFRxHER3 Bispecific ADC in NSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/astrazeneca-lynparza-phase-iii-duo-e-trial 2023-12-13T03:58:02.010Z https://assets.delveinsight.com/products/asco/1698322823-astrazeneca-lynparza-phase-iii-duo-e-trial.png Durvalumab/Olaparib maintenance yields PFS gains in advanced, recurrent endometrial cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/daiichi-merck-raludotatug-deruxtecan 2023-12-13T03:58:02.000Z https://assets.delveinsight.com/products/asco/1698322544-daiichi-merck-raludotatug-deruxtecan.png Subgroup analysis of first-in-human Phase I study reveals raludotatug deruxtecan monotherapy efficacy in previously treated ovarian cancer. daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/novartis-pluvicto-phase-iii-psmafore-trial 2023-12-13T03:58:01.988Z https://assets.delveinsight.com/products/asco/1698322269-novartis-pluvicto-phase-iii-psmafore-trial.png Novartis’ PSMAfore study, evaluating PLUVICTO in early-stage prostate cancer, reports mixed survival data, prompting the company to delay its FDA filing for the in-demand radiopharmaceutical drug. daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/abbvie-cofetuzumab-pelidotin 2023-12-13T03:58:01.977Z https://assets.delveinsight.com/products/asco/1698321957-abbvie-cofetuzumab-pelidotin.png The Uncertain Destiny of Cofetuzumab Pelidotin: An Antibody-Drug Conjugate Targeting PTK7 Expressing rNSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/keytruda-phase-iii-keynote-a18-trial 2023-12-13T03:58:01.967Z https://assets.delveinsight.com/products/asco/1698321618-keytruda-phase-iii-keynote-a18-trial.png Pembrolizumab─chemoradiotherapy combo shines in a Phase III study, unveiling impressive results for patients with high-risk locally advanced cervical cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/dato-dxd-tropion-lung05-trial 2023-12-13T03:58:01.959Z https://assets.delveinsight.com/products/asco/1698320055-dato-dxd-tropion-lung05-trial.png Promising Efficacy and Safety of Dato-DXd in Advanced NSCLC with Genomic Alterations: Insights from TROPION-Lung05 daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/merus-zenocutuzumab-enrgy-phase-i-ii-clinical-trial 2023-12-13T03:58:01.950Z https://assets.delveinsight.com/products/asco/1698319742-merus-zenocutuzumab-enrgy-phase-i-ii-clinical-trial.png Merus announced eNRGy Phase I/II clinical trial data showing robust efficacy in NRG1+ NSCLC and PDAC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/eli-lilly-imlunestrant-ember-2-trial 2023-12-13T03:58:01.942Z https://assets.delveinsight.com/products/asco/1698298425-eli-lilly-imlunestrant-ember-2-trial.png In the realm of SERD breakthroughs, the EMBER-2 trial and EMBER trial unveil imlunestrant as a promising preview of the future for next-generation SERDs. daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/welireg-litespark-trials 2023-12-13T03:58:01.934Z https://assets.delveinsight.com/products/asco/1698298020-welireg-litespark-trials.png LITESPARK trials reported encouraging efficacy and safety of WELIREG (belzutifan) in Advanced RCC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/arvinas-bavdegalutamide-phase-i-ii-trial 2023-12-13T03:58:01.926Z https://assets.delveinsight.com/products/asco/1698297739-arvinas-bavdegalutamide-phase-i-ii-trial.png Promising results and tolerability of bavdegalutamide in mCRPC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/jacobio-glecirasib-phase-i-iia-study 2023-12-13T03:58:01.919Z https://assets.delveinsight.com/products/asco/1698297503-jacobio-glecirasib-phase-i-iia-study.png Positive Outcomes in Combining Glecirasib and JAB-3312 for KRAS G12C NSCLC Treatment: Implications for SHP2 and KRAS G12C Inhibitors daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/astrazeneca-daiichi-sankyo-trop-2-adc-datopotamab-deruxtecan 2023-12-13T03:58:01.907Z https://assets.delveinsight.com/products/asco/1698294896-astrazeneca-daiichi-sankyo-trop-2-adc-datopotamab-deruxtecan.png Early promising activity and safety of TROP2-Directed ADC Datopotamab Deruxtecan + Durvalumab in first-line TNBC treatment daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/hansoh-biomedical-hs-20089 2023-12-13T03:58:01.901Z https://assets.delveinsight.com/products/asco/1698294637-hansoh-biomedical-hs-20089.png Hansoh BioMedical is making significant strides as it advances toward pivotal achievements in the initial human trials, specifically Phase I clinical trials, for HS-20089, a promising candidate for the treatment of advanced solid tumors daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/merck-belzutifan-phase-iii-litespark-005-trial 2023-12-13T03:58:01.886Z https://assets.delveinsight.com/products/asco/1698294326-merck-belzutifan-phase-iii-litespark-005-trial.png Merck’s Belzutifan: First novel mechanism to demonstrate potential in advanced RCC in recent years. daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/jansenn-akeega-magnitude-trial 2023-12-13T03:58:01.881Z https://assets.delveinsight.com/products/asco/1698294036-jansenn-akeega-magnitude-trial.png Promising Findings from the Phase III MAGNITUDE study transformed BRCA+ mCRPC Treatment Landscape daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/revolution-medicines-rmc-6236-001-phase-i-iib-trial 2023-12-13T03:58:01.839Z https://assets.delveinsight.com/products/asco/1698060483-revolution-medicines-rmc-6236-001-phase-i-iib-trial.png Revolution Medicines presented encouraging clinical activity and safety data derived from the Phase I/IB trial of RMC-6236 daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/merck-keynote-991-and-keynote-641-trials-results 2023-12-13T03:58:01.827Z https://assets.delveinsight.com/products/asco/1698058439-merck-keynote-991-and-keynote-641-trials-results.png Two Phase III pembrolizumab trials showed lack of benefit in prostate cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/kras-g12d-inhibitor-hrs-4642-phase-i-study 2023-12-13T03:58:01.814Z https://assets.delveinsight.com/products/asco/1698058146-kras-g12d-inhibitor-hrs-4642-phase-i-study.png Dose escalation part of Phase I study of HRS-4642 in patients with advanced KRAS G12D mutant solid tumors: Preliminary data daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/opdivo-and-chemotherapy-combo-phase-iii-trial-checkmate-77t 2023-12-13T03:58:01.776Z https://assets.delveinsight.com/products/asco/1697976007-opdivo-and-chemotherapy-combo-phase-iii-trial-checkmate-77t.png Promising Outcomes with Neoadjuvant and Adjuvant OPDIVO in Resectable NSCLC: CheckMate 77T Study Update daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/osimertinib-chemotherapy-combo-flaura2-study-insights 2023-12-13T03:58:01.766Z https://assets.delveinsight.com/products/asco/1697975570-osimertinib-chemotherapy-combo-flaura2-study-insights.png Osimertinib plus chemotherapy improves CNS outcomes in advanced EGFR-mutated NSCLC: FLAURA2 trial daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/garsorasib-and-cetuximab-combination-d1553-101-trial 2023-12-13T03:58:01.757Z https://assets.delveinsight.com/products/asco/1697975224-garsorasib-and-cetuximab-combination-d1553-101-trial.png Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A Phase II study daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/roche-alecensa-phase-iii-alina-study 2023-12-13T03:58:01.746Z https://assets.delveinsight.com/products/asco/1697974507-roche-alecensa-phase-iii-alina-study.png Roche’s ALECENSA demonstrated a statistically significant and clinical improvement in disease-free survival in Phase III ALINA study daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/lilly-retevmo-libretto-431-study-result 2023-12-13T03:58:01.735Z https://assets.delveinsight.com/products/asco/1697974213-lilly-retevmo-libretto-431-study-result.png Lilly announces details of randomized Phase III study of first-line RETEVMO versus KEYTRUDA and chemotherapy in RET fusion-positive NSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/janssen-rybrevant-phase-iii-papillon-study 2023-12-13T03:58:01.727Z https://assets.delveinsight.com/products/asco/1697973883-janssen-rybrevant-phase-iii-papillon-study.png RYBREVANT is all set to Change the Standard of Care of Patients Harboring EGFR Exon 20 Insertion Mutation in the First-line Setting daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/kura-tipifarnib-aim-hn-trial-results 2023-12-13T03:58:01.716Z https://assets.delveinsight.com/products/asco/1697973594-kura-tipifarnib-aim-hn-trial-results.png A Phase II pivotal study exploring tipifarnib in the untapped mHRAS, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) population offers potential to address this patient pool's huge unfulfilled need daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/merck-keytruda-phase-iii-keynote-756-trial 2023-12-13T03:58:01.706Z https://assets.delveinsight.com/products/asco/1697906002-merck-keytruda-phase-iii-keynote-756-trial.png Merck’s blockbuster product KEYTRUDA has opened a new treatment horizon for early-stage high-risk ER+/HER2– breast cancer after positive KEYNOTE-756 trial results daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/impact-senaparib-phase-iii-flames-trial 2023-12-13T03:58:01.696Z https://assets.delveinsight.com/products/asco/1697900728-impact-senaparib-phase-iii-flames-trial.png Senaparib as a maintenance treatment in advanced ovarian cancer: Insights from a pivotal Phase III Trial daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/Amgen-tarlatamab-phase-ii-dellphi-301-study 2023-12-13T03:58:01.687Z https://assets.delveinsight.com/products/asco/1697900354-Amgen-tarlatamab-phase-ii-dellphi-301-study.png Amgen's SCLC Tarlatamab Demonstrates Durable Anticancer Activity with Manageable Safety: Implications for Ongoing Phase III Study daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/nivolumab-ipilimumab-checkmate-816 2023-12-13T03:58:01.679Z https://assets.delveinsight.com/products/asco/1697899958-nivolumab-ipilimumab-checkmate-816.png Bristol Myers Squibb revealed promising late-breaking results from the Phase III CheckMate -816 study in patients with resectable NSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/eli-lilly-verzenio-phase-iii-monarche-trial 2023-12-13T03:58:01.670Z https://assets.delveinsight.com/products/asco/1697899583-eli-lilly-verzenio-phase-iii-monarche-trial.png Let's delve into the promising Phase III readout from the monarchE trial, showcasing the effectiveness of abemaciclib when combined with adjuvant endocrine therapy in the treatment of high-risk, HR+/HER2– breast cancer. daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/merck-phase-iii-keynote-522-study 2023-12-13T03:58:01.661Z https://assets.delveinsight.com/products/asco/1697898947-merck-phase-iii-keynote-522-study.png KEYTRUDA reaffirmed its status as a blockbuster drug by delivering impressive updated EFS outcomes from the Phase III KEYNOTE-522 study in the early-stage TNBC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/phase-iii-checkmate-7fl-study 2023-12-13T03:58:01.657Z https://assets.delveinsight.com/products/asco/1697898432-phase-iii-cm-7fl-study.png CheckMate 7FL reveals positive results in patients with PD-L1 Positivity. daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/astrazenecas-imfinzi-phase-iii-matterhorn-trial 2023-12-13T03:58:01.648Z https://assets.delveinsight.com/products/asco/1697897957-astrazenecas-imfinzi-phase-iii-matterhorn-trial.png Interim analysis shows that AstraZeneca's IMFINZI has the potential to 'redefine care for patients with gastrointestinal cancers' daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/merck-phase-iii-keynote-585-trial 2023-12-13T03:58:01.640Z https://assets.delveinsight.com/products/asco/1697897630-merck-phase-iii-keynote-585-trial.png Pembrolizumab with chemotherapy in localized gastric cancer - Insights from third interim analysis of the Phase III KEYNOTE-585 trial daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/amgens-bi-specific-steapxcd3s-early-stage-results 2023-12-13T03:58:01.631Z https://assets.delveinsight.com/products/asco/1697897302-amgens-bi-specific-steapxcd3s-early-stage-results.png AMG 509: A promising bispecific antibody shows strong anti-tumor activity in advanced mCRPC patients daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/merck-keynote-671-trial-results 2023-12-13T03:58:01.622Z https://assets.delveinsight.com/products/asco/1697896547-merck-keynote-671-trial-results.png Merck’s blockbuster product KEYTRUDA opened a new treatment horizon for perioperative setting after positive KEYNOTE-671 trial results daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/merck-sapphire-phase-iii-trial 2023-12-13T03:58:01.612Z https://assets.delveinsight.com/products/asco/1697896216-merck-sapphire-phase-iii-trial.png Mirati's Aspirations Took a Major Blow Following the Failure of Sitravatinib in SAPPHIRE Phase III Trial daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/gsk-jemperli-phase-ii-perla-trial 2023-12-13T03:58:01.601Z https://assets.delveinsight.com/products/asco/1697895843-gsk-jemperli-phase-ii-perla-trial.png Promising JEMPERLI (Dostarlimab) + Chemotherapy Data and GSK's Next Frontier in NSCLC Treatment daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/phase-ii-iii-krystal-7-study-esmo-2023 2023-12-13T03:58:01.590Z https://assets.delveinsight.com/products/asco/1697895406-phase-ii-iii-krystal-7-study-esmo-2023.png Efficacy and safety of KRAZATI with pembrolizumab in patients with treatment-naïve, advanced NSCLC harboring a KRASG12C mutation: Data from phase II/III KRYSTAL-7 study daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/jacobio-pharma-glecirasib-for-kras-g12c-mutations 2023-12-13T03:58:01.579Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/revolution-medicines-rmc-6236-for-pdac-nsclc 2023-12-13T03:58:01.568Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/systimmune-bl-b01d1-for-nsclc-treatment 2023-12-13T03:58:01.560Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/hansoh-biomedical-phase-i-clinical-trial-of-hs-20089 2023-12-13T03:58:01.547Z daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/er-her2-breast-cancer-esmo-2023 2023-12-13T03:58:01.539Z https://assets.delveinsight.com/products/asco/1697713393-er-her2-breast-cancer-esmo-2023.png Olema is on track to deliver on significant milestones for updated result from OP-1250 Phase Ib/II clinical study in ER+/HER2– breast cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/esmo-2023-prostate-cancer-highlights 2023-12-13T03:58:01.528Z https://assets.delveinsight.com/products/asco/1697708171-esmo-2023-prostate-cancer-highlights.png Early-Stage Results for AMG 509 (xaluritamig) Illustrate Expanding Potential of Amgen's T-Cell Engagers in mCRPC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/metastatic-castration-resistant-prostate-cancer-esmo-2023 2023-12-13T03:58:01.521Z https://assets.delveinsight.com/products/asco/1697707862-metastatic-castration-resistant-prostate-cancer-esmo-2023.png Phase III trial of \[177Lu]Lu-PSMA-617 in taxane-naïve mCRPC patients daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/nrg-fusion-nsclc-esmo-2023-highlights 2023-12-13T03:58:01.513Z https://assets.delveinsight.com/products/asco/1697635046-nrg-fusion-nsclc-esmo-2023-highlights.png ZENOCUTUZUMAB: A POTENTIAL BREAKTHROUGH IN NRG1+ CANCER TREATMENT – EXCITING INSIGHTS FROM MERUS AT ESMO CONGRESS 2023 daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/breast-cancer-advancements 2023-12-13T03:58:01.504Z https://assets.delveinsight.com/products/asco/1697633642-breast-cancer-advancements.png KEY INSIGHTS AND DEVELOPMENTS IN THE BREAST CANCER DOMAIN daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/retevmos-potential-in-nsclc-treatment 2023-12-13T03:58:01.495Z https://assets.delveinsight.com/products/asco/1697633098-retevmos-potential-in-nsclc-treatment.png Lilly to Present Interim Analysis Results from the Pivotal Phase III LIBRETTO-431 Study in Late-breaking Oral Presentation daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/kras-nsclc-esmo-2023-highlights 2023-12-13T03:58:01.487Z https://assets.delveinsight.com/products/asco/1697632798-kras-nsclc-esmo-2023-highlights.png INSIGHTS INTO KRAS EXPRESSING NSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/renal-cell-cancer-esmo-2023-preview 2023-12-13T03:58:01.478Z https://assets.delveinsight.com/products/asco/1697632510-renal-cell-cancer-esmo-2023-preview.png ESMO 2023 PREVIEW CONTENT FOR RENAL CELL CANCER (RCC) daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/prostate-cancer-esmo-2023-preview 2023-12-13T03:58:01.467Z https://assets.delveinsight.com/products/asco/1697629862-prostate-cancer-esmo-2023-preview.png ESMO 2023 PREVIEW CONTENT FOR PROSTATE CANCER daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/nsclc-esmo-2023-preview-content 2023-12-13T03:58:01.453Z https://assets.delveinsight.com/products/asco/1697629571-nsclc-esmo-2023-preview-content.png REVOLUTIONIZING NSCLC CARE: IMPORTANT INSIGHTS ON INITIAL TREATMENT daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/her2-mutated-nsclc-esmo-2023-preview 2023-12-13T03:58:01.448Z https://assets.delveinsight.com/products/asco/1697627172-her2-mutated-nsclc-esmo-2023-preview.png ESMO 2023 PREVIEW CONTENT FOR NON-SMALL CELL LUNG CANCER (NSCLC) daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/nsclc-esmo-2023-potential-abstracts 2023-12-13T03:58:01.439Z https://assets.delveinsight.com/products/asco/1697626870-nsclc-esmo-2023-potential-abstracts.png A Snippet of Potential Abstracts on NSCLC for ESMO 2023 daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/non-small-cell-lung-cancer-nsclc-therapies-esmo-2023-preview 2023-12-13T03:58:01.428Z https://assets.delveinsight.com/products/asco/1697626512-non-small-cell-lung-cancer-nsclc-therapies-esmo-2023-preview.png ESMO 2023: Let’s Not Miss Out on the Exciting Advances in Non-small Cell Lung Cancer (NSCLC) Therapies - A Sneak Peek at Abstracts! daily 0.8 https://www.delveinsight.com/esmo-conference-2023/article/breast-cancer-preview-esmo-2023 2023-12-13T03:58:01.418Z https://assets.delveinsight.com/products/asco/1697626087-breast-cancer-preview-esmo-2023.png GRIPPING INSIGHTS INTO BREAST CANCER daily 0.8 https://www.delveinsight.com/asco-conference/article/kontrast-01-trial 2023-12-13T03:58:01.411Z https://assets.delveinsight.com/products/asco/1686220982-kontrast-01-trial.png Novartis presented the promising efficacy and safety data of JDQ443 in KRAS G12C-mutated solid tumors including NSCLC (KontRASt-01) daily 0.8 https://www.delveinsight.com/asco-conference/article/ibi351-monotherapy 2023-12-13T03:58:01.398Z https://assets.delveinsight.com/products/asco/1686220755-ibi351-monotherapy.png Preliminary Data Reveals Favorable Safety and Promising Activity of IBI351 Monotherapy in KRASG12C Mutated Advanced Colorectal Cancer. daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-cartitude-4-study 2023-12-13T03:58:01.383Z https://assets.delveinsight.com/products/asco/1686157483-phase-iii-cartitude-4-study.png CARVYKTI Outperforms Two Standard Treatments in Progression-Free Survival at 16-Month Median Follow-Up in Lenalidomide-refractory Multiple Myeloma Patients daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-ii-optimize-1-study 2023-12-13T03:58:01.365Z https://assets.delveinsight.com/products/asco/1686155369-phase-ii-optimize-1-study.png Mitazalimab with mFOLFIRINOX as a Promising Treatment Option for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC). daily 0.8 https://www.delveinsight.com/asco-conference/article/padcev-for-head-and-neck-cancer 2023-12-13T03:58:01.353Z https://assets.delveinsight.com/products/asco/1686154759-padcev-for-head-and-neck-cancer.png Enfortumab Vedotin Used as a Single Treatment Showed Encouraging Effectiveness with Meaningful Clinical Responses daily 0.8 https://www.delveinsight.com/asco-conference/article/s209-and-s206-trials 2023-12-13T03:58:01.343Z https://assets.delveinsight.com/products/asco/1686154252-s209-and-s206-trials.png Sichuan Baili Pharmaceutical Presents the Updated Results of the Phase II clinical studies Performed on Patients with Recurrent and Metastatic HNSCC daily 0.8 https://www.delveinsight.com/asco-conference/article/darolutamide-for-salivary-gland-cancer 2023-12-13T03:58:01.333Z https://assets.delveinsight.com/products/asco/1686153954-darolutamide-for-salivary-gland-cancer.png With Well-established Safety and Efficacy, Darolutamide (ODM-201) can Address the Needs of Patients with Androgen Receptor-positive Salivary Gland Carcinoma. daily 0.8 https://www.delveinsight.com/asco-conference/article/jackpot8-part-b-trial 2023-12-13T03:58:01.321Z https://assets.delveinsight.com/products/asco/1686152395-jackpot8-part-b-trial.png Golidocitinib Demonstrates Promising Tumor Responses in Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL). daily 0.8 https://www.delveinsight.com/asco-conference/article/sunvozertinib-in-egfr-exon-20-mutations 2023-12-13T03:58:01.302Z https://assets.delveinsight.com/products/asco/1686151924-sunvozertinib-in-egfr-exon-20-mutations.png Dizal Pharmaceuticals unveiled the astounding results of sunvozertinib in Chinese NSCLC patients with EGFR Exon 20 insertion mutations, resistant to platinum-based chemotherapy daily 0.8 https://www.delveinsight.com/asco-conference/article/tropion-lung02-trial 2023-12-13T03:58:01.287Z https://assets.delveinsight.com/products/asco/1686151543-tropion-lung02-trial.png Daiichi Sankyo and AstraZeneca's innovative combination demonstrates significant tumor reduction in patients with advanced lung cancer: findings from the TROPION-Lung02 Phase Ib trial. daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-continuum-trial 2023-12-13T03:58:01.275Z https://assets.delveinsight.com/products/asco/1686150946-phase-iii-continuum-trial.png Innovent Biologics has released the findings of the CONTINUUM trial, which provide support for utilizing the combination of sintilimab and chemoradiotherapy as the new recommended treatment option daily 0.8 https://www.delveinsight.com/asco-conference/article/swog-s1826-trial 2023-12-13T03:58:01.264Z https://assets.delveinsight.com/products/asco/1686137556-swog-s1826-trial.png OPDIVO and AVD Combination Emerges as the New Standard Therapy for Advanced-Stage Hodgkin Lymphoma daily 0.8 https://www.delveinsight.com/asco-conference/article/pds0101-and-pembrolizumab-combo 2023-12-13T03:58:01.248Z https://assets.delveinsight.com/products/asco/1686137245-pds0101-and-pembrolizumab-combo.png With a median PFS of 10.4 months, the Combination of PDS0101 and Pembrolizumab in Subjects with HPV16 + Recurrent and/or Metastatic HNSCC appears promising. daily 0.8 https://www.delveinsight.com/asco-conference/article/isa101b-and-cemiplimab-combo 2023-12-13T03:58:01.235Z https://assets.delveinsight.com/products/asco/1686136744-isa101b-and-cemiplimab-combo.png Disease Stabilization in 26.9% of all Patients was Observed After the Treatment with ISA101b (peltopepimut-S) and Cemiplimab in Patients with Advanced HPV16+ Oropharyngeal Cancer. daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-i-ii-transcend-cll-004-trial 2023-12-13T03:58:01.224Z https://assets.delveinsight.com/products/asco/1686136434-phase-i-ii-transcend-cll-004-trial.png Bristol Myers Squibb's BREYANZI Demonstrates Swift Responses and Impressive Undetectable MRD Rates in Relapsed/Refractory CLL/SLL daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-i-ii-epcore-nhl-2-trial 2023-12-13T03:58:01.202Z https://assets.delveinsight.com/products/asco/1686135949-phase-i-ii-epcore-nhl-2-trial.png Encouraging Responses in Follicular Lymphoma with the Addition of Epcoritamab to Rituximab and Lenalidomide daily 0.8 https://www.delveinsight.com/asco-conference/article/afnt-211-for-kras-gG12v-mutations 2023-12-13T03:58:01.183Z https://assets.delveinsight.com/products/asco/1686118139-afnt-211-for-kras-gG12v-mutations.png AFNT-211: Empowering TCR-T Therapy to Conquer KRAS G12V Mutated Solid Tumors with Enhanced FAS-41BB Activation daily 0.8 https://www.delveinsight.com/asco-conference/article/codebreak-101 2023-12-13T03:58:01.168Z https://assets.delveinsight.com/products/asco/1686117644-codebreak-101.png CodeBreaK 101: Promising Safety and Efficacy of Sotorasib, Panitumumab, and FOLFIRI in Previously Treated KRAS G12C-Mutated Metastatic Colorectal Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/herkules-3-trial 2023-12-13T03:58:01.154Z https://assets.delveinsight.com/products/asco/1686117280-herkules-3-trial.png Erasca Announces Update on ERAS-007, an ERK Inhibitor, from HERKULES-3 Trial daily 0.8 https://www.delveinsight.com/asco-conference/article/d-1553-phase-i-ii-clinical-trial 2023-12-13T03:58:01.136Z https://assets.delveinsight.com/products/asco/1686116980-d-1553-phase-i-ii-clinical-trial.png InventisBio released encouraging findings from the Phase I/II clinical trial of D-1553, demonstrating its potential as a monotherapy or in combination for treating advanced colorectal cancer patients who have the KRAS G12C mutation. daily 0.8 https://www.delveinsight.com/asco-conference/article/qualigen-pan-ras-inhibitors 2023-12-13T03:58:01.116Z https://assets.delveinsight.com/products/asco/1686116664-qualigen-pan-ras-inhibitors.png Qualigen Therapeutics presented findings from the preclinical studies of their novel Pan-KRAS inhibitors, demonstrating the impact on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines. daily 0.8 https://www.delveinsight.com/asco-conference/article/keytruda-in-r-r-chl-and-r-r-pmbcl 2023-12-13T03:58:01.098Z https://assets.delveinsight.com/products/asco/1686116232-keytruda-in-r-r-chl-and-r-r-pmbcl.png KEYTRUDA: Effective Treatment for R/R cHL and R/R PMBCL with Manageable Safety Profile daily 0.8 https://www.delveinsight.com/asco-conference/article/rosewood-study 2023-12-13T03:58:01.080Z https://assets.delveinsight.com/products/asco/1686115931-rosewood-study.png BeiGene’s ROSEWOOD Study Reveals Strong Efficacy and Safety of Zanubrutinib plus Obinutuzumab in Heavily Pretreated Relapsed/Refractory FL Patients daily 0.8 https://www.delveinsight.com/asco-conference/article/gec255-phase-i-trial 2023-12-13T03:58:01.061Z https://assets.delveinsight.com/products/asco/1686115449-gec255-phase-i-trial.png GenEros released encouraging findings from the Phase I clinical trial of GEC255, demonstrating its potential in treating advanced non-small cell lung cancer (NSCLC) patients who have the KRAS G12C mutation. daily 0.8 https://www.delveinsight.com/asco-conference/article/destiny-pantumor02-phase-ii-trial 2023-12-13T03:58:01.035Z https://assets.delveinsight.com/products/asco/1686062788-destiny-pantumor02-phase-ii-trial.png Impressive ORR of 37.1%: ENHERTU by AstraZeneca and Daiichi Sankyo Shines in DESTINY-PanTumor02 Phase II Trial daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-contact-03-trial 2023-12-13T03:58:01.006Z https://assets.delveinsight.com/products/asco/1686062441-phase-iii-contact-03-trial.png Roche’s Atezolizumab and Exelixis’s Cabozantinib Combination Yields No Added Benefit in Second-Line Advanced Renal Cell Carcinoma daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-talapro-2-study 2023-12-13T03:58:00.990Z https://assets.delveinsight.com/products/asco/1686060635-phase-iii-talapro-2-study.png Pfizer revealed the promising Phase III Results from TALAPRO-2 study, paving the way for breakthrough treatment in gene-mutated mCRPC daily 0.8 https://www.delveinsight.com/asco-conference/article/jupiter-02-phase-iii-study 2023-12-13T03:58:00.966Z https://assets.delveinsight.com/products/asco/1686060136-jupiter-02-phase-iii-study.png Toripalimab in combination with gemcitabine-cisplatin chemotherapy demonstrates significant improvement in the overall survival and progression-free survival daily 0.8 https://www.delveinsight.com/asco-conference/article/clinical-findings-on-gfh018-and-toripalimab 2023-12-13T03:58:00.955Z https://assets.delveinsight.com/products/asco/1686059821-clinical-findings-on-gfh018-and-toripalimab.png Genfleet Therapeutics Presented the Updated Clinical Findings on GFH018 and Toripalimab Used in Combination for the Advanced Solid Tumor Patients daily 0.8 https://www.delveinsight.com/asco-conference/article/tacti-002-part-c-study 2023-12-13T03:58:00.939Z https://assets.delveinsight.com/products/asco/1686059371-tacti-002-part-c-study.png Immutep Presents the Final Results from TACTI-002 Part C Study, Showing Encouraging Results in Second-line HNSCC Patients daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-zuma-7-study 2023-12-13T03:58:00.928Z https://assets.delveinsight.com/products/asco/1686058925-phase-iii-zuma-7-study.png Gilead Sciences unveiled the striking results of Phase III ZUMA-7 study, highlighting YESCARTA CAR T-cell therapy's superiority over standard of care in initial treatment for curative Setting in R/R LBCL daily 0.8 https://www.delveinsight.com/asco-conference/article/zilovertamab-vedotin-phase-ii-results 2023-12-13T03:58:00.914Z https://assets.delveinsight.com/products/asco/1686055311-zilovertamab-vedotin-phase-ii-results.png Promising early Phase II results of Merck’s zilovertamab vedotin demonstrate efficacy against relapsed or refractory DLBCL daily 0.8 https://www.delveinsight.com/asco-conference/article/monumental-1-study 2023-12-13T03:58:00.899Z https://assets.delveinsight.com/products/asco/1686054916-monumental-1-study.png Janssen’s Talquetamab Shows Durable Responses in Heavily Pretreated Multiple Myeloma daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-i-ii-artemide-01-study 2023-12-13T03:58:00.880Z https://assets.delveinsight.com/products/asco/1686054275-phase-i-ii-artemide-01-study.png AstraZeneca’s rilvegostomig, a TIGIT and PD-1 bispecific, offers hope for advanced pd-l1+ NSCLC after prior treatment resistance. daily 0.8 https://www.delveinsight.com/asco-conference/article/abbv-011-phase-i-trial 2023-12-13T03:58:00.867Z https://assets.delveinsight.com/products/asco/1686051896-abbv-011-phase-i-trial.png Promising Results from Phase I Clinical Trial of Investigational Agent ABBV-011 daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-indigo-trial 2023-12-13T03:58:00.851Z https://assets.delveinsight.com/products/asco/1686051472-phase-iii-indigo-trial.png Vorasidenib Significantly Delays Disease Progression in Grade II IDH-Mutated Glioma daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-3-thor-study 2023-12-13T03:58:00.842Z https://assets.delveinsight.com/products/asco/1686051081-phase-3-thor-study.png Phase 3 THOR Study: BALVERSA Outperforms Chemotherapy, Resulting in Over Four-Month Improvement in Median Overall Survival in Cohort 1 Patients daily 0.8 https://www.delveinsight.com/asco-conference/article/adagir-study 2023-12-13T03:58:00.830Z https://assets.delveinsight.com/products/asco/1686050738-adagir-study.png Radiation Therapy Combined with TLR Agonists Like BDB001 and Atezolizumab Displays Enhanced Anti-Tumor Immunity With Promising DCR. daily 0.8 https://www.delveinsight.com/asco-conference/article/glofitamab+pola-r-chp-in-1l-dlbcl-treatment 2023-12-13T03:58:00.821Z https://assets.delveinsight.com/products/asco/1686050345-glofitamab+pola-r-chp-in-1l-dlbcl-treatment.png Roche presented the promising findings from the expansion stage of an ongoing Phase Ib study of glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) daily 0.8 https://www.delveinsight.com/asco-conference/article/kelun-pharma-skb264 2023-12-13T03:58:00.804Z https://assets.delveinsight.com/products/asco/1685975995-kelun-pharma-skb264.png Kelun Pharma’s TROP2-targeting ADC shows early signs of potential in NSCLC patients daily 0.8 https://www.delveinsight.com/asco-conference/article/sleeping-beauty-tcr-t-cells-in-phase-i-ii-study 2023-12-13T03:58:00.789Z https://assets.delveinsight.com/products/asco/1685975245-sleeping-beauty-tcr-t-cells-in-phase-i-ii-study.png Alaunos Therapeutics presented early data from their Phase I study on Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations in solid tumors, showing promising safety and efficacy. daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-ii-destiny-crc02-study 2023-12-13T03:58:00.773Z https://assets.delveinsight.com/products/asco/1685972168-phase-ii-destiny-crc02-study.png A reduced dosage of Trastuzumab Deruxtecan demonstrates anti-tumor effectiveness in patients with HER2-positive mCRC daily 0.8 https://www.delveinsight.com/asco-conference/article/linker-mm1-study 2023-12-13T03:58:00.758Z https://assets.delveinsight.com/products/asco/1685966130-linker-mm1-study.png Linvoseltamab demonstrates high response rate and manageable toxicity in pretreated myeloma patients daily 0.8 https://www.delveinsight.com/asco-conference/article/serena-2-phase-ii-trial 2023-12-13T03:58:00.736Z https://assets.delveinsight.com/products/asco/1685962597-serena-2-phase-ii-trial.png AstraZeneca demonstrated the significant findings from the SERENA-2 Phase II trial of camizestrant versus fulvestrant daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-iii-mirasol-trial 2023-12-13T03:58:00.725Z https://assets.delveinsight.com/products/asco/1685959881-phase-iii-mirasol-trial.png ELAHERE results from MIRASOL recognized as transformative for the treatment of FRα-positive platinum-resistant ovarian cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/lumakras-phase-3-trial 2023-12-13T03:58:00.711Z https://assets.delveinsight.com/products/asco/1685959283-lumakras-phase-3-trial.png Intracranial Efficacy of Sotorasib vs. Docetaxel in KRAS G12C-Mutated NSCLC: Insights from a Phase III Trial (Abstract # LBA9016) daily 0.8 https://www.delveinsight.com/asco-conference/article/elaine-2-trial-results 2023-12-13T03:58:00.694Z https://assets.delveinsight.com/products/asco/1685957795-elaine-2-trial-results.png ESR1 ER+/HER2- metastatic breast cancer market to witness the entry of a SERM in pretreated patients daily 0.8 https://www.delveinsight.com/asco-conference/article/amplify-201-phase-i-trial 2023-12-13T03:58:00.683Z https://assets.delveinsight.com/products/asco/1685957366-amplify-201-phase-i-trial.png Elicio Therapeutics shared encouraging interim findings from the AMPLIFY-201 –Phase I trial of therapeutic cancer immunotherapy. daily 0.8 https://www.delveinsight.com/asco-conference/article/nalirifox-in-metastatic-mancreatic-ductal-adenocarcinoma 2023-12-13T03:58:00.666Z https://assets.delveinsight.com/products/asco/1685956164-nalirifox-in-metastatic-mancreatic-ductal-adenocarcinoma.png Ipsen presents the updated OS (overall survival) data for NALIRIFOX compared to Gem+NabP as a first-line therapy in patients with mPDAC. daily 0.8 https://www.delveinsight.com/asco-conference/article/toripalimab-and-nab-paclitaxel-nab-p-combination 2023-12-13T03:58:00.662Z https://assets.delveinsight.com/products/asco/1685882565-toripalimab-and-nab-paclitaxel-nab-p-combination.png Junshi Biosciences revealed the impressive findings from the Phase III trial of toripalimab versus placebo, in combination with nab-P for patients with metastatic or recurrent TNBC daily 0.8 https://www.delveinsight.com/asco-conference/article/bracelet-1-pre0113-trial 2023-12-13T03:58:00.645Z https://assets.delveinsight.com/products/asco/1685881860-bracelet-1-pre0113-trial.png Oncolytics unveils groundbreaking findings from BRACELET-1 (PrE0113) trial, harnessing inflammatory phenotype in metastatic HR+/HER2- breast cancer with pelareorep, paclitaxel, and avelumab combination daily 0.8 https://www.delveinsight.com/asco-conference/article/herizon-btc-01-study-findings 2023-12-13T03:58:00.629Z https://assets.delveinsight.com/products/asco/1685880902-herizon-btc-01-study-findings.png Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase IIb Trial Data of HERIZON-BTC-01 study Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers daily 0.8 https://www.delveinsight.com/asco-conference/article/sutro-luveltamab-tazevibulin 2023-12-13T03:58:00.606Z https://assets.delveinsight.com/products/asco/1685880125-sutro-luveltamab-tazevibulin.png Luveltamab Tazevibulin provides significant clinical benefit for ovarian cancer patients, regardless of the varying levels of FolRα-expression heterogeneity daily 0.8 https://www.delveinsight.com/asco-conference/article/gracells-bcma-cd19-dual-targeting-fastcar-t-therapy 2023-12-13T03:58:00.591Z https://assets.delveinsight.com/products/asco/1685879639-gracells-bcma-cd19-dual-targeting-fastcar-t-therapy.png BCMA/CD19 dual-targeting GC012F demonstrates highly promising activity in RRMM including high-risk patients and heavily pretreated patients with prior exposure to anti-38 mAb, PI, IMIDs daily 0.8 https://www.delveinsight.com/asco-conference/article/astraZenecas-duo-o-trial 2023-12-13T03:58:00.561Z https://assets.delveinsight.com/products/asco/1685879044-astraZenecas-duo-o-trial.png Improved outcomes in advanced ovarian cancer: LYNPARZA and IMFINZI combination reduces disease progression risk by 37% in DUO-O Phase III trial for patients without tumor BRCA mutations daily 0.8 https://www.delveinsight.com/asco-conference/article/pfizers-cdk4-inhibitor-pf-07220060 2023-12-13T03:58:00.543Z https://assets.delveinsight.com/products/asco/1685878458-pfizers-cdk4-inhibitor-pf-07220060.png Next-Gen CDK4-Selective Inhibitor PF-07220060 shines in first-in-human Phase I/IIa study, unveiling impressive results for advanced solid tumors enriched with HR+ HER2- mBC patients who experienced prior CDK4/6 Inhibitor and endocrine therapy progression daily 0.8 https://www.delveinsight.com/asco-conference/article/pfizers-pf-07104091 2023-12-13T03:58:00.524Z https://assets.delveinsight.com/products/asco/1685877972-pfizers-pf-07104091.png Pfizer revealed the first-in-human data of potent and innovative CDK2-selective inhibitor PF-07104091 in advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/janssen-teclistamab-and-talquetamab-combination 2023-12-13T03:58:00.506Z https://assets.delveinsight.com/products/asco/1685877507-janssen-teclistamab-and-talquetamab-combination.png Janssen's Dual Bispecific Combination Study Achieves Unprecedented 96% Overall Response Rate in Relapsed or Refractory Multiple Myeloma Patients daily 0.8 https://www.delveinsight.com/asco-conference/article/multiple-myeloma-trimm-2-study 2023-12-13T03:58:00.472Z https://assets.delveinsight.com/products/asco/1685876821-multiple-myeloma-trimm-2-study.png Potent Responses Observed in Relapsed/Refractory Multiple Myeloma with Talquetamab Plus Daratumumab Combination Therapy daily 0.8 https://www.delveinsight.com/asco-conference/article/elranatamab-r-r-myeloma 2023-12-13T03:58:00.440Z https://assets.delveinsight.com/products/asco/1685876395-elranatamab-r-r-myeloma.png Elranatamab Sparks Remarkable Responses in Relapsed/Refractory Myeloma Patients Following BCMA Therapy daily 0.8 https://www.delveinsight.com/asco-conference/article/anti-cd123-nkp46×cd16-nk-cell-engager-sar443579 2023-12-13T03:58:00.407Z https://assets.delveinsight.com/products/asco/1685789605-anti-cd123-nkp46×cd16-nk-cell-engager-sar443579.png A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia daily 0.8 https://www.delveinsight.com/asco-conference/article/reblozyl-phase-iii-commands 2023-12-13T03:58:00.388Z https://assets.delveinsight.com/products/asco/1685789079-reblozyl-phase-iii-commands.png Can REBLOZYL become a potential new first-line standard of care (SoC) for transfusion-dependent, lower-risk myelodysplastic syndromes? daily 0.8 https://www.delveinsight.com/asco-conference/article/felix-study-obe-cel 2023-12-13T03:58:00.378Z https://assets.delveinsight.com/products/asco/1685787126-felix-study-obe-cel.png FELIX Study Validates Impressive Product Profile of Obe-cel: Efficacy and Safety in Perfect Harmony daily 0.8 https://www.delveinsight.com/asco-conference/article/natalee-trial-in-ealry-breast-cancer 2023-12-13T03:58:00.365Z https://assets.delveinsight.com/products/asco/1685786437-natalee-trial-in-ealry-breast-cancer.png Novartis unveils groundbreaking results from the pivotal Phase III NATALEE trial in early breast cancer patients daily 0.8 https://www.delveinsight.com/asco-conference/article/imetelstats-phase-iii-results-for-mds 2023-12-13T03:58:00.356Z https://assets.delveinsight.com/products/asco/1685785869-imetelstats-phase-iii-results-for-mds.png IMerge: Promising Results of a Phase III Study Show Imetelstat's Potential in Transfusion-Dependent Non-del (5q) Lower-Risk Myelodysplastic Syndromes daily 0.8 https://www.delveinsight.com/asco-conference/article/nivolumab-plus-chemotherapy-g-gej-cancer 2023-12-13T03:58:00.347Z https://assets.delveinsight.com/products/asco/1685784966-nivolumab-plus-chemotherapy-g-gej-cancer.png Nivolumab plus chemotherapy as a postoperative adjuvant therapy for stage III G/GEJ Cancer fell short of meeting the primary endpoint. However, it stimulates contemplation and prompts deeper reflection daily 0.8 https://www.delveinsight.com/asco-conference/article/asco-2023-adc-preview 2023-12-13T03:58:00.335Z https://assets.delveinsight.com/products/asco/1685702706-asco-2023-adc-preview.png Will the DESTINY-PanTumor02 trial serve to reinforce the potential of ENHERTU in treating a range of HER2-expressing cancers? daily 0.8 https://www.delveinsight.com/asco-conference/article/head-and-neck-cancer-asco-2023-preview 2023-12-13T03:58:00.330Z https://assets.delveinsight.com/products/asco/1685678986-head-and-neck-cancer-asco-2023-preview.png ASCO 2023: A Quick preview of Late-Breaking Abstracts (LBA) and Late Phase abstracts on Head and Neck Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/asco-2023-nsclc-preview 2023-12-13T03:58:00.322Z https://assets.delveinsight.com/products/asco/1685678586-asco-2023-nsclc-preview.png ASCO 2023 PREVIEW CONTENT FOR NON-SMALL CELL LUNG CANCER (NSCLC) daily 0.8 https://www.delveinsight.com/asco-conference/article/asco-2023-breast-cancer-preview 2023-12-13T03:58:00.313Z https://assets.delveinsight.com/products/asco/1685536623-KISQALI-in-early-breast-cancer.png ASCO 2023 PREVIEW CONTENT FOR BREAST CANCER: GRIPPING INSIGHTS INTO BREAST CANCER daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/belzutifan-plus-cabozantinib-in-renal-cell-carcinoma 2023-12-13T03:58:00.305Z https://assets.delveinsight.com/products/asco/1663171320-Belzutifan-plus-Cabozantinib-in-Renal-Cell-Carcinoma.png Phase II Study of Belzutifan plus Cabozantinib as First-line Treatment of Advanced Renal Cell Carcinoma (RCC): Cohort 1 of LITESPARK-003 daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/al102-in-desmoid-tumor 2023-12-13T03:58:00.295Z https://assets.delveinsight.com/products/asco/1663081566-Glimpse-of-optimism-in-desmoid-tumor.png Initial Findings from the Phase II/III Trial of AL102 for Desmoid Tumor treatment (DT) daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/nirogacestat-defi-trial 2023-12-13T03:58:00.282Z https://assets.delveinsight.com/products/asco/1663079759-nirogacestat-defi-trial.png Nirogacestat shows promising outcomes in desmoid tumor patients from the DeFi trial. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/fresco-2-trial-of-fruquintinib-in-colorectal-cancer 2023-12-13T03:58:00.268Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/tucatinib-and-trastuzumab-in-metastatic-colorectal-cancer 2023-12-13T03:58:00.258Z https://assets.delveinsight.com/products/asco/1663070567-Tucatinib-and-Trastuzumab-in-Metastatic-Colorectal-Cancer.png Tucatinib and trastuzumab show promise for HER2+ refractory mCRC patients, potentially securing a first-mover advantage. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/lumakras-codebreak200 2023-12-13T03:58:00.248Z https://assets.delveinsight.com/products/asco/1663069186-lumakras-codebreak200.png Results from the Phase III CodeBreak200 trial demonstrated that Lumakras achieved better progression-free survival (PFS) compared to docetaxel in patients with non-small cell lung cancer (NSCLC) who had received prior treatment. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/encorafenib-and-cetuximab-in-metastatic-colorectal-cancer 2023-12-13T03:58:00.234Z https://assets.delveinsight.com/products/asco/1663069495-Encorafenib-and-cetuximab-in-Metastatic-Colorectal-Cancer.png Proven combination in refractory mCRC now being tested in front-line patients to gain market share. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/sanofi-ameera-3-trial 2023-12-13T03:58:00.226Z https://assets.delveinsight.com/products/asco/1663067595-sanofi-ameera-3-trial.png Findings from the Phase II AMEERA-3 trial comparing amcenestrant with physician’s choice endocrine therapy in endocrine-resistant ER+/HER2− advanced breast cancer. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/tepotinib-osimertinib-insight-2 2023-12-13T03:58:00.213Z https://assets.delveinsight.com/products/asco/1662998395-tepotinib-osimertinib-insight-2.png Early findings from the INSIGHT 2 trial assess Tepotinib + Osimertinib in EGFRm NSCLC with MET amplification after 1L osimertinib. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/cypides-study-of-odm-208-in-mcrpc 2023-12-13T03:58:00.196Z https://assets.delveinsight.com/products/asco/1663009972-CYPIDES-study-of-ODM-208-in-mCRPC.png Preliminary Phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/tremelimumab-durvalumab-chemotherapy-nsclc 2023-12-13T03:58:00.186Z https://assets.delveinsight.com/products/asco/1663009923-Phase-III-POSEIDON-trial-in-NSCLC.png Triplet combination of tremelimumab + durvalumab + chemotherapy (T + D + CT) generated long-term overall survival (OS) benefit in frontline patients with metastatic NSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/propel-trial-of-abiraterone-and-olaparib-in-mcrpc 2023-12-13T03:58:00.174Z https://assets.delveinsight.com/products/asco/1663009850-Phase-III-PROpel-trial-in-mCRPC.png Closely watched Lynparza, the first PARP inhibitor to enter the first-line metastatic castration-resistant Prostate Cancer (mCRPC) setting demonstrated superior clinical benefit over abiraterone alone daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/pembrolizumab-keynote-412-trial-in-hnscc 2023-12-13T03:58:00.163Z https://assets.delveinsight.com/products/asco/1663009800-Keynote-412-trial-fails-in-HNSCC.png The Keynote-412 trial displays statistically insignificant results for Pembrolizumab plus CRT in locally advanced head and neck squamous cell carcinoma daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/astraZeneca-medi5752 2023-12-13T03:58:00.152Z https://assets.delveinsight.com/products/asco/1663009741-MEDI5752-plus-chemotherapy-in-non-squamous-NSCLC.png MEDI5752 plus chemotherapy doubled the duration of response among patients with treatment-naïve non-squamous NSCLC, according to findings from a phase Ib/II study daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/destiny-lung-02-enhertu 2023-12-13T03:58:00.138Z https://assets.delveinsight.com/products/asco/1663009681-Updates-on-Enhertu's-approval-as-HER2-directed-treatment.png Trastuzumab Deruxtecan (Enhertu), the first US FDA-authorized HER2-directed treatment, produces clinically significant tumor response in patients with HER2m NSCLC in the Phase II DESTINY-Lung02 study daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/durvalumab-olaparib-bevacizumab-astrazeneca 2023-12-13T03:58:00.102Z https://assets.delveinsight.com/products/asco/1663008359-MEDIOLA-clinical-Trial-Update-in-Ovarian-Cancer.png AstraZeneca’s Triplet regimen (durvalumab + Olaparib + Bevacizumab) bested over olaparib plus durvalumab doublet regimen in critical clinical profile evaluation in ovarian cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/cemiplimab-in-recurrent-metastatic-cervical-cancer 2023-12-13T03:58:00.084Z https://assets.delveinsight.com/products/asco/1663009595-cemiplimab-in-recurrentmetastatic-cervical-cancer.png Cemiplimab in comparison with Investigator’s choice (IC) of chemotherapy in recurrent/metastatic cervical carcinoma daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/intermittent-relacorilant-with-nab-paclitaxel-in-ovarian-cancer 2023-12-13T03:58:00.075Z https://assets.delveinsight.com/products/asco/1662959142-intermittent-relacorilant-with-nab-paclitaxel-in-ovarian-cancer.png Clinical efficacy and safety analysis update of intermittent relacorilant with nab-paclitaxel in heavily pretreated ovarian cancer patients daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/naporafenib-efficacy-in-melanoma 2023-12-13T03:58:00.066Z https://assets.delveinsight.com/products/asco/1663008838-Naporafenib-(LXH-254)-efficacy-in-Melanoma.png Naporafenib (LXH-254) combinations prove to exhibit favorable efficacy with a tolerable safety profile in NRAS-Mutant Unresectable/Metastatic Melanoma daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/talimogene-laherparepvec-in-melanoma 2023-12-13T03:58:00.053Z https://assets.delveinsight.com/products/asco/1663008777-T-VEC-in-IVM1a-melanoma.png Talimogene laherparepvec (T-VEC) as neoadjuvant treatment plus surgery vs immediate surgery in patients with resectable stage IVM1a melanoma daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/xevinapant-efficacy-in-head-and-Neck-cancer 2023-12-13T03:58:00.043Z https://assets.delveinsight.com/products/asco/1663008717-Updates-on-Xevinapant's-efficacy-outcomes-in-Head-and-Neck-Cancer.png A Groundbreaking Study in Head and Neck Cancer to Improve Cure Rate by Adding new Treatment to SoC daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/phase-II-fides-01-derazantinib 2023-12-13T03:58:00.032Z https://assets.delveinsight.com/products/asco/1663008655-Basilea's-lead-therapy-in-intrahepatic-cholangiocarcinoma.png Efficacy results from Phase II (FIDES-01) study with FGFR2F or FGFRMA patients with advanced iCCA with A, ≥1 prior chemotherapy daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/nivolumab-ipilimumab-checkmate-358 2023-12-13T03:58:00.016Z https://assets.delveinsight.com/products/asco/1663008567-Checkmate-358-trial-of-nivolumab-±-ipilimumab-in-cervical-cancer.png The combination of nivolumab with or without ipilimumab in R/M cervical cancer showed encouraging safety and efficacy results daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/hengruis-pyrotinib 2023-12-13T03:58:00.002Z https://assets.delveinsight.com/products/asco/1662898360-hengruis-pyrotinib.png Safety and efficacy results for Phase III trial of a dual anti-HER2 regimen of pyrotinib plus trastuzumab and docetaxel compared with placebo plus trastuzumab and docetaxel in untreated HER2-positive metastatic breast cancer (PHILA) daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/rucaparib-ariel-4-confirmatory-clinical-study 2023-12-13T03:57:59.988Z https://assets.delveinsight.com/products/asco/1662897360-rucaparib-ariel-4-confirmatory-clinical-study.png Confirmatory clinical OS results raising questions about the use of rucaparib in advanced Ovarian Cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/trodelvy-tropics-02-result 2023-12-13T03:57:59.971Z https://assets.delveinsight.com/products/asco/1662811676-Trodelvy-TROPiCS-02-result.png Data from the planned second interim overall survival (OS) analysis further support Trodelvy (sacituzumab govitecan) in HR+/HER2– metastatic breast cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/eli-lilly-trials-of-verzenio 2023-12-13T03:57:59.959Z https://assets.delveinsight.com/products/asco/1663008294-Eli-Lilly's-Key-Update-on-MONARCH-3-trial-of-Verzenio.png Verzenio, an Eli Lilly CDK4/6 inhibitor, missed the statistical significance in the second interim overall survival analysis, but exhibited a favorable trend; all eyes are now on the final OS analysis. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/hengruis-dalpiciclib-dawna-2 2023-12-13T03:57:59.950Z https://assets.delveinsight.com/products/asco/1663007974-Hengrui's-Dalpiciclib-in-HR+HER2-advanced-breast-cancer.png Interim analysis of Phase III trial of Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2) daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/gdc-6036 2023-12-13T03:57:59.936Z https://assets.delveinsight.com/products/asco/1663007898-GDC-6036-monotherapy-KRAS-G12C-mutation.png Beyond Adagrasib and Lumakras, Roche's GDC-6036's phase I data are also scheduled to be presented at ESMO 2022. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/colorectal-cancer-market 2023-12-13T03:57:59.926Z https://assets.delveinsight.com/products/asco/1663007842-Sotorasib-in-combination-with-panitumumab-in-colorectal-cancer.png Amgen plans to target the colorectal cancer market with a LUMAKRAS–VECTIBIX combo, though past lung cancer data showed possible liver toxicity risks. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/krystal-1-study 2023-12-13T03:57:59.921Z https://assets.delveinsight.com/products/asco/1663007775-Miratis-KRYSTAL-1-study-in-advance-CRC.png KRYSTAL-1 study updates: adagrasib ± cetuximab shows efficacy and safety in KRASG12C-mutated advanced CRC. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/ds-7300-esmo 2023-12-13T03:57:59.912Z https://assets.delveinsight.com/products/asco/1663007705-B7-H3-(CD276)-in-the-treatment-of-resistant-cancer.png Extended follow-up results of Phase I/II study of DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) in patients with advanced solid tumors (Lung Cancer, Esophageal Cancer, and Prostate Cancer) daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/rucaparib-vs-chemotherapy 2023-12-13T03:57:59.900Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/ovarian-cancer-esmo 2023-12-13T03:57:59.892Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/astrazeneca-durvalumab-olaparib-bevacizumab 2023-12-13T03:57:59.883Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/fruquintinib-colorectal-cancer 2023-12-13T03:57:59.877Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/encorafenib-plus-cetuximab 2023-12-13T03:57:59.861Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/cholangiocarcinoma-esmo-highlights 2023-12-13T03:57:59.852Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/amb-05x-esmo 2023-12-13T03:57:59.845Z daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/regeneron-lag-3-update 2023-12-13T03:57:59.835Z https://assets.delveinsight.com/products/asco/1662554352-regeneron-lag-3-update.jpg Preliminary findings of fianlimab (LAG-3 antibody) combined with cemiplimab in advanced melanoma. daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/mcrpc-preview-esmo 2023-12-13T03:57:59.821Z https://assets.delveinsight.com/products/asco/1662534067-mcrpc-highlights.png Preview of ESMO 2022: Metastatic Castration-Resistant Prostate Cancer (mCRPC) daily 0.8 https://www.delveinsight.com/esmo-conference-2022/article/next-generation-serds-esmo 2023-12-13T03:57:59.810Z https://assets.delveinsight.com/products/asco/1662521899-Next-generation-SERDs.png Challenges for Next-gen SERDs and Verzenio’s Lead in Adjuvant ER+/HER2− Early Breast Cancer Insights daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-3-it-matters-study 2023-12-13T03:57:59.797Z daily 0.8 https://www.delveinsight.com/asco-conference/article/dostarlimab-rectal-cancer 2023-12-13T03:57:59.776Z daily 0.8 https://www.delveinsight.com/asco-conference/article/veracity-trial 2023-12-13T03:57:59.761Z daily 0.8 https://www.delveinsight.com/asco-conference/article/sanofi-adc-is-targeting-ceacam5 2023-12-13T03:57:59.750Z daily 0.8 https://www.delveinsight.com/asco-conference/article/elranatamab-exhibits-asco 2023-12-13T03:57:59.739Z daily 0.8 https://www.delveinsight.com/asco-conference/article/next-generation-serds 2023-12-13T03:57:59.703Z daily 0.8 https://www.delveinsight.com/asco-conference/article/paxalisib-kazia-therapeutics 2023-12-13T03:57:59.695Z daily 0.8 https://www.delveinsight.com/asco-conference/article/novartis-tafinlar-and-mekinists-combo 2023-12-13T03:57:59.685Z daily 0.8 https://www.delveinsight.com/asco-conference/article/mimivaxs-survaxm 2023-12-13T03:57:59.675Z daily 0.8 https://www.delveinsight.com/asco-conference/article/sermonixs-lasofoxifene 2023-12-13T03:57:59.626Z daily 0.8 https://www.delveinsight.com/asco-conference/article/junshis-domestic-toripalimabs 2023-12-13T03:57:59.589Z daily 0.8 https://www.delveinsight.com/asco-conference/article/her3-breast-cancer-trial 2023-12-13T03:57:59.577Z daily 0.8 https://www.delveinsight.com/asco-conference/article/abbvies-telisotuzumab-vedotin 2023-12-13T03:57:59.544Z daily 0.8 https://www.delveinsight.com/asco-conference/article/competitive-therapeutic-landscape-of-multiple-myeloma 2023-12-13T03:57:59.524Z daily 0.8 https://www.delveinsight.com/asco-conference/article/neratinib-puma-biotech 2023-12-13T03:57:59.508Z daily 0.8 https://www.delveinsight.com/asco-conference/article/durvalumab-immunotherapy 2023-12-13T03:57:59.502Z daily 0.8 https://www.delveinsight.com/asco-conference/article/panitumumab-mfolfox6-versus-bevacizumab 2023-12-13T03:57:59.493Z daily 0.8 https://www.delveinsight.com/asco-conference/article/durvalumab-chemo-highlights 2023-12-13T03:57:59.483Z daily 0.8 https://www.delveinsight.com/asco-conference/article/breyanzi-for-large-b-cell-lymphoma-treatment 2023-12-13T03:57:59.469Z daily 0.8 https://www.delveinsight.com/asco-conference/article/teclistamab-asco 2023-12-13T03:57:59.454Z daily 0.8 https://www.delveinsight.com/asco-conference/article/merus-zenocutuzumab 2023-12-13T03:57:59.436Z daily 0.8 https://www.delveinsight.com/asco-conference/article/colorectal-cancer-asco 2023-12-13T03:57:59.431Z daily 0.8 https://www.delveinsight.com/asco-conference/article/lag-3-combination-drug-opdualag 2023-12-13T03:57:59.426Z daily 0.8 https://www.delveinsight.com/asco-conference/article/skyscraper-02-fails 2023-12-13T03:57:59.415Z daily 0.8 https://www.delveinsight.com/asco-conference/article/enhertu-her2-low-patients 2023-12-13T03:57:59.403Z daily 0.8 https://www.delveinsight.com/asco-conference/article/daiichis-patritumab 2023-12-13T03:57:59.395Z daily 0.8 https://www.delveinsight.com/asco-conference/article/gilead-trodelvy 2023-12-13T03:57:59.387Z daily 0.8 https://www.delveinsight.com/asco-conference/article/cartitude-2-trial 2023-12-13T03:57:59.372Z daily 0.8 https://www.delveinsight.com/asco-conference/article/braftovi-microsatellite-stable-metastatic-colorectal-cancer 2023-12-13T03:57:59.364Z daily 0.8 https://www.delveinsight.com/asco-conference/article/roche-glofitamab 2023-12-13T03:57:59.350Z daily 0.8 https://www.delveinsight.com/asco-conference/article/exelixis-cabozantinib 2023-12-13T03:57:59.335Z daily 0.8 https://www.delveinsight.com/asco-conference/article/miratis-adagrasib-overthrows-amgens-sotorasib 2023-12-13T03:57:59.329Z https://assets.delveinsight.com/case-studies/1708078247502-miratis-adagrasib-overthrows-amgens-sotorasib.png Mirati’s Adagrasib overthrows Amgen’s Sotorasib and yielded a response rate of 43% in KRAS G12C mutation mNSCLC. Do first-mover advantage and safety give an edge to Sotorasib? daily 0.8 https://www.delveinsight.com/asco-conference/article/immuteps-next-generation-immunotherapy 2023-12-13T03:57:59.317Z daily 0.8 https://www.delveinsight.com/asco-conference/article/nsclc-patients-with-egfr-exon-20-insertion-mutations 2023-12-13T03:57:59.308Z https://assets.delveinsight.com/products/asco/1654352428-NSCLC-Highlights.png Cullinan Oncology’s CLN-081 demonstrates encouraging response in NSCLC patients with EGFR Exon 20 Insertion Mutations. daily 0.8 https://www.delveinsight.com/asco-conference/article/gynecologic-cancer 2023-12-13T03:57:59.295Z daily 0.8 https://www.delveinsight.com/asco-conference/article/dlbcl-preview 2023-12-13T03:57:59.289Z https://assets.delveinsight.com/products/asco/1654172638-preview-on-Diffuse-large-B-cell-lymphoma.png A Quick preview on Diffuse large B-cell lymphoma daily 0.8 https://www.delveinsight.com/asco-conference/article/melanoma-preview 2023-12-13T03:57:59.280Z daily 0.8 https://www.delveinsight.com/asco-conference/article/follicular-lymphoma-preview 2023-12-13T03:57:59.276Z https://assets.delveinsight.com/products/asco/1654157737-Follicular-Lymphoma.png Follicular Lymphoma daily 0.8 https://www.delveinsight.com/asco-conference/article/prostate-cancer-market 2023-12-13T03:57:59.270Z https://assets.delveinsight.com/products/asco/1654057395-ASCO-Article-5.jpg ASCO 2022 Preview daily 0.8 https://www.delveinsight.com/asco-conference/article/breast-cancer-preview 2023-12-13T03:57:59.263Z https://assets.delveinsight.com/products/asco/1654057371-ADAURA-trial-results-presented-at-esmo-2020.jpg ASCO 2022 Preview Content for Breast Cancer daily 0.8 https://www.delveinsight.com/asco-conference/article/lung-cancer-abstracts 2023-12-13T03:57:59.255Z https://assets.delveinsight.com/products/asco/1653393214-Lung-Cancer-Market.png ASCO 2022: A Quick preview of Late-Breaking Abstracts (LBA) on Lung Cancer. Let’s not miss it! daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/thyroid-cancer-esmo 2023-12-13T03:57:59.247Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/keynote-716-esmo 2023-12-13T03:57:59.242Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/melanoma-highlights 2023-12-13T03:57:59.236Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/esmo-breast-cancer-highlights 2023-12-13T03:57:59.231Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/cervical-cancer-esmo-highlights 2023-12-13T03:57:59.223Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/gi-cancer-highlights 2023-12-13T03:57:59.216Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/lung-cancer-highlight-esmo 2023-12-13T03:57:59.211Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/lung-cancer-highlights-esmo 2023-12-13T03:57:59.201Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/cervical-cancer-highlights 2023-12-13T03:57:59.192Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/advanced-clear-cell-renal-cell-carcinoma-esmo 2023-12-13T03:57:59.187Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/esmo-2021-highlights 2023-12-13T03:57:59.179Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/colorectal-cancer-highlight-esmo 2023-12-13T03:57:59.170Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/adenoid-cystic-carcinoma 2023-12-13T03:57:59.164Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/gastroesophageal-adenocarcinoma 2023-12-13T03:57:59.159Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/gastrointestinal-cancer-esmo-2021 2023-12-13T03:57:59.153Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/keynote-355-esmo 2023-12-13T03:57:59.148Z https://assets.delveinsight.com/products/asco/1631787267-ASCO-Article-5.jpg Merck to present overall survival results from KEYNOTE-355 in frontline Triple-Negative Breast Cancer to further support accelerated approval received in late 2020 daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/head-and-neck-cancer-highlights-esmo 2023-12-13T03:57:59.141Z https://assets.delveinsight.com/products/asco/1631786423-ASCO-Article-2.jpg Bristol Myers Squibb to disclose data on Checkmate-651 trial evaluating Opdivo and Yervoy combination in frontline SCCHN after the regimen surprisingly fails to meet the primary endpoint daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/esmo-2021-abstract-lba1 2023-12-13T03:57:59.135Z https://assets.delveinsight.com/products/asco/1631785140-ADAURA-trial-results-presented-at-esmo-2020.jpg DS-8201 highlights the need for advanced therapies to enhance outcomes for Breast Cancer patients. daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/cervical-cancer-esmo-2021 2023-12-13T03:57:59.128Z daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/advanced-nsclc-highlights 2023-12-13T03:57:59.123Z https://assets.delveinsight.com/products/asco/1631717891-Head-and-Neck-Cancers.jpg Preview of ESMO 2021: Daiichi & AstraZeneca’s ADC for Advanced NSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/adagrasib-esmo-2021 2023-12-13T03:57:59.115Z https://assets.delveinsight.com/products/asco/1631716398-ASCO-Article-3.jpg Mirati’s Adagrasib was expected to rival Amgen’s Lumakras at ESMO 2021, but toxicity risks raised concerns. daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/renal-cell-carcinoma-esmo-2021 2023-12-13T03:57:59.110Z https://assets.delveinsight.com/products/asco/1631699955-ASCO-Article-2.jpg ESMO 2021 Preview: Merck now Moving Ahead with Welireg and Cabozantinib Combination in Advanced ccRCC, Post-Welireg’s Speedy Approval in VHL-associated RCC daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/new-headways-in-oncology 2023-12-13T03:57:59.104Z https://assets.delveinsight.com/products/asco/1631697214-ASCO-Article-5.jpg Cheers to new headways in Oncology: Are you all ready for ESMO 2021 Annual Meeting? daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/lilly-and-innovents-sintilimab 2023-12-13T03:57:59.097Z https://assets.delveinsight.com/products/asco/1631626342-adrenocortical.jpg ESMO 2021 Preview: Lilly and Innovent’s Sintilimab all set to present its high phase results in Esophageal Squamous Cell Cancer and Gastroesophageal Adenocarcinoma daily 0.8 https://www.delveinsight.com/esmo-conference-2021/article/margenza-esmo-2021 2023-12-13T03:57:59.090Z https://assets.delveinsight.com/products/asco/1631626425-Argininosuccinic-Aciduria-Article.jpg ESMO 2021 Preview: Margenza—a breast cancer drug—sets its niche in HER2 positive Gastric Cancer Space daily 0.8 https://www.delveinsight.com/asco-conference/article/highlights-from-melanoma 2023-12-13T03:57:59.082Z daily 0.8 https://www.delveinsight.com/asco-conference/article/thyroid-cancer-highlights 2023-12-13T03:57:59.077Z daily 0.8 https://www.delveinsight.com/asco-conference/article/colorectal-cancer-highlight 2023-12-13T03:57:59.072Z daily 0.8 https://www.delveinsight.com/asco-conference/article/nasopharyngeal-cancer-asco 2023-12-13T03:57:59.066Z daily 0.8 https://www.delveinsight.com/asco-conference/article/gynecological-cancer-highlights 2023-12-13T03:57:59.061Z daily 0.8 https://www.delveinsight.com/asco-conference/article/hematological-cancers-highlights 2023-12-13T03:57:59.057Z daily 0.8 https://www.delveinsight.com/asco-conference/article/prostate-cancer-highlight 2023-12-13T03:57:59.051Z daily 0.8 https://www.delveinsight.com/asco-conference/article/melanoma-highlight 2023-12-13T03:57:59.045Z daily 0.8 https://www.delveinsight.com/asco-conference/article/rcc-highlights 2023-12-13T03:57:59.041Z daily 0.8 https://www.delveinsight.com/asco-conference/article/lung-cancer-highlight 2023-12-13T03:57:59.035Z daily 0.8 https://www.delveinsight.com/asco-conference/article/glioblastoma-multiforme-highlights 2023-12-13T03:57:59.028Z daily 0.8 https://www.delveinsight.com/asco-conference/article/nasopharyngeal-carcinoma-highlights 2023-12-13T03:57:59.025Z daily 0.8 https://www.delveinsight.com/asco-conference/article/hematological-cancer-highlight 2023-12-13T03:57:59.019Z daily 0.8 https://www.delveinsight.com/asco-conference/article/breast-cancer-highlight 2023-12-13T03:57:59.015Z daily 0.8 https://www.delveinsight.com/asco-conference/article/colorectal-cancer-highlights 2023-12-13T03:57:59.009Z daily 0.8 https://www.delveinsight.com/asco-conference/article/head-and-neck-cancer-highlights 2023-12-13T03:57:59.004Z daily 0.8 https://www.delveinsight.com/asco-conference/article/gastric-or-gastroesophageal-junction-cancer 2023-12-13T03:57:58.999Z daily 0.8 https://www.delveinsight.com/asco-conference/article/hematological-cancer-highlights 2023-12-13T03:57:58.994Z daily 0.8 https://www.delveinsight.com/asco-conference/article/lung-cancer-highlights 2023-12-13T03:57:58.989Z daily 0.8 https://www.delveinsight.com/asco-conference/article/pancreatic-cancer-highlights 2023-12-13T03:57:58.981Z daily 0.8 https://www.delveinsight.com/asco-conference/article/breast-cancer-highlights 2023-12-13T03:57:58.976Z daily 0.8 https://www.delveinsight.com/asco-conference/article/squamous-cell-carcinoma-highlights 2023-12-13T03:57:58.968Z daily 0.8 https://www.delveinsight.com/asco-conference/article/sarcoma-highlights 2023-12-13T03:57:58.963Z daily 0.8 https://www.delveinsight.com/asco-conference/article/renal-cell-carcinoma-highlights 2023-12-13T03:57:58.956Z daily 0.8 https://www.delveinsight.com/asco-conference/article/cholangiocarcinoma-highlights 2023-12-13T03:57:58.948Z daily 0.8 https://www.delveinsight.com/asco-conference/article/bladder-cancer-highlights 2023-12-13T03:57:58.945Z https://assets.delveinsight.com/case-studies/1710135871353-bladder-cancer-highlights.png Day 1: ASCO 2021 Bladder Cancer Highlights daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-3-vision-study 2023-12-13T03:57:58.937Z https://assets.delveinsight.com/products/asco/1622727375-phase-3-vision-study.jpg Novartis’ Phase III VISION Study: Radio-ligand Therapy Heading for Regulatory Approval daily 0.8 https://www.delveinsight.com/asco-conference/article/antibody-drug-conjugates-market 2023-12-13T03:57:58.930Z https://assets.delveinsight.com/products/asco/1622648390-dna-helix-structure-closeup.jpg Expansion of the Antibody Drug Conjugates Market: Establishing a Solid Presence in Cancer Treatment with Key Collaborations daily 0.8 https://www.delveinsight.com/asco-conference/article/asco-2021-olympia-trial 2023-12-13T03:57:58.926Z https://assets.delveinsight.com/products/asco/1622627408-ASCO-Article-2.jpg ASCO 2021-OlympiA Trial: Label Expansion of Lynparza Could Open New Commercial Opportunities daily 0.8 https://www.delveinsight.com/asco-conference/article/mage-a4-most-promising-target-in-oncology 2023-12-13T03:57:58.917Z https://assets.delveinsight.com/products/asco/1622471994-mage-a4-most-promising-target-in-oncology.png.jpg ASCO 2021 – MAGE-A4: Expectations from one of the most promising target in Oncology daily 0.8 https://www.delveinsight.com/asco-conference/article/trop-2-in-antibody-drug-conjugate 2023-12-13T03:57:58.909Z https://assets.delveinsight.com/products/asco/1622218612-Antibody-Drug-Conjugate.png Triumph of Trop-2 in Antibody-Drug Conjugate daily 0.8 https://www.delveinsight.com/asco-conference/article/opdivo-boosting-relatlimab 2023-12-13T03:57:58.905Z https://assets.delveinsight.com/products/asco/1622177565-3d-render-medical-background-with-abstract-virus-cells.jpg ASC0 2021 Preview: Opdivo Boosting Relatlimab (LAG-3 Immunotherapy) Expected to Steal the Show? daily 0.8 https://www.delveinsight.com/asco-conference/article/asco-2021-annual-meeting 2023-12-13T03:57:58.897Z https://assets.delveinsight.com/products/asco/1622177906-Article-3.jpg We Have Got You Covered – Major Data Readouts at ASCO 2021 Annual Meeting daily 0.8 https://www.delveinsight.com/asco-conference/article/leading-players-in-undruggable-kras-mutation 2023-12-13T03:57:58.893Z https://assets.delveinsight.com/products/asco/1621666655-ASCO-Article-2.jpg Amgen and Mirati – Leading Players With High Hopes for the Undruggable KRAS Mutation? daily 0.8 https://www.delveinsight.com/asco-conference/article/showstoppers-in-gastric-cancers 2023-12-13T03:57:58.883Z https://assets.delveinsight.com/products/asco/1621666038-ASCO-Article-5.jpg ASCO 2021 Preview - Showstoppers in Gastric Cancers daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/ovarian-cancer-esmo-2020 2023-12-13T03:57:58.876Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/cosmic-021-esmo-2020 2023-12-13T03:57:58.869Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/gi-cancers-esmo-2020 2023-12-13T03:57:58.863Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/urothelial-carcinoma-esmo-2020 2023-12-13T03:57:58.859Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/profound-esmo-2020 2023-12-13T03:57:58.849Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/hr-positive-her2-breast-cancer-esmo-2020-insights 2023-12-13T03:57:58.844Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/profound-NCT02987543-esmo-2020 2023-12-13T03:57:58.840Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/empower-lung-1-esmo-2020 2023-12-13T03:57:58.833Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/checkmate-577-esmo-2020 2023-12-13T03:57:58.828Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/checkmate-649-NCT02872116-esmo-2020 2023-12-13T03:57:58.823Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/keynote-590-NCT03189719-esmo-2020 2023-12-13T03:57:58.815Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/trophy-u-01-esmo-2020 2023-12-13T03:57:58.811Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/pembrorad-NCT02707588-esmo-2020 2023-12-13T03:57:58.806Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/javelin-head-and-neck-100 2023-12-13T03:57:58.800Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/keynote-048-NCT02358031-esmo-2020 2023-12-13T03:57:58.796Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/danube-NCT02516241-esmo-2020 2023-12-13T03:57:58.792Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/NCT03401788-esmo-2020 2023-12-13T03:57:58.784Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/keynote-146-NCT02501096-esmo-2020 2023-12-13T03:57:58.778Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/alexander-study-NCT03287817-esmo-2020 2023-12-13T03:57:58.771Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/pod1um-201-NCT03599713-esmo-2020 2023-12-13T03:57:58.766Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/libretto-001-NCT03157128-esmo-2020 2023-12-13T03:57:58.761Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/chrysalis-study-NCT02609776-esmo-2020 2023-12-13T03:57:58.757Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/codebreak-100-NCT03600883-esmo-2020 2023-12-13T03:57:58.750Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/leap-005-NCT03797326-esmo-2020 2023-12-13T03:57:58.744Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/secombit-NCT02631447-esmo-2020 2023-12-13T03:57:58.740Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/checkmate-067-NCT01844505-esmo-2020 2023-12-13T03:57:58.732Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/checkmate-238-NCT02388906-esmo-2020 2023-12-13T03:57:58.726Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/leap-004-study-esmo-2020 2023-12-13T03:57:58.717Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/combi-i-NCT02967692-esmo-2020 2023-12-13T03:57:58.711Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/keynote-054-NCT02362594-esmo-2020 2023-12-13T03:57:58.707Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/impassion031-NCT03197935-esmo-2020 2023-12-13T03:57:58.701Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/impassion130-NCT02425891-esmo-2020 2023-12-13T03:57:58.695Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/impassion131-NCT03125902-esmo-2020 2023-12-13T03:57:58.689Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/nextMONARCH-lilly-esmo-2020 2023-12-13T03:57:58.683Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/PALLAS-pfizer-esmo-2020 2023-12-13T03:57:58.676Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/breast-cancer-solar1-NCT02437318 2023-12-13T03:57:58.669Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/breast-cancer-IPATunity130-NCT03337724 2023-12-13T03:57:58.663Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/colorectal-cancer-NCT03168139-esmo-2020 2023-12-13T03:57:58.654Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/checkmate-577-NCT02743494-esmo-2020 2023-12-13T03:57:58.649Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/cave-cetuximab-avelumab-merck-esmo 2023-12-13T03:57:58.645Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/keynote-177-colorectal-cancer 2023-12-13T03:57:58.642Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/head-neck-cancers-esmo-2020-insights 2023-12-13T03:57:58.633Z https://assets.delveinsight.com/products/asco/1600622943-Head-and-Neck-Cancers.jpg Head & Neck Cancers ESMO 2020 Insights daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/checkmate-9er-renal-cell-carcinoma-highlights-esmo-2020 2023-12-13T03:57:58.628Z https://assets.delveinsight.com/products/asco/1600617886-ASCO-Article-2.jpg ESMO 2020: CheckMate 9ER Provides New First-Line Treatment Option for Patients Advanced RCC daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/CROWN-trial-supports-lorbrena-lorlatinib-as-future-treatment-in-ALK-NSCLC 2023-12-13T03:57:58.621Z https://assets.delveinsight.com/products/asco/1600617323-CROWN-Study.jpg Promising results from the CROWN trial supports Lorbrena (lorlatinib) as a future first-line standard treatment in ALK+ NSCLC daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/ascent-trial-results-sacituzumab-esmo 2023-12-13T03:57:58.614Z https://assets.delveinsight.com/products/asco/1600615881-ASCENT.jpg ASCENT trial results establish Sacituzumab as new standard of care in third line for metastatic TNBC daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/ADAURA-trial-results-presented-at-esmo-2020 2023-12-13T03:57:58.608Z https://assets.delveinsight.com/products/asco/1600612686-ADAURA-trial-results-presented-at-esmo-2020.jpg ADAURA trial results presented at ESMO established proven clinical activity of Tagrisso (osimertinib) in the adjuvant treatment of early-stage EGFR-mutated lung cancer (EGFRm) daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/gilead-sacituzumab-oncology-results-esmo-2020 2023-12-13T03:57:58.601Z https://assets.delveinsight.com/products/asco/1600519916-Gilead's-ASCENT-into-Oncology-Sacituzumab-results-at-ESMO-2020.jpg Gilead's ASCENT into Oncology: Sacituzumab results at ESMO 2020 daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/bms-exelixis-face-off-merck-keytruda-renal-cancer 2023-12-13T03:57:58.595Z https://assets.delveinsight.com/products/asco/1600520034-BMS.jpg BMS/Exelixis face-off with Merck’s Keytruda in front-line renal cancer daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/adc-in-esmo 2023-12-13T03:57:58.591Z https://assets.delveinsight.com/products/asco/1600431443-ADC-will-be-in-focus-in-ESMO-2020-too.jpg Will ADC’s be in focus in ESMO? daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/melanoma-combi-i-trial-failure-story 2023-12-13T03:57:58.585Z https://assets.delveinsight.com/products/asco/1600431284-riumphs-and-troubles-for-combination.jpg Triumphs and Troubles for Combination Therapies in Melanoma: COMBI-I Trial Failure Story daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/major-trials-in-focus 2023-12-13T03:57:58.581Z https://assets.delveinsight.com/products/asco/1600431826-Major-trials-in-focus.jpg ESMO 2020 – Major trials in focus and Our View Points daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/lilly-pfizer-in-early-hr-positive-her2-negative-breast-cancer 2023-12-13T03:57:58.577Z daily 0.8 https://www.delveinsight.com/esmo-conference-2020/article/tumor-mutation-burden 2023-12-13T03:57:58.568Z https://assets.delveinsight.com/products/asco/1600434395-Tumor-Mutation-Burden-TMB.jpg Tumor Mutation Burden (TMB) daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02501096 2023-12-13T03:57:58.564Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02853331 2023-12-13T03:57:58.560Z daily 0.8 https://www.delveinsight.com/asco-conference/article/cabozantinib 2023-12-13T03:57:58.555Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02627963 2023-12-13T03:57:58.550Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03091192 2023-12-13T03:57:58.546Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03174197 2023-12-13T03:57:58.542Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03491683 2023-12-13T03:57:58.536Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02858895 2023-12-13T03:57:58.533Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01986348 2023-12-13T03:57:58.528Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02446600 2023-12-13T03:57:58.523Z daily 0.8 https://www.delveinsight.com/asco-conference/article/Gastroesophageal 2023-12-13T03:57:58.517Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03116152 2023-12-13T03:57:58.513Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT023704981 2023-12-13T03:57:58.508Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02370498 2023-12-13T03:57:58.502Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01196390 2023-12-13T03:57:58.498Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02485691 2023-12-13T03:57:58.494Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03148795 2023-12-13T03:57:58.488Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03170960 2023-12-13T03:57:58.482Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02987544 2023-12-13T03:57:58.476Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02987543 2023-12-13T03:57:58.469Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03085095 2023-12-13T03:57:58.463Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02861573 2023-12-13T03:57:58.458Z daily 0.8 https://www.delveinsight.com/asco-conference/article/ISRCTN-69139368 2023-12-13T03:57:58.451Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01946204 2023-12-13T03:57:58.446Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02003924 2023-12-13T03:57:58.441Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02200614 2023-12-13T03:57:58.435Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01485861 2023-12-13T03:57:58.430Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03056001 2023-12-13T03:57:58.425Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03009201 2023-12-13T03:57:58.418Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03899805 2023-12-13T03:57:58.413Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02601950 2023-12-13T03:57:58.408Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02005471 2023-12-13T03:57:58.399Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03382561 2023-12-13T03:57:58.395Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02242942 2023-12-13T03:57:58.390Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02029443 2023-12-13T03:57:58.384Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03373760 2023-12-13T03:57:58.379Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02927340 2023-12-13T03:57:58.374Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02301156 2023-12-13T03:57:58.368Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02409342 2023-12-13T03:57:58.362Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01336634 2023-12-13T03:57:58.358Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02578680 2023-12-13T03:57:58.351Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02970318 2023-12-13T03:57:58.346Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02716116 2023-12-13T03:57:58.342Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02108964 2023-12-13T03:57:58.335Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03824483 2023-12-13T03:57:58.330Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02638090 2023-12-13T03:57:58.325Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03054896 2023-12-13T03:57:58.318Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02411448 2023-12-13T03:57:58.313Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03382899 2023-12-13T03:57:58.309Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02659059 2023-12-13T03:57:58.301Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02517398 2023-12-13T03:57:58.296Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02864992 2023-12-13T03:57:58.291Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02492568 2023-12-13T03:57:58.285Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02439450 2023-12-13T03:57:58.280Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03410108 2023-12-13T03:57:58.275Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT024141391 2023-12-13T03:57:58.268Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02897479 2023-12-13T03:57:58.263Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02075840 2023-12-13T03:57:58.258Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03191149 2023-12-13T03:57:58.251Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02414139 2023-12-13T03:57:58.247Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03563716 2023-12-13T03:57:58.242Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03057106 2023-12-13T03:57:58.235Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03215706 2023-12-13T03:57:58.231Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02477826 2023-12-13T03:57:58.226Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03276468 2023-12-13T03:57:58.219Z daily 0.8 https://www.delveinsight.com/asco-conference/article/lisocabtagene-maraleucel-1 2023-12-13T03:57:58.215Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT04150328 2023-12-13T03:57:58.210Z daily 0.8 https://www.delveinsight.com/asco-conference/article/EudraCT-2014-001620-29 2023-12-13T03:57:58.205Z daily 0.8 https://www.delveinsight.com/asco-conference/article/zuma-1 2023-12-13T03:57:58.199Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03625037 2023-12-13T03:57:58.194Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03287817 2023-12-13T03:57:58.188Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03283202 2023-12-13T03:57:58.183Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03097770 2023-12-13T03:57:58.178Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT00924326 2023-12-13T03:57:58.174Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03655483 2023-12-13T03:57:58.167Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01716806 2023-12-13T03:57:58.162Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02467946 2023-12-13T03:57:58.157Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02684292 2023-12-13T03:57:58.151Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02228382 2023-12-13T03:57:58.146Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01207440 2023-12-13T03:57:58.142Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT00261846 2023-12-13T03:57:58.136Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT013329681 2023-12-13T03:57:58.131Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01332968 2023-12-13T03:57:58.126Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03939026 2023-12-13T03:57:58.121Z daily 0.8 https://www.delveinsight.com/asco-conference/article/dreamm-6 2023-12-13T03:57:58.115Z daily 0.8 https://www.delveinsight.com/asco-conference/article/bellini-study 2023-12-13T03:57:58.089Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03525678 2023-12-13T03:57:58.082Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02312258 2023-12-13T03:57:58.077Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01685814 2023-12-13T03:57:58.064Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02343042 2023-12-13T03:57:58.015Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT02755597 2023-12-13T03:57:58.009Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03104842 2023-12-13T03:57:57.975Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01668719 2023-12-13T03:57:57.968Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03548207 2023-12-13T03:57:57.962Z daily 0.8 https://www.delveinsight.com/asco-conference/article/safety-and-efficacy-results-of-GC027 2023-12-13T03:57:57.959Z daily 0.8 https://www.delveinsight.com/asco-conference/article/SCRI-CAR19x22-t-cell-product 2023-12-13T03:57:57.951Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03430011 2023-12-13T03:57:57.947Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03361748 2023-12-13T03:57:57.942Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03110562 2023-12-13T03:57:57.937Z daily 0.8 https://www.delveinsight.com/asco-conference/article/teclistamab 2023-12-13T03:57:57.927Z daily 0.8 https://www.delveinsight.com/asco-conference/article/Pracinostat 2023-12-13T03:57:57.921Z daily 0.8 https://www.delveinsight.com/asco-conference/article/Venetoclax 2023-12-13T03:57:57.915Z daily 0.8 https://www.delveinsight.com/asco-conference/article/CC-486 2023-12-13T03:57:57.909Z daily 0.8 https://www.delveinsight.com/asco-conference/article/CC-486-is-safe 2023-12-13T03:57:57.901Z daily 0.8 https://www.delveinsight.com/asco-conference/article/glasdegib-in-combination-with-azacitidine 2023-12-13T03:57:57.895Z daily 0.8 https://www.delveinsight.com/asco-conference/article/Gilteritinib 2023-12-13T03:57:57.891Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT03069352 2023-12-13T03:57:57.885Z daily 0.8 https://www.delveinsight.com/asco-conference/article/NCT01696084 2023-12-13T03:57:57.878Z daily 0.8 https://www.delveinsight.com/asco-conference/article/nct01546038 2023-12-13T03:57:57.873Z daily 0.8 https://www.delveinsight.com/asco-conference/article/anti-CD47-antibody-magrolimab 2023-12-13T03:57:57.867Z daily 0.8 https://www.delveinsight.com/asco-conference/article/effect-of-enasidenib-plus-azacitidine 2023-12-13T03:57:57.860Z daily 0.8 https://www.delveinsight.com/asco-conference/article/lisocabtagene-maraleucel 2023-12-13T03:57:57.854Z daily 0.8 https://www.delveinsight.com/asco-conference/article/zuma-5 2023-12-13T03:57:57.848Z daily 0.8 https://www.delveinsight.com/asco-conference/article/DESTINYCRC01 2023-12-13T03:57:57.843Z daily 0.8 https://www.delveinsight.com/asco-conference/article/checkmate-142 2023-12-13T03:57:57.838Z daily 0.8 https://www.delveinsight.com/asco-conference/article/keynote-164 2023-12-13T03:57:57.831Z daily 0.8 https://www.delveinsight.com/asco-conference/article/beacon-crc 2023-12-13T03:57:57.825Z daily 0.8 https://www.delveinsight.com/asco-conference/article/keynote-048 2023-12-13T03:57:57.820Z daily 0.8 https://www.delveinsight.com/asco-conference/article/future-directions-for-head-and-neck-treatment 2023-12-13T03:57:57.814Z daily 0.8 https://www.delveinsight.com/asco-conference/article/lifileucel-LN-144 2023-12-13T03:57:57.810Z daily 0.8 https://www.delveinsight.com/asco-conference/article/atezolizumab-bevacizumab 2023-12-13T03:57:57.805Z daily 0.8 https://www.delveinsight.com/asco-conference/article/imbrave150 2023-12-13T03:57:57.799Z daily 0.8 https://www.delveinsight.com/asco-conference/article/imvigor010 2023-12-13T03:57:57.794Z daily 0.8 https://www.delveinsight.com/asco-conference/article/imvigor130 2023-12-13T03:57:57.790Z daily 0.8 https://www.delveinsight.com/asco-conference/article/trastuzumab-emtansine-pertuzumab 2023-12-13T03:57:57.784Z daily 0.8 https://www.delveinsight.com/asco-conference/article/cyclin-dependent-kinase-inhibitor-dinaciclib 2023-12-13T03:57:57.778Z daily 0.8 https://www.delveinsight.com/asco-conference/article/dual-anti-ctla-4-anti-pd-1-blockade 2023-12-13T03:57:57.748Z daily 0.8 https://www.delveinsight.com/asco-conference/article/sar439859-oral-selective-estrogen-receptor-degrader 2023-12-13T03:57:57.742Z daily 0.8 https://www.delveinsight.com/asco-conference/article/taktic 2023-12-13T03:57:57.730Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/trelegy-ellipta 2023-12-13T03:57:57.714Z https://assets.delveinsight.com/img/ats-conference/1655209905-Trelegy-Ellipta-Highlight.png Is Trelegy Ellipta more efficacious than other COPD therapies? daily 0.8 https://www.delveinsight.com/asco-conference/article/abemaciclib-in-combination-with-pembrolizumab 2023-12-13T03:57:57.691Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/triple-vs-dual-therapy 2023-12-13T03:57:57.663Z https://assets.delveinsight.com/img/ats-conference/1655209512-Triple-vs-dual-therapy-for-COPD.png Triple vs. dual therapy for the management of COPD daily 0.8 https://www.delveinsight.com/asco-conference/article/kn026-alphamab 2023-12-13T03:57:57.626Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/paradigm-of-pulmonary-arterial-hypertension 2023-12-13T03:57:57.622Z https://assets.delveinsight.com/img/ats-conference/1654596883-Paradigm-for-PAH.png An evolving Treatment Paradigm daily 0.8 https://www.delveinsight.com/asco-conference/article/sophia-analysis 2023-12-13T03:57:57.616Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/future-of-pulmonary-rehabilitation 2023-12-13T03:57:57.610Z https://assets.delveinsight.com/img/ats-conference/1654596807-Future-of-Pulmonary-Rehabilitation-feature.png Future of Pulmonary Rehabilitation daily 0.8 https://www.delveinsight.com/asco-conference/article/gdc-9545 2023-12-13T03:57:57.604Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/MRx-4DP0004 2023-12-13T03:57:57.599Z https://assets.delveinsight.com/img/ats-conference/1654595299-MRx-4DP0004--a-next-generation-drug-for-management-of-Severe-Asthma-(2).png MRx-4DP0004- a next-generation drug for management daily 0.8 https://www.delveinsight.com/asco-conference/article/phase-2-trial-of-bicalutamide 2023-12-13T03:57:57.593Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/pde5i-in-pah 2023-12-13T03:57:57.582Z https://assets.delveinsight.com/img/ats-conference/1654512289-PDE5i-in-PAH.png Riociguat potential benefit daily 0.8 https://www.delveinsight.com/asco-conference/article/enhance-1 2023-12-13T03:57:57.575Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/p492-verona-pharma 2023-12-13T03:57:57.567Z https://assets.delveinsight.com/img/ats-conference/1654511764-Verona-Pharma-New-TQT-Analysis-P492.png P492 –New TQT Analysis by Verona Pharma supports planned NDA Submission daily 0.8 https://www.delveinsight.com/asco-conference/article/encore-602 2023-12-13T03:57:57.563Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/atyr-pharma-efzofitimod 2023-12-13T03:57:57.551Z https://assets.delveinsight.com/img/ats-conference/1654511137-atyr-pharma-efzofitimod-ats-2022.png aTyr Pharma finds its way to the untapped Market of Pulmonary Sarcoidosis daily 0.8 https://www.delveinsight.com/asco-conference/article/keynote-119 2023-12-13T03:57:57.534Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/pieris-leading-drug-prs220 2023-12-13T03:57:57.513Z https://assets.delveinsight.com/img/ats-conference/1654510647-Pieris-leading-drug-PRS220-(2).png Pieris Pharmaceuticals: The new superior in Idiopathic pulmonary fibrosis daily 0.8 https://www.delveinsight.com/asco-conference/article/parsifal 2023-12-13T03:57:57.506Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/freedom-ev-highlights 2023-12-13T03:57:57.498Z https://assets.delveinsight.com/img/ats-conference/1654253105-Oral-Treprostinil-FREEDOM-EV-feature.png Oral Treprostinil: FREEDOM daily 0.8 https://www.delveinsight.com/asco-conference/article/BYLieve 2023-12-13T03:57:57.492Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/dpp1-inhibitor 2023-12-13T03:57:57.484Z https://assets.delveinsight.com/img/ats-conference/1654252935-DPP1-Inhibitor.png DPP1 Inhibitor paving its way for approval daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/oxc-201 2023-12-13T03:57:57.481Z https://assets.delveinsight.com/img/ers-conference/1695011815-will-oxc-201-prove-itself-in-ipf.png OXC-201 in IPF daily 0.8 https://www.delveinsight.com/asco-conference/article/keynote-355 2023-12-13T03:57:57.477Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/ofev-pf-ild-market 2023-12-13T03:57:57.471Z https://assets.delveinsight.com/img/ats-conference/1654253613-Ofev-PF-ILD-Market.png A Blockbuster drug in PF-ILD Market daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/treprostinil-palmitil 2023-12-13T03:57:57.465Z https://assets.delveinsight.com/img/ers-conference/1694752386-treprostinil-palmitil-ers.png Treprostinil palmitil data presented for PH-ILD daily 0.8 https://www.delveinsight.com/asco-conference/article/approval-for-osimertinib 2023-12-13T03:57:57.459Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/ssc-ild-treatment 2023-12-13T03:57:57.453Z https://assets.delveinsight.com/img/ats-conference/1654253407-Ssc-ILD-Treatment.png Ssc-ILD Treatment daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/efzofitimod-ers 2023-12-13T03:57:57.448Z https://assets.delveinsight.com/img/ers-conference/1694693375-efzofitimod-victory-in-ers.png Efzofitimod's Victory daily 0.8 https://www.delveinsight.com/asco-conference/article/keynote-177 2023-12-13T03:57:57.441Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/next-generation-therapeutics-in-copd 2023-12-13T03:57:57.432Z https://assets.delveinsight.com/img/ats-conference/1654252804-AstraZeneca-Next-generation-therapeutics.png AstraZeneca: Next Generation Therapeutics in COPD daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/brensocatib-for-cystic-fibrosis 2023-12-13T03:57:57.419Z https://assets.delveinsight.com/img/ers-conference/1694693395-brensocatib-cystic-fibrosis.png Brensocatib’s Breakthrough: A Ray of Hope for Cystic Fibrosis and Beyond at ERS International Congress 2023 daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/musculoskeletal-imaging-in-rheumatological-practice 2023-12-13T03:57:57.414Z https://assets.delveinsight.com/img/eular-conference/1655466422-Musculoskeletal-Imaging-in-Rheumatology.png Musculoskeletal Imaging in Rheumatology daily 0.8 https://www.delveinsight.com/asco-conference/article/carfilzomib-lenalidomide-dexamethasone 2023-12-13T03:57:57.409Z daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/copd-treatment 2023-12-13T03:57:57.400Z https://assets.delveinsight.com/img/ats-conference/1654147583-COPD-treatment-Belimumab.png Belimumab addressing unmet need in COPD treatment daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/ssc-ild-efzofitimod 2023-12-13T03:57:57.396Z https://assets.delveinsight.com/img/ers-conference/1694676487-efzofitimod-ssc-ild.png ERS 2023 Reveals Efzofitimod Data daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/abx464 2023-12-13T03:57:57.391Z https://assets.delveinsight.com/img/eular-conference/1654614726-ABX464-Highlights.png ABX464: A Potential Candidate With a Novel Mechanism of Action for the Treatment of Rheumatoid Arthritis daily 0.8 https://www.delveinsight.com/asco-conference/article/javelin-bladder-100 2023-12-13T03:57:57.383Z https://assets.delveinsight.com/products/asco/1622536792-3d-render-medical-background-with-abstract-virus-cells.jpg Can much awaited JAVELIN data give any surprise in ASCO 2020? daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/gsk-exhibits-anoro-ellipta 2023-12-13T03:57:57.376Z https://assets.delveinsight.com/img/ats-conference/1654146666-COPD-Highlights.png GSK exhibits Anoro Ellipta's superior efficacy in dual therapy in ATS conference daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/arrowhead-rnai-candidate 2023-12-13T03:57:57.370Z https://assets.delveinsight.com/img/ers-conference/1694669038-arrowhead-rNAi-candidate.png Arrowhead’s RNAi Candidate at ERS 2023 daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/bimekizumab 2023-12-13T03:57:57.364Z https://assets.delveinsight.com/img/eular-conference/1654614194-bimekizumab-feature.png Bimekizumab to Benefit Psoriatic Arthritis Patients According to the Phase III Clinical Trial Results daily 0.8 https://www.delveinsight.com/asco-conference/article/gsk-cell-therapy-next-generation-immuno-oncology 2023-12-13T03:57:57.358Z https://assets.delveinsight.com/products/asco/ASCO-Article-new.jpg GSK has a strong say in ASCO 2020 as they are announcing key data on Cell Therapy and Next-generation Immuno-oncology daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/pt027-asthma-rescue-therapy 2023-12-13T03:57:57.351Z https://assets.delveinsight.com/img/ats-conference/1654145975-Abstract3.png PT027: A first-in-class fixed dose combination for Asthma rescue therapy daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/bacteriophage-ers 2023-12-13T03:57:57.345Z https://assets.delveinsight.com/img/ers-conference/1694669356-bacteriophage-cystic-fibrosis.png Will Bacteriophage bear the burden in Cystic Fibrosis? daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/deucravacitinib-highlights 2023-12-13T03:57:57.334Z https://assets.delveinsight.com/img/eular-conference/1654598169-Deucravacitinib-Highlights.png Deucravacitinib: A Ray of Hope after a decade of wait! BMS plans to progress its potential game changer oral TYK2 inhibitor into late stage clinical development daily 0.8 https://www.delveinsight.com/asco-conference/article/roche-ipatasertib 2023-12-13T03:57:57.318Z https://assets.delveinsight.com/products/asco/ASCO-Article-5.jpg Roche’s Ipatasertib (RG7440) in Metastatic Castration-resistant Prostate Cancer (mCRPC) daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/trio-cidpr-data-repository 2023-12-13T03:57:57.312Z https://assets.delveinsight.com/img/ats-conference/1654145779-Abstract2.png TRIO CIPDR Data Repository: Improving Pulmonary Arterial Hypertension patient outcomes daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/pah-treatment 2023-12-13T03:57:57.306Z https://assets.delveinsight.com/img/ers-conference/1694602699-sotatercept-pah-treatment.png Merck’s Sotatercept daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/il-17a-il-17f-with-bimekizumab 2023-12-13T03:57:57.299Z https://assets.delveinsight.com/img/eular-conference/1654594601-IL-17A-&-IL-17F-with-bimekizumab.png Dual inhibition of IL-17A & IL-17F with bimekizumab may be a promising treatment option for AS, suggests BE MOBILE 2 trial. daily 0.8 https://www.delveinsight.com/asco-conference/article/bayer-healthcare-orion-nubeqa 2023-12-13T03:57:57.290Z https://assets.delveinsight.com/products/asco/ASCO-Article-4.jpg Bayer Healthcare and Orion's Nubeqa (darolutamide) in Non-metastatic castration-resistant prostate cancer (nmCRPC) daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/pliant-idiopathic-pulmonary-fibrosis 2023-12-13T03:57:57.283Z daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/allergic-asthma-treatment 2023-12-13T03:57:57.278Z https://assets.delveinsight.com/img/ers-conference/1694521419-allergic-asthma-treatment.png Developments in Allergic Asthma Treatment: Promising Findings from Adermastat (FP-025) Study at ERS 2023 daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/upadacitinib-eular 2023-12-13T03:57:57.269Z https://assets.delveinsight.com/img/eular-conference/1654594547-Upadacitinib.png Upadacitinib shows promising results for nr-axSpA treatment of patients with inadequate response to biologic disease-modifying antirheumatic drugs. daily 0.8 https://www.delveinsight.com/asco-conference/article/astrazeneca-merck-lynparza 2023-12-13T03:57:57.256Z https://assets.delveinsight.com/products/asco/ASCO-Article-2.jpg AstraZeneca and Merck’s Lynparza (olaparib) in Metastatic Castration-resistant Prostate Cancer (mCRPC) daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/insmed-trepostinil 2023-12-13T03:57:57.219Z https://assets.delveinsight.com/img/ats-conference/1654141517-Idiopathic-pulmonary-Fibrosis.png Insmed presents new data on Treprostinil for IPF daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/progressive-pulmonary-fibrosis-highlights 2023-12-13T03:57:57.213Z https://assets.delveinsight.com/img/ers-conference/1694520567-ppf-highlight.png Advancements in Progressive Pulmonary Fibrosis (PPF) Research: Insights from ERS 2023 daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/novel-biomarkers-in-rheumatic-diseases 2023-12-13T03:57:57.204Z https://assets.delveinsight.com/img/eular-conference/1654254378-Rheumatic-and-Musculoskeletal-Diseases-Highlights.png Novel biomarkers: Rheumatic & Musculoskeletal Diseases daily 0.8 https://www.delveinsight.com/asco-conference/article/pfizer-tala 2023-12-13T03:57:57.197Z https://assets.delveinsight.com/products/asco/ASCO-Article-pfizer.jpg Pfizer’s TALA (talazoparib) in metastatic castration-resistant prostate cancer (mCRPC) daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/pulmonary-arterial-hypertension 2023-12-13T03:57:57.175Z https://assets.delveinsight.com/img/ats-conference/1653927273-Pulmonary-Arterial-Hypertension-Market.png Ralinepag to strengthen United Therapeutics’ PAH portfolio daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/seralutinib-pulmonary-arterial-hypertension 2023-12-13T03:57:57.169Z https://assets.delveinsight.com/img/ers-conference/1694520239-seralutinib-pulmonary-arterial-hypertension.png Seralutinib’s Triumph at ERS Presentation 2023 daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/remote-health-applications 2023-12-13T03:57:57.133Z https://assets.delveinsight.com/img/eular-conference/1654239010-Remote-Health-Applications-for-Self-management.png Digital/Remote Health Applications for Self-management in Patients With Rheumatic Diseases daily 0.8 https://www.delveinsight.com/ats-conference/ats-2021/severe-uncontrolled-asthma 2023-12-13T03:57:57.111Z https://assets.delveinsight.com/img/ats-conference/1653926068-Asthma.png Is TSLP a new game-changer for Severe Uncontrolled Asthma? daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/dupixent-for-copd 2023-12-13T03:57:57.106Z https://assets.delveinsight.com/img/ers-conference/1694520303-dupixent-for-copd.png Is Dupixent the Next COPD Breakthrough? daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/lillys-baricitinib 2023-12-13T03:57:57.100Z https://assets.delveinsight.com/img/eular-conference/1654239188-Lillys-Baricitinib-Late-Breaking-Abstract.png Eli Lilly to present baricitinib’s results for juvenile idiopathic arthritis from its Phase III safety and efficacy study at EULAR 2022. daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/ipf-treatment 2023-12-13T03:57:57.080Z https://assets.delveinsight.com/img/ats-conference/1653910232-Idiopathic-pulmonary-Fibrosis.png PDE4-B Inhibitors: New Class in Idiopathic Pulmonary Fibrosis treatment daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/revolutionizing-treatments-for-copd 2023-12-13T03:57:57.073Z https://assets.delveinsight.com/img/ers-conference/1694502200-dupixent-copd.png COPD: The advent of revolutionizing treatments daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/upadacitinib-for-nonradiographic-axial-spondyloarthritis 2023-12-13T03:57:57.036Z https://assets.delveinsight.com/img/eular-conference/1653716411-Upadacitinib-for-treatment-of-nr-Axial-Spondyloarthritis.png EULAR 2022: A glimpse of Abbvie’s Oral Presentation on Upadacitinib for treatment of Nonradiographic Axial Spondyloarthritis. daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/ensifentrine-copd 2023-12-13T03:57:57.009Z https://assets.delveinsight.com/img/ers-conference/1694501211-ensifentrine-highlights.png Ensifentrine: A value addition to the COPD paradigm daily 0.8 https://www.delveinsight.com/aacr-annual-meeting/aacr-2025/preview-content 2023-12-13T03:57:57.009Z https://assets.delveinsight.com/case-studies/1745502172135-aacr-2025-preview-content.png American Association for Cancer Research (AACR) 2025: Gearing up for the early innovations in the upcoming week daily 0.8 https://www.delveinsight.com/aacr-annual-meeting/aacr-2025/key-abstracts-and-insights 2023-12-13T03:57:57.009Z https://assets.delveinsight.com/case-studies/1745501315966-aacr-2025-key-abstracts-and-insights.png AACR 2025: A Deep Dive into Cancer’s Next Frontier – Key Abstracts & Insights daily 0.8 https://www.delveinsight.com/eular-conference/eular-2022/ucb-bimekizumab-abstract 2023-12-13T03:57:56.991Z https://assets.delveinsight.com/img/eular-conference/1653714545-UCB’s-Bimekizumab-Highlights.png EULAR 2022: A sneak peek at UCB’s Bimekizumab abstract presentations daily 0.8 https://www.delveinsight.com/ats-conference/ats-2022/american-journal-of-respiratory-and-critical-care-medicine 2023-12-13T03:57:56.978Z https://assets.delveinsight.com/img/ats-conference/1653458485-ATS-2022-short-image.jpg American Journal of Respiratory and Critical Care Medicine daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/idiopathic-pulmonary-fibrosis-ers 2023-12-13T03:57:56.961Z https://assets.delveinsight.com/img/ers-conference/1694500481-idiopathic-pulmonary-fibrosis-highlights.png ERS Congress 2023: A Glimpse into the Future of IPF Treatment daily 0.8 https://www.delveinsight.com/ers-conference/ers-2023/ad109-abstracts 2023-12-13T03:57:56.907Z https://assets.delveinsight.com/img/ers-conference/1694498937-ad109-ers-2023.png Obstructive Sleep Apnea Emerging Therapy Highlights daily 0.8